{"nbformat":4,"nbformat_minor":0,"metadata":{"colab":{"name":"Assignment 1 3-1.ipynb","provenance":[],"collapsed_sections":[]},"kernelspec":{"name":"python3","display_name":"Python 3"}},"cells":[{"cell_type":"code","metadata":{"id":"lantIuel-ip5","executionInfo":{"status":"ok","timestamp":1604211942158,"user_tz":-480,"elapsed":1027,"user":{"displayName":"Nicholas Neo","photoUrl":"","userId":"02359484661843204503"}},"outputId":"bdff2bf0-6b57-44f5-965a-ec3525de52d3","colab":{"base_uri":"https://localhost:8080/"}},"source":["from google.colab import drive\n","drive.mount(\"/content/drive\")"],"execution_count":1,"outputs":[{"output_type":"stream","text":["Drive already mounted at /content/drive; to attempt to forcibly remount, call drive.mount(\"/content/drive\", force_remount=True).\n"],"name":"stdout"}]},{"cell_type":"markdown","metadata":{"id":"Ylr3lbQ9wwhZ"},"source":["### Optometry Dataset"]},{"cell_type":"code","metadata":{"id":"soHYrNbZMZcV","executionInfo":{"status":"ok","timestamp":1604211944644,"user_tz":-480,"elapsed":1165,"user":{"displayName":"Nicholas Neo","photoUrl":"","userId":"02359484661843204503"}}},"source":["#Set file path to Optometry dataset\n","COLAB_FILEPATH = './drive/My Drive/4045-assignment-1/data/optometry/'\n","filepath_1 = COLAB_FILEPATH + \"Journal_of_Optometry_bibliometrics.txt\"\n","filepath_2 = COLAB_FILEPATH + \"Visual_Deficits_and_Dysfunctions_Associated_with.2.txt\"\n","filepath_3 = COLAB_FILEPATH + \"The_Safety_of_Soft_Contact_Lenses_in_Children.2.txt\"\n","filepath_4 = COLAB_FILEPATH + \"The_Effect_of_a_Head_mounted_Low_Vision_Device_on.12.txt\"\n","filepath_5 = COLAB_FILEPATH + \"The_Berkeley_Rudimentary_Vision_Test.7.txt\"\n","filepath_6 = COLAB_FILEPATH + \"Studying_Age_Related_Macular_Degeneration_Using.13.txt\"\n","filepath_7 = COLAB_FILEPATH + \"Spectral_Evaluation_of_Eyeglass_Blocking.8.txt\"\n","filepath_8 = COLAB_FILEPATH + \"Scleral_Contact_Lenses__Past_and_Future.1.txt\"\n","filepath_9 = COLAB_FILEPATH + \"Safety_and_Efficacy_of_Scleral_Lenses_for.14.txt\"\n","filepath_10 = COLAB_FILEPATH + \"Research_in_Optometry_A_challenge_and_a_chance.txt\"\n","filepath_11 = COLAB_FILEPATH + \"Orthokeratology_for_Myopia_Control__A.4.txt\"\n","filepath_12 = COLAB_FILEPATH + \"IOP_and_Optic_Nerve_Head_Morphology_during_Scleral.3.txt\"\n","filepath_13 = COLAB_FILEPATH + \"Impact_of_Dry_Eye_on_Visual_Acuity_and_Contrast.2.txt\"\n","filepath_14 = COLAB_FILEPATH + \"Font_Size_and_Viewing_Distance_of_Handheld_Smart.5.txt\"\n","filepath_15 = COLAB_FILEPATH + \"Eye_Examination_Testability_in_Children_with.9.txt\"\n","filepath_16 = COLAB_FILEPATH + \"Different_Amounts_of_Alcohol_Consumption_and.13.txt\"\n","filepath_17 = COLAB_FILEPATH + \"Corneal_Neuralgia_after_LASIK.16.txt\"\n","filepath_18 = COLAB_FILEPATH + \"Clinical_Procedures_in_Primary_Eye_Care,_4th_ed_.26.txt\"\n","filepath_19 = COLAB_FILEPATH + \"Advances_in_Scleral_Lenses.2.txt\"\n","filepath_20 = COLAB_FILEPATH + \"A_3_year_Randomized_Clinical_Trial_of_MiSight.3.txt\""],"execution_count":2,"outputs":[]},{"cell_type":"markdown","metadata":{"id":"tgHf2LiEw0cB"},"source":["### Petroleum Dataset"]},{"cell_type":"code","metadata":{"id":"GLCf1HxooaIF","executionInfo":{"status":"ok","timestamp":1604211853871,"user_tz":-480,"elapsed":779,"user":{"displayName":"Nicholas Neo","photoUrl":"","userId":"02359484661843204503"}}},"source":["#Set file path to petroleum dataset\n","COLAB_FILEPATH = './drive/My Drive/4045-assignment-1/data/petroleum/'\n","filepath_1 = COLAB_FILEPATH + \"1-s2.0-S209624951730039X-main.txt\"\n","filepath_2 = COLAB_FILEPATH + \"1-s2.0-S209624951730042X-main.txt\"\n","filepath_3 = COLAB_FILEPATH + \"1-s2.0-S2096249517300121-main.txt\"\n","filepath_4 = COLAB_FILEPATH + \"1-s2.0-S2096249517300261-main.txt\"\n","filepath_5 = COLAB_FILEPATH + \"1-s2.0-S2096249517300273-main.txt\"\n","filepath_6 = COLAB_FILEPATH + \"1-s2.0-S2096249517300285-main.txt\"\n","filepath_7 = COLAB_FILEPATH + \"1-s2.0-S2096249517300297-main.txt\"\n","filepath_8 = COLAB_FILEPATH + \"1-s2.0-S2096249517300303-main.txt\"\n","filepath_9 = COLAB_FILEPATH + \"1-s2.0-S2096249517300315-main.txt\"\n","filepath_10 = COLAB_FILEPATH + \"1-s2.0-S2096249517300327-main.txt\"\n","filepath_11 = COLAB_FILEPATH + \"1-s2.0-S2096249517300339-main.txt\"\n","filepath_12 = COLAB_FILEPATH + \"1-s2.0-S2096249517300340-main.txt\"\n","filepath_13 = COLAB_FILEPATH + \"1-s2.0-S2096249517300352-main.txt\"\n","filepath_14 = COLAB_FILEPATH + \"1-s2.0-S2096249517300364-main.txt\"\n","filepath_15 = COLAB_FILEPATH + \"1-s2.0-S2096249517300388-main.txt\"\n","filepath_16 = COLAB_FILEPATH + \"1-s2.0-S2096249517300406-main.txt\"\n","filepath_17 = COLAB_FILEPATH + \"1-s2.0-S2096249517300418-main.txt\"\n","filepath_18 = COLAB_FILEPATH + \"1-s2.0-S2096249517300431-main.txt\"\n","filepath_19 = COLAB_FILEPATH + \"87837.txt\"\n","filepath_20 = COLAB_FILEPATH + \"PracticalAdvancesChapter1aspublished.txt\""],"execution_count":2,"outputs":[]},{"cell_type":"markdown","metadata":{"id":"fc55SbNgw45N"},"source":["### NLP Dataset"]},{"cell_type":"code","metadata":{"id":"OSez3fnS1IDR","executionInfo":{"status":"ok","timestamp":1604211958326,"user_tz":-480,"elapsed":827,"user":{"displayName":"Nicholas Neo","photoUrl":"","userId":"02359484661843204503"}}},"source":["#Set file path to nlp dataset\n","COLAB_FILEPATH = './drive/My Drive/4045-assignment-1/data/nlp/'\n","filepath_1 = COLAB_FILEPATH + \"tacl_a_00254.txt\"\n","filepath_2 = COLAB_FILEPATH + \"strathprints002611.txt\"\n","filepath_3 = COLAB_FILEPATH + \"NLP4RE_paper13.txt\"\n","filepath_4 = COLAB_FILEPATH + \"NLP.web.txt\"\n","filepath_5 = COLAB_FILEPATH + \"neural_transfer_learning_for_nlp.txt\"\n","filepath_6 = COLAB_FILEPATH + \"Natural_Language_Processing.txt\"\n","filepath_7 = COLAB_FILEPATH + \"Natural_Language_Processing_State_of_The_Art_Curre.txt\"\n","filepath_8 = COLAB_FILEPATH + \"Natural Language Processing.txt\"\n","filepath_9 = COLAB_FILEPATH + \"jumping-nlp-curves.txt\"\n","filepath_10 = COLAB_FILEPATH + \"H89-2078.txt\"\n","filepath_11 = COLAB_FILEPATH + \"document.txt\"\n","filepath_12 = COLAB_FILEPATH + \"Dialnet-TextAnalyticsTheConvergenceOfBigDataAndArtificialI-5573981.txt\"\n","filepath_13 = COLAB_FILEPATH + \"advances.txt\"\n","filepath_14 = COLAB_FILEPATH + \"35671.txt\"\n","filepath_15 = COLAB_FILEPATH + \"7181-attention-is-all-you-need.txt\"\n","filepath_16 = COLAB_FILEPATH + \"1708.05148.txt\"\n","filepath_17 = COLAB_FILEPATH + \"18-5-544.txt\"\n","filepath_18 = COLAB_FILEPATH + \"17vol3no1.txt\"\n","filepath_19 = COLAB_FILEPATH + \"10.1.1.98.6002.txt\"\n","filepath_20 = COLAB_FILEPATH + \"07bookchapter-biomed-IE.txt\""],"execution_count":3,"outputs":[]},{"cell_type":"code","metadata":{"id":"Iw8zA-Ro_Bgy","executionInfo":{"status":"ok","timestamp":1604211962210,"user_tz":-480,"elapsed":1080,"user":{"displayName":"Nicholas Neo","photoUrl":"","userId":"02359484661843204503"}}},"source":["# Open function to open the file \".txt\"\n","file1 = open(filepath_1,\"r\")\n","file2 = open(filepath_2,\"r\")\n","file3 = open(filepath_3,\"r\")\n","file4 = open(filepath_4,\"r\")\n","file5 = open(filepath_5,\"r\")\n","file6 = open(filepath_6,\"r\")\n","file7 = open(filepath_7,\"r\")\n","file8 = open(filepath_8,\"r\")\n","file9 = open(filepath_9,\"r\")\n","file10 = open(filepath_10,\"r\")\n","file11 = open(filepath_11,\"r\")\n","file12 = open(filepath_12,\"r\")\n","file13 = open(filepath_13,\"r\")\n","file14 = open(filepath_14,\"r\")\n","file15 = open(filepath_15,\"r\")\n","file16 = open(filepath_16,\"r\")\n","file17 = open(filepath_17,\"r\")\n","file18 = open(filepath_18,\"r\")\n","file19 = open(filepath_19,\"r\")\n","file20 = open(filepath_20,\"r\")"],"execution_count":4,"outputs":[]},{"cell_type":"code","metadata":{"id":"Q2Y4K1GXVjtR","executionInfo":{"status":"ok","timestamp":1604211966240,"user_tz":-480,"elapsed":1816,"user":{"displayName":"Nicholas Neo","photoUrl":"","userId":"02359484661843204503"}},"outputId":"881e2235-c5eb-4cca-aa9d-e6fc9b9ae12e","colab":{"base_uri":"https://localhost:8080/"}},"source":["#Import NLTK\n","import nltk \n","nltk.download('stopwords')\n","from nltk.corpus import stopwords \n","from nltk.tokenize import word_tokenize, sent_tokenize, RegexpTokenizer\n","stop_words = set(stopwords.words('english')) \n","nltk.download('punkt')\n","nltk.download('averaged_perceptron_tagger')\n","from nltk.stem.porter import PorterStemmer\n","import matplotlib.pyplot as plt\n","import random"],"execution_count":5,"outputs":[{"output_type":"stream","text":["[nltk_data] Downloading package stopwords to /root/nltk_data...\n","[nltk_data]   Package stopwords is already up-to-date!\n","[nltk_data] Downloading package punkt to /root/nltk_data...\n","[nltk_data]   Package punkt is already up-to-date!\n","[nltk_data] Downloading package averaged_perceptron_tagger to\n","[nltk_data]     /root/nltk_data...\n","[nltk_data]   Package averaged_perceptron_tagger is already up-to-\n","[nltk_data]       date!\n"],"name":"stdout"}]},{"cell_type":"code","metadata":{"id":"HoDdIhVieLqs","executionInfo":{"status":"ok","timestamp":1604211974912,"user_tz":-480,"elapsed":7455,"user":{"displayName":"Nicholas Neo","photoUrl":"","userId":"02359484661843204503"}}},"source":["#Store files\n","files = list()\n","files.append(file1.read())\n","files.append(file2.read())\n","files.append(file3.read())\n","files.append(file4.read())\n","files.append(file5.read())\n","files.append(file6.read())\n","files.append(file7.read())\n","files.append(file8.read())\n","files.append(file9.read())\n","files.append(file10.read())\n","files.append(file11.read())\n","files.append(file12.read())\n","files.append(file13.read())\n","files.append(file14.read())\n","files.append(file15.read())\n","files.append(file16.read())\n","files.append(file17.read())\n","files.append(file18.read())\n","files.append(file19.read())\n","files.append(file20.read())"],"execution_count":6,"outputs":[]},{"cell_type":"code","metadata":{"id":"GJr9Pr0fV_xH","executionInfo":{"status":"ok","timestamp":1604211981439,"user_tz":-480,"elapsed":754,"user":{"displayName":"Nicholas Neo","photoUrl":"","userId":"02359484661843204503"}}},"source":["def tokenize_library(txt_files):\n","  #Create a token library\n","  token_library = {}\n","  #Set tokenizer to only regex words\n","  tokenizer = RegexpTokenizer(r'\\w+')\n","  #Loop for each file\n","  for i in txt_files:\n","    #Tokenization into words\n","    tokenized = tokenizer.tokenize(i.lower())\n","    #Loop for each token\n","    for j in tokenized:\n","      if j.isdigit():\n","        #If j is a number, ignore\n","        pass\n","      else:\n","        #If token not in library\n","        if j.lower() not in token_library and j.lower() not in stop_words:\n","          #Add 1 to dictionary\n","          token_library[j.lower()] = 1\n","        elif j.lower() not in stop_words:\n","          #Add 1 to dictionary\n","          token_library[j.lower()] += 1\n","  sorted_dict = dict( sorted(token_library.items(),\n","                          key=lambda item: item[1],\n","                          reverse=True))\n","  return sorted_dict"],"execution_count":7,"outputs":[]},{"cell_type":"code","metadata":{"id":"AH-5UIMVYBxP","executionInfo":{"status":"ok","timestamp":1604211984277,"user_tz":-480,"elapsed":762,"user":{"displayName":"Nicholas Neo","photoUrl":"","userId":"02359484661843204503"}}},"source":["#Get count of tokens in library\n","tokens_lib = tokenize_library(files)"],"execution_count":8,"outputs":[]},{"cell_type":"code","metadata":{"id":"dqUt-1dblhbX","executionInfo":{"status":"ok","timestamp":1604211986686,"user_tz":-480,"elapsed":791,"user":{"displayName":"Nicholas Neo","photoUrl":"","userId":"02359484661843204503"}},"outputId":"5d634658-8792-4f93-f57d-8226db02a283","colab":{"base_uri":"https://localhost:8080/"}},"source":["tokens_lib"],"execution_count":9,"outputs":[{"output_type":"execute_result","data":{"text/plain":["{'language': 1792,\n"," 'learning': 1623,\n"," 'et': 1512,\n"," 'al': 1512,\n"," 'data': 1072,\n"," 'task': 1064,\n"," 'information': 1051,\n"," 'model': 1034,\n"," 'text': 1018,\n"," 'word': 973,\n"," 'nlp': 934,\n"," 'j': 883,\n"," 'tasks': 848,\n"," 'natural': 841,\n"," 'processing': 788,\n"," 'p': 718,\n"," 'e': 682,\n"," 'proceedings': 676,\n"," 'domain': 672,\n"," 'based': 658,\n"," 'models': 644,\n"," 'x': 630,\n"," 'using': 622,\n"," 'words': 616,\n"," 'used': 612,\n"," 'systems': 608,\n"," 'training': 598,\n"," 'use': 585,\n"," 'neural': 556,\n"," 'c': 541,\n"," 'machine': 528,\n"," 'methods': 504,\n"," 'r': 484,\n"," 'knowledge': 480,\n"," 'research': 475,\n"," 'computational': 475,\n"," 'g': 471,\n"," 'different': 462,\n"," 'sentence': 461,\n"," 'system': 460,\n"," 'n': 460,\n"," 'also': 459,\n"," 'one': 455,\n"," 'approaches': 443,\n"," 'analysis': 435,\n"," 'conference': 426,\n"," 'k': 426,\n"," 'multi': 423,\n"," 'l': 421,\n"," 'linguistics': 417,\n"," 'transfer': 415,\n"," 'two': 402,\n"," 'representations': 384,\n"," 'speech': 383,\n"," 'translation': 378,\n"," 'b': 376,\n"," 'pages': 376,\n"," 'target': 373,\n"," 'networks': 365,\n"," 'association': 364,\n"," 'work': 346,\n"," 'cross': 340,\n"," 'h': 340,\n"," 'w': 335,\n"," 'set': 334,\n"," 'performance': 332,\n"," 'approach': 330,\n"," 'semantic': 321,\n"," 'features': 318,\n"," 'may': 318,\n"," 'source': 308,\n"," 'languages': 304,\n"," 'embeddings': 303,\n"," 'level': 303,\n"," 'network': 302,\n"," 'results': 302,\n"," 'number': 292,\n"," 'adaptation': 286,\n"," 'extraction': 283,\n"," 'representation': 282,\n"," 'example': 280,\n"," 'human': 280,\n"," 'pp': 277,\n"," 'large': 276,\n"," 'f': 269,\n"," 'first': 267,\n"," 'examples': 267,\n"," 'international': 260,\n"," 'new': 255,\n"," 'state': 249,\n"," 'similar': 247,\n"," 'evaluation': 246,\n"," 'lingual': 243,\n"," 'classification': 242,\n"," 'specific': 240,\n"," 'many': 239,\n"," 'supervised': 236,\n"," 'input': 235,\n"," 'domains': 234,\n"," 'table': 231,\n"," 'english': 230,\n"," 'parameters': 230,\n"," 'feature': 228,\n"," 'layer': 227,\n"," 'similarity': 226,\n"," 'sentiment': 225,\n"," 'computer': 223,\n"," 'well': 223,\n"," 'learn': 220,\n"," 'layers': 218,\n"," 'method': 218,\n"," 'fine': 217,\n"," 'recognition': 217,\n"," 'techniques': 214,\n"," 'medical': 213,\n"," 'output': 212,\n"," 'embedding': 211,\n"," 'retrieval': 211,\n"," 'θ': 208,\n"," 'available': 206,\n"," 'propose': 206,\n"," 'http': 205,\n"," 'sequence': 204,\n"," 'unsupervised': 203,\n"," 'applications': 202,\n"," 'given': 202,\n"," 'however': 200,\n"," 'statistical': 199,\n"," 'pos': 199,\n"," 'document': 195,\n"," 'v': 191,\n"," 'section': 191,\n"," 'deep': 190,\n"," 'common': 189,\n"," 'trained': 188,\n"," 'technology': 188,\n"," 'clinical': 188,\n"," 'order': 187,\n"," 'time': 187,\n"," 'related': 186,\n"," 'across': 184,\n"," 'understanding': 181,\n"," 'user': 181,\n"," 'linguistic': 178,\n"," 'arxiv': 178,\n"," 'full': 176,\n"," 'science': 173,\n"," 'tagging': 173,\n"," 'sentences': 171,\n"," 'automatic': 170,\n"," 'probability': 169,\n"," 'documents': 169,\n"," 'review': 165,\n"," 'tuning': 164,\n"," 'part': 163,\n"," 'papers': 163,\n"," 'intelligence': 162,\n"," 'figure': 162,\n"," 'parsing': 161,\n"," 'distribution': 161,\n"," 'meaning': 161,\n"," 'web': 161,\n"," 'multiple': 161,\n"," 'annual': 159,\n"," 'several': 158,\n"," 'algorithm': 158,\n"," 'mt': 156,\n"," 'structure': 155,\n"," 'corpus': 154,\n"," 'particular': 153,\n"," 'matrix': 152,\n"," 'attention': 151,\n"," 'art': 151,\n"," 'term': 150,\n"," 'bilingual': 150,\n"," 'function': 149,\n"," 'free': 148,\n"," 'case': 147,\n"," 'ieee': 147,\n"," 'topic': 146,\n"," 'mining': 145,\n"," 'process': 144,\n"," 'label': 143,\n"," 'sharing': 143,\n"," 'auxiliary': 141,\n"," 'see': 140,\n"," 'form': 138,\n"," 'application': 138,\n"," 'general': 137,\n"," 'often': 136,\n"," 'vol': 136,\n"," 'tri': 136,\n"," 'sets': 135,\n"," 'following': 135,\n"," 'recent': 134,\n"," 'volume': 134,\n"," 'question': 133,\n"," 'context': 133,\n"," 'www': 133,\n"," 'datasets': 133,\n"," 'another': 131,\n"," 'useful': 131,\n"," 'like': 130,\n"," 'syntactic': 130,\n"," 'online': 130,\n"," 'development': 130,\n"," 'problem': 130,\n"," 'doi': 130,\n"," 'medline': 130,\n"," 'thus': 129,\n"," 'test': 129,\n"," 'main': 129,\n"," 'terms': 129,\n"," 'experiments': 129,\n"," 'artificial': 128,\n"," 'three': 128,\n"," 'simple': 128,\n"," 'learned': 127,\n"," 'journal': 127,\n"," 'tools': 126,\n"," 'single': 126,\n"," 'algorithms': 126,\n"," 'better': 125,\n"," 'vector': 125,\n"," 'chapter': 125,\n"," 'texts': 125,\n"," 'pretrained': 125,\n"," 'meeting': 123,\n"," 'show': 123,\n"," 'lexical': 122,\n"," 'space': 122,\n"," 'best': 122,\n"," 'typically': 121,\n"," 'hidden': 121,\n"," 'levels': 121,\n"," 'dictionary': 121,\n"," 'inform': 121,\n"," 'much': 120,\n"," 'various': 120,\n"," 'empirical': 120,\n"," 'alignment': 120,\n"," 'linear': 119,\n"," 'summarization': 119,\n"," 'previous': 119,\n"," 'would': 119,\n"," 'within': 119,\n"," 'known': 117,\n"," 'corpora': 117,\n"," 'world': 117,\n"," 'random': 116,\n"," 'high': 115,\n"," 'discourse': 115,\n"," 'important': 114,\n"," 'uses': 114,\n"," 'provide': 114,\n"," 'rules': 113,\n"," 'literature': 113,\n"," 'long': 113,\n"," 'architecture': 113,\n"," 'way': 113,\n"," 'challenge': 112,\n"," 'generation': 112,\n"," 'report': 112,\n"," 'selection': 112,\n"," 'train': 112,\n"," 'current': 110,\n"," 'latent': 109,\n"," 'z': 109,\n"," 'database': 109,\n"," 'parameter': 109,\n"," 'could': 108,\n"," 'ner': 108,\n"," 'joint': 107,\n"," 'even': 107,\n"," 'search': 107,\n"," 'engineering': 106,\n"," 'negative': 106,\n"," 'semi': 106,\n"," 'monolingual': 106,\n"," 'field': 105,\n"," 'small': 105,\n"," 'second': 105,\n"," 'self': 105,\n"," 'pretraining': 105,\n"," 'etc': 104,\n"," 'proposed': 104,\n"," 'including': 104,\n"," 'rather': 104,\n"," 'management': 103,\n"," 'types': 103,\n"," 'concepts': 102,\n"," 'values': 102,\n"," 'semantics': 102,\n"," 'mtl': 102,\n"," 'need': 101,\n"," 'error': 101,\n"," 'support': 100,\n"," 'low': 100,\n"," 'possible': 100,\n"," 'university': 100,\n"," 'researchers': 99,\n"," 'adversarial': 99,\n"," 'sense': 99,\n"," 'q': 99,\n"," 'multilingual': 98,\n"," 'since': 98,\n"," 'identify': 98,\n"," 'lexicon': 98,\n"," 'whether': 97,\n"," 'tags': 97,\n"," 'phrase': 97,\n"," 'sequential': 97,\n"," 'trec': 97,\n"," 'acl': 96,\n"," 'studies': 95,\n"," 'include': 95,\n"," 'make': 95,\n"," 'accuracy': 95,\n"," 'chen': 95,\n"," 'shared': 95,\n"," 'automatically': 95,\n"," 'articles': 95,\n"," 'med': 95,\n"," 'relevant': 94,\n"," 'detection': 94,\n"," 'type': 94,\n"," 'entity': 94,\n"," 'role': 93,\n"," 'query': 92,\n"," 'modeling': 91,\n"," 'without': 91,\n"," 'zhang': 91,\n"," 'scale': 91,\n"," 'non': 91,\n"," 'tag': 91,\n"," 'ie': 91,\n"," 'able': 90,\n"," 'american': 90,\n"," 'org': 90,\n"," 'project': 90,\n"," 'future': 89,\n"," 'finally': 89,\n"," 'requires': 89,\n"," 'problems': 89,\n"," 'søgaard': 89,\n"," 'existing': 88,\n"," 'prediction': 88,\n"," 'parallel': 88,\n"," 'perform': 88,\n"," 'labels': 88,\n"," 'preprint': 88,\n"," 'press': 88,\n"," 'addition': 88,\n"," 'ed': 88,\n"," 'regularization': 88,\n"," 'loss': 87,\n"," 'reports': 87,\n"," 'applied': 86,\n"," 'introduction': 86,\n"," 'next': 86,\n"," 'found': 86,\n"," 'log': 86,\n"," 'li': 85,\n"," 'framework': 85,\n"," 'rule': 85,\n"," 'software': 85,\n"," 'called': 85,\n"," 'patterns': 85,\n"," 'experimental': 85,\n"," 'relations': 84,\n"," '2018a': 84,\n"," 'require': 84,\n"," 'base': 84,\n"," 'end': 83,\n"," 'pairs': 83,\n"," 'defined': 83,\n"," 'inference': 83,\n"," 'study': 83,\n"," 'advances': 83,\n"," 'complex': 83,\n"," 'intelligent': 83,\n"," 'additional': 83,\n"," 'theory': 82,\n"," 'weights': 82,\n"," 'might': 82,\n"," 'ruder': 82,\n"," 'instance': 81,\n"," 'still': 81,\n"," 'acm': 81,\n"," 'seen': 80,\n"," 'com': 80,\n"," 'recurrent': 80,\n"," 'find': 80,\n"," 'every': 80,\n"," 'disease': 80,\n"," 'cases': 79,\n"," 'developed': 79,\n"," 'answering': 79,\n"," 'area': 79,\n"," 'us': 79,\n"," 'wang': 79,\n"," 'phrases': 79,\n"," 'named': 79,\n"," 'notes': 79,\n"," 'novel': 78,\n"," 'present': 78,\n"," 'resources': 78,\n"," 'last': 78,\n"," 'impact': 78,\n"," 'step': 78,\n"," 'evaluate': 77,\n"," 'classifier': 77,\n"," 'provides': 77,\n"," 'years': 76,\n"," 'describe': 76,\n"," 'liu': 76,\n"," 'help': 76,\n"," 'setting': 76,\n"," 'distance': 75,\n"," 'optimization': 75,\n"," 'workshop': 75,\n"," 'shown': 75,\n"," 'variable': 75,\n"," 'focused': 74,\n"," 'predictions': 74,\n"," 'generally': 74,\n"," 'standard': 74,\n"," 'mean': 74,\n"," 'less': 74,\n"," 'score': 74,\n"," 'universal': 74,\n"," 'jointly': 74,\n"," 'rate': 74,\n"," 'graph': 74,\n"," 'en': 74,\n"," 'diseases': 74,\n"," 'compared': 73,\n"," 'vectors': 73,\n"," 'parts': 73,\n"," 'via': 73,\n"," 'noun': 73,\n"," 'individual': 73,\n"," 'range': 73,\n"," 'obtain': 73,\n"," 'functions': 73,\n"," 'induction': 73,\n"," 'labeling': 73,\n"," 'conditional': 73,\n"," 'technologies': 72,\n"," 'extract': 72,\n"," 'community': 71,\n"," 'size': 71,\n"," 'focus': 71,\n"," 'dataset': 71,\n"," 'access': 71,\n"," 'diversity': 71,\n"," 'electronic': 71,\n"," 'major': 71,\n"," 'structured': 71,\n"," 'instead': 71,\n"," 'become': 70,\n"," 'key': 70,\n"," 'bayesian': 70,\n"," 'objective': 70,\n"," 'ω': 70,\n"," 'translations': 69,\n"," 'social': 69,\n"," 'content': 69,\n"," 'prior': 69,\n"," 'ex': 69,\n"," 'corresponding': 68,\n"," 'improved': 68,\n"," 'matching': 68,\n"," 'u': 68,\n"," 'dependency': 68,\n"," 'informatics': 68,\n"," 'top': 68,\n"," 'reviews': 67,\n"," 'quality': 67,\n"," 'measures': 67,\n"," 'hard': 67,\n"," 'issues': 67,\n"," 'higher': 67,\n"," 'aligned': 67,\n"," 'records': 67,\n"," 'architectures': 66,\n"," 'identifying': 66,\n"," 'memory': 66,\n"," 'lstm': 66,\n"," 'fields': 66,\n"," 'google': 66,\n"," 'ai': 66,\n"," 'digital': 66,\n"," 'labeled': 66,\n"," 'gradient': 66,\n"," 'german': 65,\n"," 'compare': 65,\n"," 'categorization': 65,\n"," 'extracting': 65,\n"," 'max': 65,\n"," 'bias': 65,\n"," 'product': 65,\n"," 'chunking': 65,\n"," 'srl': 65,\n"," 'jmir': 65,\n"," 'classifiers': 64,\n"," 'early': 64,\n"," 'co': 64,\n"," 'biomedical': 64,\n"," 'usually': 63,\n"," 'paper': 63,\n"," 'textual': 63,\n"," 'works': 63,\n"," 'summary': 63,\n"," 'requirements': 63,\n"," 'relationships': 63,\n"," 'distributions': 63,\n"," 'discriminative': 63,\n"," 'humans': 62,\n"," 'categories': 62,\n"," 'goldberg': 62,\n"," 'contrast': 62,\n"," 'predict': 62,\n"," 'artetxe': 62,\n"," 'positive': 62,\n"," 'users': 62,\n"," 'open': 62,\n"," 'group': 62,\n"," 'ir': 62,\n"," 'must': 62,\n"," 'made': 62,\n"," 'spaces': 62,\n"," 'understand': 61,\n"," 'limited': 61,\n"," 'verb': 61,\n"," 'syntax': 61,\n"," 'required': 61,\n"," 'ability': 61,\n"," 'analytics': 61,\n"," 'good': 61,\n"," 'grammar': 61,\n"," 'real': 61,\n"," 'challenges': 61,\n"," 'edu': 60,\n"," 'past': 60,\n"," 'goal': 60,\n"," 'respectively': 60,\n"," 'measure': 60,\n"," 'mapping': 60,\n"," 'society': 60,\n"," 'dialogue': 60,\n"," 'fact': 60,\n"," 'databases': 60,\n"," 'lm': 60,\n"," 'health': 60,\n"," 'α': 60,\n"," 'note': 59,\n"," 'annotated': 59,\n"," 'short': 59,\n"," 'improve': 59,\n"," 'appropriate': 59,\n"," 'areas': 59,\n"," 'projects': 59,\n"," 'among': 59,\n"," 'news': 59,\n"," 'efficient': 59,\n"," 'event': 59,\n"," 'variables': 59,\n"," 'evaluating': 58,\n"," 'computing': 58,\n"," 'vision': 58,\n"," 'supervision': 58,\n"," 'wide': 58,\n"," 'aaai': 58,\n"," 'means': 58,\n"," 'concept': 58,\n"," 'building': 58,\n"," 'per': 58,\n"," 'selecting': 58,\n"," 'value': 58,\n"," 'xi': 58,\n"," 'constraint': 58,\n"," 'difficult': 57,\n"," 'view': 57,\n"," 'either': 57,\n"," 'vocabulary': 57,\n"," 'metric': 57,\n"," 'allows': 57,\n"," 'pair': 57,\n"," 'almost': 57,\n"," 'xt': 57,\n"," 'according': 56,\n"," 'point': 56,\n"," 'states': 56,\n"," 'reading': 56,\n"," 'practice': 56,\n"," 'yang': 56,\n"," 'people': 56,\n"," 'provided': 56,\n"," 'items': 56,\n"," 'scientific': 56,\n"," 'entities': 56,\n"," 'comparison': 56,\n"," 'meta': 56,\n"," 'apply': 55,\n"," 'accessed': 55,\n"," 'certain': 55,\n"," 'learns': 55,\n"," 'interest': 55,\n"," 'consists': 55,\n"," 'class': 55,\n"," 'pattern': 55,\n"," 'overview': 55,\n"," 'medicine': 55,\n"," 'independent': 55,\n"," 'discovery': 55,\n"," 'pre': 55,\n"," 'html': 55,\n"," 'together': 55,\n"," 'hlt': 55,\n"," 'morphological': 54,\n"," 'properties': 54,\n"," 'structures': 54,\n"," 'components': 54,\n"," 'image': 54,\n"," 'tool': 54,\n"," 'although': 54,\n"," 'gram': 54,\n"," 'resource': 54,\n"," 'bibliography': 54,\n"," 'parse': 54,\n"," 'cancer': 54,\n"," 'manning': 53,\n"," 'lower': 53,\n"," 'tree': 53,\n"," 'conneau': 53,\n"," 'aspects': 53,\n"," 'huang': 53,\n"," 'conll': 53,\n"," 'thesis': 53,\n"," 'de': 53,\n"," 'allow': 53,\n"," 'dependent': 53,\n"," 'heart': 53,\n"," 'mit': 52,\n"," 'cambridge': 52,\n"," 'others': 52,\n"," 'obtained': 52,\n"," 'acquisition': 52,\n"," 'phenomena': 52,\n"," 'directly': 52,\n"," 'reported': 52,\n"," 'questions': 52,\n"," 'far': 52,\n"," 'average': 52,\n"," 'extracted': 52,\n"," 'van': 52,\n"," 'effective': 52,\n"," 'disambiguation': 52,\n"," 'big': 52,\n"," 'naacl': 52,\n"," 'july': 52,\n"," 'entropy': 52,\n"," 'units': 51,\n"," 'capture': 51,\n"," 'significant': 51,\n"," 'media': 51,\n"," 'benchmark': 51,\n"," 'follows': 51,\n"," 'due': 51,\n"," 'emnlp': 51,\n"," 'produce': 51,\n"," 'issue': 51,\n"," 'sources': 51,\n"," 'particularly': 51,\n"," 'queries': 51,\n"," 'combination': 51,\n"," 'enable': 51,\n"," 'classic': 51,\n"," 'unlabeled': 51,\n"," 'smith': 50,\n"," 'consider': 50,\n"," 'https': 50,\n"," 'regression': 50,\n"," 'recently': 50,\n"," 'take': 50,\n"," 'interfaces': 50,\n"," 'national': 50,\n"," 'determine': 50,\n"," 'experiment': 50,\n"," 'statistics': 50,\n"," 'parser': 50,\n"," 'scenarios': 50,\n"," 'therefore': 50,\n"," 'instances': 50,\n"," 'softmax': 50,\n"," 'pseudo': 50,\n"," 'basic': 49,\n"," 'share': 49,\n"," 'four': 49,\n"," 'metrics': 49,\n"," 'shift': 49,\n"," 'article': 49,\n"," 'similarly': 49,\n"," 'design': 49,\n"," 'conceptual': 49,\n"," 'ontology': 49,\n"," 'springer': 49,\n"," 'validation': 49,\n"," 'adapting': 49,\n"," 'divergence': 49,\n"," 'generalization': 48,\n"," 'result': 48,\n"," 'weight': 48,\n"," 'scores': 48,\n"," 'likely': 48,\n"," 'weakly': 48,\n"," 'presented': 48,\n"," 'practical': 48,\n"," 'library': 48,\n"," 'comparable': 48,\n"," 'necessary': 48,\n"," 'person': 48,\n"," 'achieve': 48,\n"," 'identification': 48,\n"," 'patient': 48,\n"," 'seed': 48,\n"," 'scratch': 48,\n"," 't1': 48,\n"," 'proc': 48,\n"," 'traditional': 47,\n"," 'length': 47,\n"," 'hierarchical': 47,\n"," 'making': 47,\n"," 'hand': 47,\n"," 'compute': 47,\n"," 'forms': 47,\n"," 'separate': 47,\n"," 'written': 47,\n"," 'deal': 47,\n"," 'topics': 47,\n"," 'program': 47,\n"," 'diverse': 46,\n"," 'convolutional': 46,\n"," 'logic': 46,\n"," 'generate': 46,\n"," 'done': 46,\n"," 'towards': 46,\n"," 'track': 46,\n"," 'grammars': 46,\n"," 'reasoning': 46,\n"," 'symbolic': 46,\n"," 'purpose': 46,\n"," 'strong': 46,\n"," 'baseline': 46,\n"," 'wi': 46,\n"," 'plank': 46,\n"," 'limitations': 45,\n"," 'amount': 45,\n"," 'represent': 45,\n"," 'commonly': 45,\n"," 'involves': 45,\n"," 'makes': 45,\n"," 'baselines': 45,\n"," 'special': 45,\n"," 'discussed': 45,\n"," 'decision': 45,\n"," 'events': 45,\n"," 'pdf': 45,\n"," 'nearest': 45,\n"," 'bert': 45,\n"," 'ft': 45,\n"," 'f1': 45,\n"," 'xs': 45,\n"," 'risk': 45,\n"," 'care': 45,\n"," 'progress': 44,\n"," 'today': 44,\n"," 'already': 44,\n"," 'original': 44,\n"," 'aspect': 44,\n"," 'evaluated': 44,\n"," 'annotation': 44,\n"," 'robust': 44,\n"," 'right': 44,\n"," 'interface': 44,\n"," 'build': 44,\n"," 'achieved': 44,\n"," 'contains': 44,\n"," 'interaction': 44,\n"," 'inductive': 44,\n"," 'eds': 44,\n"," 'previously': 44,\n"," 'settings': 44,\n"," 'outputs': 44,\n"," 'ti': 44,\n"," 'ltn': 44,\n"," 'chronic': 44,\n"," 'larger': 43,\n"," 'discuss': 43,\n"," 'frequent': 43,\n"," 'correct': 43,\n"," 'european': 43,\n"," 'respect': 43,\n"," 'described': 43,\n"," 'iclr': 43,\n"," 'select': 43,\n"," 'maximum': 43,\n"," 'true': 43,\n"," 'labelling': 43,\n"," 'sluice': 43,\n"," 'window': 43,\n"," 'chunk': 43,\n"," 'assoc': 43,\n"," 'needs': 42,\n"," 'distributed': 42,\n"," 'generated': 42,\n"," 'french': 42,\n"," 'nature': 42,\n"," 'widely': 42,\n"," 'tokens': 42,\n"," 'adapt': 42,\n"," 'considered': 42,\n"," 'page': 42,\n"," 'ambiguity': 42,\n"," 'computers': 42,\n"," 'expert': 42,\n"," 'groups': 42,\n"," 'sub': 42,\n"," 'legal': 42,\n"," 'cost': 42,\n"," 'active': 42,\n"," 'times': 42,\n"," 'outperforms': 42,\n"," 'sum': 42,\n"," 'patients': 42,\n"," 'analyzing': 41,\n"," 'mikolov': 41,\n"," 'predicting': 41,\n"," 'takes': 41,\n"," 'aims': 41,\n"," 'criteria': 41,\n"," 'difference': 41,\n"," 'idea': 41,\n"," 'frequency': 41,\n"," 'generative': 41,\n"," 'performed': 41,\n"," 'bengio': 41,\n"," 'north': 41,\n"," 'signal': 41,\n"," 'iii': 41,\n"," 'reference': 41,\n"," 'performs': 41,\n"," 'background': 41,\n"," 'skip': 41,\n"," 'graphs': 41,\n"," 'nn': 41,\n"," 'th': 41,\n"," 'pt': 41,\n"," 'kim': 40,\n"," 'published': 40,\n"," 'beyond': 40,\n"," 'primary': 40,\n"," 'finding': 40,\n"," 'computed': 40,\n"," 'encoder': 40,\n"," 'authors': 40,\n"," 'theoretical': 40,\n"," 'place': 40,\n"," 'grammatical': 40,\n"," 'develop': 40,\n"," 'define': 40,\n"," 'associated': 40,\n"," 'norm': 40,\n"," 'lee': 40,\n"," 'capabilities': 40,\n"," 'connectionist': 40,\n"," 'sparse': 40,\n"," 'efforts': 40,\n"," 'spanish': 40,\n"," 'get': 40,\n"," 'keywords': 40,\n"," 'relation': 40,\n"," 'probabilities': 40,\n"," 'machines': 39,\n"," 'resolution': 39,\n"," 'wu': 39,\n"," 'specifically': 39,\n"," 'underlying': 39,\n"," 'ibm': 39,\n"," 'decoder': 39,\n"," 'synthesis': 39,\n"," 'vulic': 39,\n"," 'dictionaries': 39,\n"," 'wordnet': 39,\n"," 'segmentation': 39,\n"," 'shallow': 39,\n"," 'reason': 39,\n"," 'ca': 39,\n"," 'left': 39,\n"," 'ps': 39,\n"," 'e12239': 39,\n"," 'survey': 38,\n"," 'ways': 38,\n"," 'back': 38,\n"," 'clustering': 38,\n"," 'references': 38,\n"," 'generating': 38,\n"," 'speaker': 38,\n"," 'correlation': 38,\n"," 'applying': 38,\n"," 'overall': 38,\n"," 'interpretation': 38,\n"," 'adding': 38,\n"," 'mainly': 38,\n"," 'differences': 38,\n"," 'throughout': 38,\n"," 'communication': 38,\n"," 'address': 38,\n"," 'environment': 38,\n"," 'internet': 38,\n"," 'complete': 38,\n"," 'answer': 38,\n"," 'around': 38,\n"," 'rates': 38,\n"," 'dec': 38,\n"," 'simply': 38,\n"," 'sampling': 38,\n"," 'unlabelled': 38,\n"," 'transactions': 37,\n"," 'built': 37,\n"," 'version': 37,\n"," 'relatively': 37,\n"," 'encoding': 37,\n"," 'cannot': 37,\n"," 'filtering': 37,\n"," 'probabilistic': 37,\n"," 'create': 37,\n"," 'rely': 37,\n"," 'modelling': 37,\n"," 'abstracting': 37,\n"," 'working': 37,\n"," 'significantly': 37,\n"," 'employ': 37,\n"," 'likelihood': 37,\n"," 'crf': 37,\n"," 'ulmfit': 37,\n"," 'potential': 36,\n"," 'conditions': 36,\n"," 'concerned': 36,\n"," 'answers': 36,\n"," 'trees': 36,\n"," 'processes': 36,\n"," 'cognitive': 36,\n"," 'relationship': 36,\n"," 'le': 36,\n"," 'precision': 36,\n"," 'stanford': 36,\n"," 'combining': 36,\n"," 'facts': 36,\n"," 'qa': 36,\n"," 'basis': 36,\n"," 'phase': 36,\n"," 'stage': 36,\n"," 'sim': 36,\n"," 'choice': 36,\n"," 'hyper': 36,\n"," 'leverage': 36,\n"," 'bayes': 36,\n"," 'analyze': 35,\n"," 'subject': 35,\n"," 'importance': 35,\n"," 'trends': 35,\n"," 'aim': 35,\n"," 'dimensional': 35,\n"," 'variety': 35,\n"," 'visualization': 35,\n"," 'conclusion': 35,\n"," 'names': 35,\n"," 'minimize': 35,\n"," 'hypothesis': 35,\n"," 'zhou': 35,\n"," 'lexicons': 35,\n"," 'extend': 35,\n"," 'except': 35,\n"," 'symposium': 35,\n"," 'add': 35,\n"," 'lifelong': 35,\n"," 'elmo': 35,\n"," 'σ': 35,\n"," 'equation': 35,\n"," 'bi': 35,\n"," 'spam': 35,\n"," 'connections': 34,\n"," 'classes': 34,\n"," 'improvements': 34,\n"," 'position': 34,\n"," 'alignments': 34,\n"," 'selected': 34,\n"," 'control': 34,\n"," ...}"]},"metadata":{"tags":[]},"execution_count":9}]},{"cell_type":"code","metadata":{"id":"79tOT7zZnaIX","executionInfo":{"status":"ok","timestamp":1604211989143,"user_tz":-480,"elapsed":760,"user":{"displayName":"Nicholas Neo","photoUrl":"","userId":"02359484661843204503"}}},"source":["#Stemmer\n","porter_stemmer = PorterStemmer()"],"execution_count":10,"outputs":[]},{"cell_type":"code","metadata":{"id":"FymlwQn1uuuL","executionInfo":{"status":"ok","timestamp":1604211990906,"user_tz":-480,"elapsed":867,"user":{"displayName":"Nicholas Neo","photoUrl":"","userId":"02359484661843204503"}},"outputId":"c45dcf1c-bd0f-4814-e056-373961232cdf","colab":{"base_uri":"https://localhost:8080/"}},"source":["#Stemming\n","#Initialize new dict\n","stemm_dict = {}\n","#Loop for each item in dictionary\n","for w in tokens_lib:\n","  stemmed_w = porter_stemmer.stem(w)\n","  #print(\"Actual: %s  Stem: %s\"  % (w,porter_stemmer.stem(w)))\n","  if stemmed_w not in stemm_dict:\n","    stemm_dict[stemmed_w] = 1\n","  else:\n","    stemm_dict[stemmed_w] += 1\n","\n","stemm_dict = dict( sorted(stemm_dict.items(),\n","                           key=lambda item: item[1],\n","                           reverse=True))\n","stemm_dict"],"execution_count":11,"outputs":[{"output_type":"execute_result","data":{"text/plain":["{'gener': 21,\n"," 'comput': 12,\n"," 'initi': 12,\n"," 'adapt': 11,\n"," 'depend': 11,\n"," 'express': 10,\n"," 'organ': 10,\n"," 'formal': 10,\n"," 'translat': 9,\n"," 'regular': 9,\n"," 'compar': 9,\n"," 'commun': 9,\n"," 'design': 9,\n"," 'interpret': 9,\n"," 'continu': 9,\n"," 'transform': 9,\n"," 'deriv': 9,\n"," 'indic': 9,\n"," 'associ': 8,\n"," 'relat': 8,\n"," 'distribut': 8,\n"," 'develop': 8,\n"," 'annot': 8,\n"," 'separ': 8,\n"," 'origin': 8,\n"," 'activ': 8,\n"," 'visual': 8,\n"," 'connect': 8,\n"," 'collect': 8,\n"," 'observ': 8,\n"," 'oper': 8,\n"," 'normal': 8,\n"," 'maxim': 8,\n"," 'demonstr': 8,\n"," 'use': 7,\n"," 'differ': 7,\n"," 'transfer': 7,\n"," 'perform': 7,\n"," 'extract': 7,\n"," 'evalu': 7,\n"," 'structur': 7,\n"," 'align': 7,\n"," 'select': 7,\n"," 'predict': 7,\n"," 'present': 7,\n"," 'optim': 7,\n"," 'measur': 7,\n"," 'categor': 7,\n"," 'posit': 7,\n"," 'consist': 7,\n"," 'effect': 7,\n"," 'valid': 7,\n"," 'person': 7,\n"," 'repres': 7,\n"," 'special': 7,\n"," 'discuss': 7,\n"," 'interact': 7,\n"," 'encod': 7,\n"," 'correl': 7,\n"," 'minim': 7,\n"," 'estim': 7,\n"," 'factor': 7,\n"," 'construct': 7,\n"," 'success': 7,\n"," 'altern': 7,\n"," 'util': 7,\n"," 'replac': 7,\n"," 'approxim': 7,\n"," 'emerg': 7,\n"," 'accept': 7,\n"," 'particip': 7,\n"," 'differenti': 7,\n"," 'inform': 6,\n"," 'model': 6,\n"," 'natur': 6,\n"," 'retriev': 6,\n"," 'propos': 6,\n"," 'review': 6,\n"," 'label': 6,\n"," 'experi': 6,\n"," 'summar': 6,\n"," 'provid': 6,\n"," 'engin': 6,\n"," 'manag': 6,\n"," 'identifi': 6,\n"," 'project': 6,\n"," 'requir': 6,\n"," 'exist': 6,\n"," 'addit': 6,\n"," 'advanc': 6,\n"," 'classifi': 6,\n"," 'improv': 6,\n"," 'product': 6,\n"," 'limit': 6,\n"," 'practic': 6,\n"," 'combin': 6,\n"," 'enabl': 6,\n"," 'achiev': 6,\n"," 'correct': 6,\n"," 'token': 6,\n"," 'analyz': 6,\n"," 'refer': 6,\n"," 'publish': 6,\n"," 'author': 6,\n"," 'abstract': 6,\n"," 'subject': 6,\n"," 'implement': 6,\n"," 'suggest': 6,\n"," 'definit': 6,\n"," 'respons': 6,\n"," 'recogn': 6,\n"," 'margin': 6,\n"," 'assign': 6,\n"," 'denot': 6,\n"," 'exploit': 6,\n"," 'explor': 6,\n"," 'iter': 6,\n"," 'convers': 6,\n"," 'motiv': 6,\n"," 'calcul': 6,\n"," 'integr': 6,\n"," 'reflect': 6,\n"," 'modifi': 6,\n"," 'manipul': 6,\n"," 'edit': 6,\n"," 'examin': 6,\n"," 'research': 5,\n"," 'linguist': 5,\n"," 'target': 5,\n"," 'result': 5,\n"," 'intern': 5,\n"," 'specif': 5,\n"," 'understand': 5,\n"," 'function': 5,\n"," 'form': 5,\n"," 'tri': 5,\n"," 'empir': 5,\n"," 'challeng': 5,\n"," 'report': 5,\n"," 'univers': 5,\n"," 'phrase': 5,\n"," 'detect': 5,\n"," 'pair': 5,\n"," 'infer': 5,\n"," 'name': 5,\n"," 'help': 5,\n"," 'standard': 5,\n"," 'condit': 5,\n"," 'access': 5,\n"," 'correspond': 5,\n"," 'match': 5,\n"," 'discrimin': 5,\n"," 'map': 5,\n"," 'averag': 5,\n"," 'disambigu': 5,\n"," 'produc': 5,\n"," 'determin': 5,\n"," 'reason': 5,\n"," 'involv': 5,\n"," 'aim': 5,\n"," 'segment': 5,\n"," 'cluster': 5,\n"," 'address': 5,\n"," 'employ': 5,\n"," 'control': 5,\n"," 'analys': 5,\n"," 'direct': 5,\n"," 'index': 5,\n"," 'contribut': 5,\n"," 'occur': 5,\n"," 'investig': 5,\n"," 'restrict': 5,\n"," 'mention': 5,\n"," 'chang': 5,\n"," 'facilit': 5,\n"," 'head': 5,\n"," 'locat': 5,\n"," 'download': 5,\n"," 'appear': 5,\n"," 'extens': 5,\n"," 'offer': 5,\n"," 'institut': 5,\n"," 'custom': 5,\n"," 'converg': 5,\n"," 'explain': 5,\n"," 'augment': 5,\n"," 'prefer': 5,\n"," 'establish': 5,\n"," 'mark': 5,\n"," 'attribut': 5,\n"," 'illustr': 5,\n"," 'influenc': 5,\n"," 'assist': 5,\n"," 'accomplish': 5,\n"," 'affect': 5,\n"," 'emphas': 5,\n"," 'incorpor': 5,\n"," 'fit': 5,\n"," 'compil': 5,\n"," 'reconstruct': 5,\n"," 'recommend': 5,\n"," 'collabor': 5,\n"," 'format': 5,\n"," 'realiz': 5,\n"," 'analog': 5,\n"," 'quantifi': 5,\n"," 'prepar': 5,\n"," 'adopt': 5,\n"," 'refin': 5,\n"," 'instruct': 5,\n"," 'execut': 5,\n"," 'acknowledg': 5,\n"," 'decompos': 5,\n"," 'confus': 5,\n"," 'notic': 5,\n"," 'domin': 5,\n"," 'assert': 5,\n"," 'simul': 5,\n"," 'color': 5,\n"," 'declar': 5,\n"," 'inspect': 5,\n"," 'termin': 5,\n"," 'learn': 4,\n"," 'process': 4,\n"," 'system': 4,\n"," 'train': 4,\n"," 'approach': 4,\n"," 'work': 4,\n"," 'set': 4,\n"," 'semant': 4,\n"," 'human': 4,\n"," 'state': 4,\n"," 'medic': 4,\n"," 'applic': 4,\n"," 'statist': 4,\n"," 'document': 4,\n"," 'common': 4,\n"," 'technolog': 4,\n"," 'order': 4,\n"," 'time': 4,\n"," 'tag': 4,\n"," 'probabl': 4,\n"," 'tune': 4,\n"," 'intellig': 4,\n"," 'figur': 4,\n"," 'pars': 4,\n"," 'mean': 4,\n"," 'topic': 4,\n"," 'mine': 4,\n"," 'share': 4,\n"," 'follow': 4,\n"," 'question': 4,\n"," 'syntact': 4,\n"," 'test': 4,\n"," 'pretrain': 4,\n"," 'meet': 4,\n"," 'show': 4,\n"," 'search': 4,\n"," 'includ': 4,\n"," 'type': 4,\n"," 'need': 4,\n"," 'support': 4,\n"," 'possibl': 4,\n"," 'adversari': 4,\n"," 'studi': 4,\n"," 'queri': 4,\n"," 'scale': 4,\n"," 'parallel': 4,\n"," 'appli': 4,\n"," 'end': 4,\n"," 'defin': 4,\n"," 'weight': 4,\n"," 'find': 4,\n"," 'answer': 4,\n"," 'note': 4,\n"," 'impact': 4,\n"," 'step': 4,\n"," 'describ': 4,\n"," 'score': 4,\n"," 'rate': 4,\n"," 'obtain': 4,\n"," 'object': 4,\n"," 'record': 4,\n"," 'contrast': 4,\n"," 'group': 4,\n"," 'respect': 4,\n"," 'appropri': 4,\n"," 'view': 4,\n"," 'allow': 4,\n"," 'point': 4,\n"," 'interest': 4,\n"," 'captur': 4,\n"," 'consid': 4,\n"," 'shift': 4,\n"," 'conceptu': 4,\n"," 'diverg': 4,\n"," 'tradit': 4,\n"," 'track': 4,\n"," 'purpos': 4,\n"," 'care': 4,\n"," 'progress': 4,\n"," 'contain': 4,\n"," 'outperform': 4,\n"," 'sum': 4,\n"," 'signal': 4,\n"," 'place': 4,\n"," 'decod': 4,\n"," 'ad': 4,\n"," 'complet': 4,\n"," 'sampl': 4,\n"," 'rel': 4,\n"," 'creat': 4,\n"," 'reli': 4,\n"," 'concern': 4,\n"," 'leverag': 4,\n"," 'extend': 4,\n"," 'except': 4,\n"," 'increas': 4,\n"," 'expect': 4,\n"," 'reduc': 4,\n"," 'rank': 4,\n"," 'introduc': 4,\n"," 'close': 4,\n"," 'notat': 4,\n"," 'evid': 4,\n"," 'store': 4,\n"," 'list': 4,\n"," 'link': 4,\n"," 'date': 4,\n"," 'autom': 4,\n"," 'assum': 4,\n"," 'turn': 4,\n"," 'look': 4,\n"," 'promis': 4,\n"," 'center': 4,\n"," 'dynam': 4,\n"," 'induc': 4,\n"," 'emot': 4,\n"," 'code': 4,\n"," 'attack': 4,\n"," 'lack': 4,\n"," 'consequ': 4,\n"," 'frame': 4,\n"," 'propag': 4,\n"," 'argument': 4,\n"," 'batch': 4,\n"," 'handl': 4,\n"," 'benefit': 4,\n"," 'composit': 4,\n"," 'character': 4,\n"," 'fund': 4,\n"," 'start': 4,\n"," 'updat': 4,\n"," 'ask': 4,\n"," 'comment': 4,\n"," 'variat': 4,\n"," 'reach': 4,\n"," 'formul': 4,\n"," 'equal': 4,\n"," 'yield': 4,\n"," 'critic': 4,\n"," 'regard': 4,\n"," 'act': 4,\n"," 'inject': 4,\n"," 'switch': 4,\n"," 'capit': 4,\n"," 'gain': 4,\n"," 'remain': 4,\n"," 'desir': 4,\n"," 'reveal': 4,\n"," 'entail': 4,\n"," 'argu': 4,\n"," 'encourag': 4,\n"," 'account': 4,\n"," 'concaten': 4,\n"," 'robot': 4,\n"," 'numer': 4,\n"," 'specifi': 4,\n"," 'conduct': 4,\n"," 'vari': 4,\n"," 'unifi': 4,\n"," 'popul': 4,\n"," 'stem': 4,\n"," 'caus': 4,\n"," 'convey': 4,\n"," 'divid': 4,\n"," 'intent': 4,\n"," 'synonym': 4,\n"," 'complement': 4,\n"," 'central': 4,\n"," 'request': 4,\n"," 'treat': 4,\n"," 'discov': 4,\n"," 'gate': 4,\n"," 'receiv': 4,\n"," 'fail': 4,\n"," 'contextu': 4,\n"," 'enhanc': 4,\n"," 'isol': 4,\n"," 'intuit': 4,\n"," 'spell': 4,\n"," 'preserv': 4,\n"," 'post': 4,\n"," 'cover': 4,\n"," 'tackl': 4,\n"," 'simplifi': 4,\n"," 'suit': 4,\n"," 'count': 4,\n"," 'return': 4,\n"," 'attempt': 4,\n"," 'happen': 4,\n"," 'govern': 4,\n"," 'aid': 4,\n"," 'check': 4,\n"," 'serv': 4,\n"," 'graphic': 4,\n"," 'highlight': 4,\n"," 'put': 4,\n"," 'move': 4,\n"," 'consider': 4,\n"," 'ensur': 4,\n"," 'forc': 4,\n"," 'transcript': 4,\n"," 'hypothes': 4,\n"," 'distinct': 4,\n"," 'enforc': 4,\n"," 'mask': 4,\n"," 'remov': 4,\n"," 'push': 4,\n"," 'econom': 4,\n"," 'decreas': 4,\n"," 'option': 4,\n"," 'stack': 4,\n"," 'compris': 4,\n"," 'narrow': 4,\n"," 'pass': 4,\n"," 'aris': 4,\n"," 'repeat': 4,\n"," 'constrain': 4,\n"," 'constitu': 4,\n"," 'carri': 4,\n"," 'merg': 4,\n"," 'convert': 4,\n"," 'releas': 4,\n"," 'expand': 4,\n"," 'synthes': 4,\n"," 'deviat': 4,\n"," 'drop': 4,\n"," 'wit': 4,\n"," 'arriv': 4,\n"," 'evolv': 4,\n"," 'gather': 4,\n"," 'suffer': 4,\n"," 'convent': 4,\n"," 'face': 4,\n"," 'innov': 4,\n"," 'pursu': 4,\n"," 'play': 4,\n"," 'arrang': 4,\n"," 'instanti': 4,\n"," 'resolv': 4,\n"," 'complic': 4,\n"," 'judg': 4,\n"," 'permit': 4,\n"," 'balanc': 4,\n"," 'substitut': 4,\n"," 'compet': 4,\n"," 'deliv': 4,\n"," 'exhibit': 4,\n"," 'aggreg': 4,\n"," 'coordin': 4,\n"," 'perturb': 4,\n"," 'stay': 4,\n"," 'acceler': 4,\n"," 'forecast': 4,\n"," 'confirm': 4,\n"," 'duplic': 4,\n"," 'interpol': 4,\n"," 'replic': 4,\n"," 'optimis': 4,\n"," 'concentr': 4,\n"," 'regul': 4,\n"," 'pioneer': 4,\n"," 'prospect': 4,\n"," 'reproduc': 4,\n"," 'impos': 4,\n"," 'insert': 4,\n"," 'imped': 4,\n"," 'archiv': 4,\n"," 'genom': 4,\n"," 'fulfil': 4,\n"," 'task': 3,\n"," 'text': 3,\n"," 'proceed': 3,\n"," 'base': 3,\n"," 'represent': 3,\n"," 'network': 3,\n"," 'embed': 3,\n"," 'similar': 3,\n"," 'tabl': 3,\n"," 'layer': 3,\n"," 'output': 3,\n"," 'sequenc': 3,\n"," 'section': 3,\n"," 'automat': 3,\n"," 'multipl': 3,\n"," 'sever': 3,\n"," 'algorithm': 3,\n"," 'attent': 3,\n"," 'term': 3,\n"," 'case': 3,\n"," 'see': 3,\n"," 'like': 3,\n"," 'typic': 3,\n"," 'neg': 3,\n"," 'second': 3,\n"," 'concept': 3,\n"," 'valu': 3,\n"," 'error': 3,\n"," 'sens': 3,\n"," 'multilingu': 3,\n"," 'make': 3,\n"," 'relev': 3,\n"," 'final': 3,\n"," 'call': 3,\n"," 'experiment': 3,\n"," 'complex': 3,\n"," 'recurr': 3,\n"," 'distanc': 3,\n"," 'variabl': 3,\n"," 'focus': 3,\n"," 'individu': 3,\n"," 'rang': 3,\n"," 'size': 3,\n"," 'electron': 3,\n"," 'becom': 3,\n"," 'key': 3,\n"," 'social': 3,\n"," 'issu': 3,\n"," 'digit': 3,\n"," 'chunk': 3,\n"," 'open': 3,\n"," 'effici': 3,\n"," 'build': 3,\n"," 'read': 3,\n"," 'independ': 3,\n"," 'morpholog': 3,\n"," 'imag': 3,\n"," 'man': 3,\n"," 'unit': 3,\n"," 'classic': 3,\n"," 'take': 3,\n"," 'interfac': 3,\n"," 'nation': 3,\n"," 'basic': 3,\n"," 'ontolog': 3,\n"," 'seed': 3,\n"," 'deal': 3,\n"," 'program': 3,\n"," 'convolut': 3,\n"," 'logic': 3,\n"," 'symbol': 3,\n"," 'ambigu': 3,\n"," 'theoret': 3,\n"," 'grammat': 3,\n"," 'norm': 3,\n"," 'capabl': 3,\n"," 'spars': 3,\n"," 'get': 3,\n"," 'underli': 3,\n"," 'filter': 3,\n"," 'precis': 3,\n"," 'stage': 3,\n"," 'trend': 3,\n"," 'fix': 3,\n"," 'biolog': 3,\n"," 'systemat': 3,\n"," 'know': 3,\n"," 'detail': 3,\n"," 'lead': 3,\n"," 'manual': 3,\n"," 'public': 3,\n"," 'inspir': 3,\n"," 'commerci': 3,\n"," 'modul': 3,\n"," 'squar': 3,\n"," 'local': 3,\n"," 'messag': 3,\n"," 'ident': 3,\n"," 'dimens': 3,\n"," 'seek': 3,\n"," 'partial': 3,\n"," 'give': 3,\n"," 'treebank': 3,\n"," 'radiolog': 3,\n"," 'neighbor': 3,\n"," 'methodolog': 3,\n"," 'let': 3,\n"," 'equival': 3,\n"," 'assess': 3,\n"," 'run': 3,\n"," 'templat': 3,\n"," 'power': 3,\n"," 'subset': 3,\n"," 'choos': 3,\n"," 'reliabl': 3,\n"," 'descript': 3,\n"," 'want': 3,\n"," 'say': 3,\n"," 'solv': 3,\n"," 'suitabl': 3,\n"," 'servic': 3,\n"," 'market': 3,\n"," 'situat': 3,\n"," 'mathemat': 3,\n"," 'weak': 3,\n"," 'autoencod': 3,\n"," 'come': 3,\n"," 'pipelin': 3,\n"," 'row': 3,\n"," 'sound': 3,\n"," 'comprehens': 3,\n"," 'overfit': 3,\n"," 'ensembl': 3,\n"," 'school': 3,\n"," 'advantag': 3,\n"," 'sensit': 3,\n"," 'behavior': 3,\n"," 'competit': 3,\n"," 'procedur': 3,\n"," 'chain': 3,\n"," 'side': 3,\n"," 'unfreez': 3,\n"," 'promin': 3,\n"," 'mechan': 3,\n"," 'flexibl': 3,\n"," 'principl': 3,\n"," 'believ': 3,\n"," 'transit': 3,\n"," 'pool': 3,\n"," 'profil': 3,\n"," 'foundat': 3,\n"," 'depart': 3,\n"," 'terminolog': 3,\n"," 'plan': 3,\n"," 'decad': 3,\n"," 'subsequ': 3,\n"," 'region': 3,\n"," 'overcom': 3,\n"," 'grow': 3,\n"," 'bring': 3,\n"," 'edg': 3,\n"," 'compos': 3,\n"," 'materi': 3,\n"," 'phonem': 3,\n"," 'hope': 3,\n"," 'modular': 3,\n"," 'feed': 3,\n"," 'keep': 3,\n"," 'relabel': 3,\n"," 'acoust': 3,\n"," 'break': 3,\n"," 'encount': 3,\n"," 'abbrevi': 3,\n"," 'schedul': 3,\n"," 'bridg': 3,\n"," 'ignor': 3,\n"," 'neurosci': 3,\n"," 'fall': 3,\n"," 'agre': 3,\n"," 'extrem': 3,\n"," 'genet': 3,\n"," 'ground': 3,\n"," 'recurs': 3,\n"," 'centr': 3,\n"," 'trade': 3,\n"," 'reus': 3,\n"," 'interdepend': 3,\n"," 'homograph': 3,\n"," 'ablat': 3,\n"," 'preprocess': 3,\n"," 'modal': 3,\n"," 'prevent': 3,\n"," 'curat': 3,\n"," 'leav': 3,\n"," 'paraphras': 3,\n"," 'copi': 3,\n"," 'excel': 3,\n"," 'connot': 3,\n"," 'acquir': 3,\n"," 'speed': 3,\n"," 'proposit': 3,\n"," 'avoid': 3,\n"," 'covari': 3,\n"," 'partit': 3,\n"," 'split': 3,\n"," 'trick': 3,\n"," 'stop': 3,\n"," 'bound': 3,\n"," 'branch': 3,\n"," 'confid': 3,\n"," 'distinguish': 3,\n"," 'intens': 3,\n"," 'impli': 3,\n"," 'industri': 3,\n"," 'pivot': 3,\n"," 'compound': 3,\n"," 'talk': 3,\n"," 'draw': 3,\n"," 'conclud': 3,\n"," 'neuron': 3,\n"," 'predic': 3,\n"," 'caption': 3,\n"," 'thank': 3,\n"," 'psycholog': 3,\n"," 'satisfi': 3,\n"," 'guid': 3,\n"," 'preposit': 3,\n"," 'maintain': 3,\n"," 'surpris': 3,\n"," 'bias': 3,\n"," 'freez': 3,\n"," 'opportun': 3,\n"," 'phenotyp': 3,\n"," 'speciﬁc': 3,\n"," 'cycl': 3,\n"," 'foster': 3,\n"," 'skill': 3,\n"," 'cite': 3,\n"," 'prefix': 3,\n"," 'suppos': 3,\n"," 'display': 3,\n"," 'overlap': 3,\n"," 'send': 3,\n"," 'mitig': 3,\n"," 'consum': 3,\n"," 'invari': 3,\n"," 'price': 3,\n"," 'cooper': 3,\n"," 'outlin': 3,\n"," 'imagin': 3,\n"," 'game': 3,\n"," 'teach': 3,\n"," 'adjust': 3,\n"," 'rememb': 3,\n"," 'decid': 3,\n"," 'compress': 3,\n"," 'smooth': 3,\n"," 'slow': 3,\n"," 'invert': 3,\n"," 'boost': 3,\n"," 'attend': 3,\n"," 'brand': 3,\n"," 'coupl': 3,\n"," 'fragment': 3,\n"," 'percept': 3,\n"," 'demand': 3,\n"," 'bin': 3,\n"," 'fill': 3,\n"," 'facil': 3,\n"," 'conflict': 3,\n"," 'educ': 3,\n"," 'pick': 3,\n"," 'tell': 3,\n"," 'guarante': 3,\n"," 'retain': 3,\n"," 'depict': 3,\n"," 'exclus': 3,\n"," 'underlin': 3,\n"," 'intrud': 3,\n"," 'settl': 3,\n"," 'proport': 3,\n"," 'matur': 3,\n"," 'stream': 3,\n"," 'computer': 3,\n"," 'biocur': 3,\n"," 'favor': 3,\n"," 'histor': 3,\n"," 'sort': 3,\n"," 'stylist': 3,\n"," 'stand': 3,\n"," 'sustain': 3,\n"," 'guess': 3,\n"," 'feder': 3,\n"," 'deploy': 3,\n"," 'grant': 3,\n"," 'tailor': 3,\n"," 'vote': 3,\n"," 'polynomi': 3,\n"," 'surround': 3,\n"," 'prototyp': 3,\n"," 'consult': 3,\n"," 'regularis': 3,\n"," 'delay': 3,\n"," 'licens': 3,\n"," 'omit': 3,\n"," 'monoton': 3,\n"," 'revisit': 3,\n"," 'respond': 3,\n"," 'bracket': 3,\n"," 'cultur': 3,\n"," 'brook': 3,\n"," 'save': 3,\n"," 'discard': 3,\n"," 'thread': 3,\n"," 'land': 3,\n"," 'span': 3,\n"," 'parameter': 3,\n"," 'generalis': 3,\n"," 'condens': 3,\n"," 'multipli': 3,\n"," 'render': 3,\n"," 'bear': 3,\n"," 'resembl': 3,\n"," 'succeed': 3,\n"," 'hotel': 3,\n"," 'degrad': 3,\n"," 'accommod': 3,\n"," 'behav': 3,\n"," 'uncov': 3,\n"," 'enter': 3,\n"," 'borrow': 3,\n"," 'attract': 3,\n"," 'titl': 3,\n"," 'bill': 3,\n"," 'travers': 3,\n"," 'exhaust': 3,\n"," 'specul': 3,\n"," 'miss': 3,\n"," 'visualis': 3,\n"," 'secur': 3,\n"," 'excit': 3,\n"," 'brows': 3,\n"," 'struggl': 3,\n"," 'exemplifi': 3,\n"," 'distil': 3,\n"," 'interview': 3,\n"," 'inequ': 3,\n"," 'penal': 3,\n"," 'corrupt': 3,\n"," 'occupi': 3,\n"," 'port': 3,\n"," 'summaris': 3,\n"," 'scrutin': 3,\n"," 'psycholinguist': 3,\n"," 'dictat': 3,\n"," 'endow': 3,\n"," 'quot': 3,\n"," 'digest': 3,\n"," 'engag': 3,\n"," 'hedg': 3,\n"," 'sinusoid': 3,\n"," 'persist': 3,\n"," 'host': 3,\n"," 'paint': 3,\n"," 'blow': 3,\n"," 'presuppos': 3,\n"," 'habit': 3,\n"," 'breed': 3,\n"," 'collat': 3,\n"," 'grade': 3,\n"," 'languag': 2,\n"," 'word': 2,\n"," 'domain': 2,\n"," 'machin': 2,\n"," 'method': 2,\n"," 'knowledg': 2,\n"," 'sentenc': 2,\n"," 'one': 2,\n"," 'confer': 2,\n"," 'page': 2,\n"," 'cross': 2,\n"," 'featur': 2,\n"," 'sourc': 2,\n"," 'level': 2,\n"," 'number': 2,\n"," 'exampl': 2,\n"," 'larg': 2,\n"," 'classif': 2,\n"," 'mani': 2,\n"," 'supervis': 2,\n"," 'input': 2,\n"," 'paramet': 2,\n"," 'sentiment': 2,\n"," 'well': 2,\n"," 'recognit': 2,\n"," 'techniqu': 2,\n"," 'avail': 2,\n"," 'http': 2,\n"," 'clinic': 2,\n"," 'user': 2,\n"," 'scienc': 2,\n"," 'part': 2,\n"," 'paper': 2,\n"," 'annual': 2,\n"," 'art': 2,\n"," 'recent': 2,\n"," 'volum': 2,\n"," 'context': 2,\n"," 'dataset': 2,\n"," 'problem': 2,\n"," 'artifici': 2,\n"," 'journal': 2,\n"," 'tool': 2,\n"," 'better': 2,\n"," 'vector': 2,\n"," 'chapter': 2,\n"," 'lexic': 2,\n"," 'space': 2,\n"," 'dictionari': 2,\n"," 'linear': 2,\n"," 'world': 2,\n"," 'random': 2,\n"," 'import': 2,\n"," 'rule': 2,\n"," 'architectur': 2,\n"," 'way': 2,\n"," 'current': 2,\n"," 'databas': 2,\n"," 'field': 2,\n"," 'low': 2,\n"," 'lexicon': 2,\n"," 'sequenti': 2,\n"," 'trec': 2,\n"," 'accuraci': 2,\n"," 'articl': 2,\n"," 'entiti': 2,\n"," 'role': 2,\n"," 'abl': 2,\n"," 'futur': 2,\n"," 'preprint': 2,\n"," 'press': 2,\n"," 'ed': 2,\n"," 'loss': 2,\n"," 'introduct': 2,\n"," 'found': 2,\n"," 'framework': 2,\n"," 'pattern': 2,\n"," 'theori': 2,\n"," 'instanc': 2,\n"," 'diseas': 2,\n"," 'area': 2,\n"," 'resourc': 2,\n"," 'year': 2,\n"," 'workshop': 2,\n"," 'graph': 2,\n"," 'noun': 2,\n"," 'induct': 2,\n"," 'divers': 2,\n"," 'major': 2,\n"," 'content': 2,\n"," 'prior': 2,\n"," 'qualiti': 2,\n"," 'hard': 2,\n"," 'memori': 2,\n"," 'lstm': 2,\n"," 'gradient': 2,\n"," 'co': 2,\n"," 'usual': 2,\n"," 'textual': 2,\n"," 'summari': 2,\n"," 'relationship': 2,\n"," 'categori': 2,\n"," 'verb': 2,\n"," 'abil': 2,\n"," 'analyt': 2,\n"," 'good': 2,\n"," 'grammar': 2,\n"," 'past': 2,\n"," 'goal': 2,\n"," 'dialogu': 2,\n"," 'fact': 2,\n"," 'lm': 2,\n"," 'event': 2,\n"," 'wide': 2,\n"," 'constraint': 2,\n"," 'vocabulari': 2,\n"," 'metric': 2,\n"," 'accord': 2,\n"," 'item': 2,\n"," 'scientif': 2,\n"," 'comparison': 2,\n"," 'class': 2,\n"," 'discoveri': 2,\n"," 'properti': 2,\n"," 'compon': 2,\n"," 'gram': 2,\n"," 'cancer': 2,\n"," 'tree': 2,\n"," 'aspect': 2,\n"," 'de': 2,\n"," 'juli': 2,\n"," 'entropi': 2,\n"," 'signific': 2,\n"," 'benchmark': 2,\n"," 'unlabel': 2,\n"," 'regress': 2,\n"," 'parser': 2,\n"," 'scenario': 2,\n"," 'librari': 2,\n"," ...}"]},"metadata":{"tags":[]},"execution_count":11}]},{"cell_type":"code","metadata":{"id":"c952fWw5wFqz","executionInfo":{"status":"ok","timestamp":1604211993428,"user_tz":-480,"elapsed":722,"user":{"displayName":"Nicholas Neo","photoUrl":"","userId":"02359484661843204503"}},"outputId":"c1b15923-6695-4718-ca7b-4c9cff7ba48a","colab":{"base_uri":"https://localhost:8080/"}},"source":["#Comparision\n","print(\"Total unique tokens before stemming: \"+str(len(tokens_lib)))\n","print(\"Total unique tokens after stemming: \"+str(len(stemm_dict)))"],"execution_count":12,"outputs":[{"output_type":"stream","text":["Total unique tokens before stemming: 15111\n","Total unique tokens after stemming: 11293\n"],"name":"stdout"}]},{"cell_type":"code","metadata":{"id":"hzAAOHTaw3TN","executionInfo":{"status":"ok","timestamp":1604211995710,"user_tz":-480,"elapsed":781,"user":{"displayName":"Nicholas Neo","photoUrl":"","userId":"02359484661843204503"}}},"source":["#Function to return the length distribution of a dictionary\n","def getLengthDistri(target_dict):\n","  #Initialize counter dictionary\n","  counter = {}\n","  #Loop for each word in dictionary\n","  for word in target_dict:\n","    if len(word) not in counter:\n","      counter[len(word)] = 1\n","    else:\n","      counter[len(word)] += 1\n","  return counter"],"execution_count":13,"outputs":[]},{"cell_type":"code","metadata":{"id":"ogXtptrkw_Dn","executionInfo":{"status":"ok","timestamp":1604211998162,"user_tz":-480,"elapsed":799,"user":{"displayName":"Nicholas Neo","photoUrl":"","userId":"02359484661843204503"}},"outputId":"a1c1a4c9-328f-4eb0-dca5-d7c3bfb46ddf","colab":{"base_uri":"https://localhost:8080/"}},"source":["getLengthDistri(stemm_dict)"],"execution_count":14,"outputs":[{"output_type":"execute_result","data":{"text/plain":["{1: 37,\n"," 2: 541,\n"," 3: 952,\n"," 4: 1539,\n"," 5: 1806,\n"," 6: 1981,\n"," 7: 1617,\n"," 8: 1184,\n"," 9: 676,\n"," 10: 413,\n"," 11: 223,\n"," 12: 116,\n"," 13: 74,\n"," 14: 49,\n"," 15: 31,\n"," 16: 22,\n"," 17: 11,\n"," 18: 11,\n"," 19: 1,\n"," 20: 2,\n"," 21: 2,\n"," 22: 2,\n"," 25: 1,\n"," 27: 1,\n"," 30: 1}"]},"metadata":{"tags":[]},"execution_count":14}]},{"cell_type":"code","metadata":{"id":"qzIAzSHpzVhe","executionInfo":{"status":"ok","timestamp":1604212001283,"user_tz":-480,"elapsed":1531,"user":{"displayName":"Nicholas Neo","photoUrl":"","userId":"02359484661843204503"}},"outputId":"75a1ae4b-2c17-4afb-a5cd-abf1c7856161","colab":{"base_uri":"https://localhost:8080/","height":610}},"source":["plt.figure(figsize=(20,10))\n","D = getLengthDistri(tokens_lib)\n","\n","plt.bar(range(len(D)), list(D.values()), align='center', alpha=0.5,label=\"Before Stemming\", edgecolor='black', hatch=\"/\")\n","plt.xticks(range(len(D)), list(D.keys()))\n","plt.xticks(rotation=90)\n","\n","## after stemming\n","D = getLengthDistri(stemm_dict)\n","\n","plt.bar(range(len(D)), list(D.values()), align='center', alpha=0.5, label=\"After Stemming\", edgecolor='black', hatch=\".\")\n","plt.xticks(range(len(D)), list(D.keys()))\n","plt.xticks(rotation=90)\n","plt.title('Length distribution of tokens')\n","plt.legend(prop={'size': 40})\n","\n","plt.show()"],"execution_count":15,"outputs":[{"output_type":"display_data","data":{"image/png":"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\n","text/plain":["<Figure size 1440x720 with 1 Axes>"]},"metadata":{"tags":[],"needs_background":"light"}}]},{"cell_type":"code","metadata":{"id":"BR1cKkZ419iR","executionInfo":{"status":"ok","timestamp":1604211731600,"user_tz":-480,"elapsed":996,"user":{"displayName":"Nicholas Neo","photoUrl":"","userId":"02359484661843204503"}}},"source":["#Sentence Segmentation\n","def sentence_seg(txt_files):\n","  s_seg = []\n","  #Loop for each file\n","  for txt_file in txt_files:\n","    #Tokenize the file into sentences\n","    sentences = sent_tokenize(str(txt_file))\n","    #Append sentence to the full dictionary\n","    for sentence in sentences:\n","      s_seg.append(sentence)\n","  return s_seg"],"execution_count":21,"outputs":[]},{"cell_type":"code","metadata":{"id":"np10NZpQ5y3U","executionInfo":{"status":"ok","timestamp":1604211733525,"user_tz":-480,"elapsed":1159,"user":{"displayName":"Nicholas Neo","photoUrl":"","userId":"02359484661843204503"}},"outputId":"61db1e13-44c0-4439-c6e2-db2c36f82456","colab":{"base_uri":"https://localhost:8080/"}},"source":["#Get sentences\n","sentences = sentence_seg(files)\n","sentences"],"execution_count":22,"outputs":[{"output_type":"execute_result","data":{"text/plain":["['Journal of Optometry (2020) 13, 71---73\\n\\nwww.journalofoptometry.org\\n\\nEDITORIAL\\n\\nJournal of Optometry bibliometrics\\nÍndices bibliométricos de Journal of Optometry\\nJosé M. González-Méijome ∗\\nEditor-in-Chief, Clinical and Experimental Optometry Research Lab (CEORLab), Center of Physics, University of Minho, Portugal\\n\\nScientiﬁc bibliometrics or ‘‘Scientometrics’’ are increasingly used to evaluate the impact of scientiﬁc publication.',\n"," 'Most of them rank the scientiﬁc work visibility for individuals, journals or institutions based on different algorithms\\nthat generally compute the number of citations received by\\nthe publications.',\n"," 'They have a signiﬁcant effect on the public\\nand peers perception of scientiﬁc merit for authors, journals\\nand institutions.',\n"," 'Not dismissing the limitations of those metrics, which\\nhave been object of previous publications1,2 they provide\\nan objective methodology to evaluate the impact of the\\nresearch published.',\n"," 'Other applications of bibliometrics aim\\nto identify the interaction between researchers in different\\nﬁelds highlighting the predominant authors or the countries\\nwhere such research is conducted.3---7 One of the most traditionally used metrics is the Impact Factor (IF) published\\nevery year by Clarivate Analytics in the Web of Science.8 This\\nindex ranks the journals according to the number of citations\\nreceived over the previous two years.',\n"," 'So, the IF uses a simple algorithm resulting from a quotient between citations\\nreceived (numerator) and articles published (denominator)\\nover the 2 year period.',\n"," 'Journal of Optometry has evolved signiﬁcantly in the\\nnumber of manuscripts submitted for publication as well as\\nin the number of citations collected from other publications.',\n"," 'Figure 1 shows a picture of other rankings for Journal\\nof Optometry as obtained on March 22nd , 2020.',\n"," 'Notably, J\\nOptom SJR has increased steadily over the last 4 years.',\n"," 'Out\\nof the 10 indexed journals in its category, J Optom ranks\\n\\n3rd along with the other two main journals Optometry and\\nVision Science (OVS) published by the American Academy of\\nOptometry and Ophthalmic and Physiological Optics (OPO)\\npublished by the British College of Optometrists.',\n"," 'J Optom\\nis also the only one that provides Open Access to readers,\\nbeing also free for authors publishing in the journal.',\n"," 'Consequently, metrics calculated by different platforms\\nhas increased steadily over the past years.',\n"," 'All the estimated\\nmetrics have increased consistently over the last years.',\n"," '(Figure 1).',\n"," 'Clarivate IF metric is not available as J Optom is\\nnot indexed in that database.',\n"," 'Lower absolute values of SJR\\nand SNIP (see ﬁgure caption for deﬁnitions) should not surprise the reader as they result from the calculation method\\nand this behavior is also common to other journals in the\\nﬁeld.',\n"," 'A summarized view of relevant aspects and calculation\\n\\n∗ Corresponding author.',\n"," 'José M. González-Méijome, PhD CEORLab\\n--- Center of Physics University of Minho, Portugal.',\n"," 'E-mail address: jgmeijome@ﬁsica.uminho.pt\\n\\nFigure 1 Evolution of Journal of Optometry metric values\\nfrom 2011 to 2018 Scopus CiteScore (CiteScore), SCIMago Journal Ranking (SJR), and CWTS Source Normalized Impact per\\nPaper (SNIP).',\n"," 'https://doi.org/10.1016/j.optom.2020.03.005\\n1888-4296/© 2020 Spanish General Council of Optometry.',\n"," 'Published by Elsevier España, S.L.U.',\n"," 'This is an open access article under the CC\\nBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).',\n"," '72\\n\\nJ.M.',\n"," 'González-Méijome\\n\\nmethods of the different metrics introduced in this editorial\\nis are summarized in Table 1.',\n"," 'One of those important metrics adopted by several academic institutions around the world has been delivered\\nby SCImago.',\n"," 'According to Scimago ranking, the Journal of\\nOptometry ended the year 2018 in the 1st quartile (3rd in the\\nranking) in the section of Health Professions (Optometry)\\nalong with other 9 publications.9 SCImago Journal Ranking\\n(SJR) index is a metric based on the idea that not all citations\\nare the same.',\n"," 'SJR uses a similar algorithm as the Google page\\nrank; it provides a quantitative and qualitative measure of\\nthe journal’s impact.',\n"," 'In the words of SCImago ‘‘SJR is a measure of scientiﬁc inﬂuence of journals that accounts for both\\nthe number of citations received by a journal and the importance or prestige of the journals where such citations are\\noriginated.',\n"," 'It measures the scientiﬁc inﬂuence of the average article in a journal, it expresses how central to the global\\nscientiﬁc discussion an average article of the journal is’’.',\n"," 'The H-index, after Argentinean-American Professor Jorge\\nE. Hirsch is another metric that now has been extended to\\nrank not only individuals but also institutions and journals.10\\nH-index represents the number of publications by a given\\nauthor, journal or institution being cited equal or superior\\nnumber of times.',\n"," 'Despite its merits in differentiating highly\\ncited publications, this metric tends to favor the older publications compared to the new publications as well as older\\n\\nauthors compared to youngest that had less time to accumulate citations.',\n"," 'As an example, J Optom ranks 6th in the SJR\\ninstead of 3rd , when ordered by H-index which is perfectly\\nunderstandable as the ﬁrst 4 ranked are covered from the\\n1980’s for the calculation of this index compared to 2007\\nfor the 5th ranked journal and third semester of 2008 for J\\nOptom.',\n"," 'Another emerging index is the Scopus CiteScoreTM that\\nmeasures average citations received per document published.',\n"," 'In its 2018 metrics covering citations during 2015,\\n2016 and 2017, J Optom ranks 3rd among the 14 journals\\nindexed in the Optometry ﬁeld.',\n"," 'As stated in CiteScore webpage, all types of documents (research articles, review\\narticles, conference proceedings, editorials errata, letters,\\nnotes, and short surveys) are included in the CiteScore calculation.',\n"," 'Although articles in press are included in Scopus\\nthey are not included in the CiteScore calculation.11\\nNo single metric is perfect and one of the ﬂaws pointed\\nis that comparing journals or authors in different ﬁelds\\nis difﬁcult because of the asymmetry between the scientiﬁc activity.',\n"," 'For example, comparing Cancer research ﬁeld\\nwhere thousands of articles are published covering a very\\nlarge scope of biological, pharmaceutical, medical specialties among many others and being potentially cited by all of\\nthem, with other sub-specialties as Ophthalmology, Optometry, etc, is not possible.',\n"," 'To avoid this, some metrics such\\n\\nTable 1 Different citation metrics and Journal of Optometry position in the ranking.',\n"," 'Information collected between last\\ntrimester 2019 and ﬁrst trimester 2020.',\n"," 'Impact Factor (IF)a\\n\\nSCImago Journal\\nRanking (SJR)b\\n\\nH-index*c\\n\\nCiteScored\\n\\nSource Normalized\\nImpact per Paper\\n(SNIP)e\\n\\nOwner/Developer\\n\\nClarivate Analytics\\n\\nSCImago\\n\\nDatabase owner\\n\\nScopus-Elsevier\\n\\nSourceDatabase\\nAlgorithm(i.e.',\n"," 'year 2018)\\n\\nWeb of Science\\nCitations\\n(2016+2017)\\nPublications\\n(2016+2017)\\n\\nScopus\\nNumber of\\nPublications with\\n≥ Number of\\nCitations Each\\n\\nScopus\\nCitations (2018)\\nPublications\\n(2015+2016+2017)\\n\\nNumber of\\nJournals analyzed\\nPositive aspects\\n\\n≈12.000\\n\\nScopus\\nNot disclosed,\\n‘‘claimed to be\\nsimilar to the\\nGoogle PageRank\\nalgorithm’’\\n≈32.000\\n\\nCWTS at Leiden\\nUniversity\\nScopus\\nNot disclosed,\\n‘‘weights citations\\naccording to ﬁelds\\npotential’’\\n\\n≈25.000\\n\\n≈25.000\\n\\n≈25.000\\n\\nSimple metric\\nAvailable every\\nyear\\n\\nFree Access\\nConsiders wider\\nscope of journals\\n\\nPositive\\ndiscrimination of\\nhighly cited items\\n\\nNegative aspect\\n\\nPaid Access Only\\ncounts citations in\\njournals with IF\\n\\nAlgorithm not fully\\ndisclosed\\n\\nNo timeframe,\\nfavors older\\npublications\\n\\nFree Access Direct\\ncomparison of\\nsubﬁelds Considers\\nwider scope of\\njournals\\nAlgorithm not fully\\ndisclosed\\n\\nJ Optom Ranking‡\\n(2018)\\n\\nNot indexed\\n\\n3rd out of 10\\n\\n6th\\n\\nFree Access\\nConsiders a longer\\nperiod (3years)\\nConsiders wider\\nscope of journals\\nCitations of one\\nyear, signiﬁcant\\nshort-term\\nvariations\\n3rd out of 14\\n\\n*\\n\\nH-index as reported in the in SCImago Journal Ranking (SJR) using Scopus Database\\nSubject Area and Category: Health Professions / Optometry\\nSources:\\na https://jcr.clarivate.com/JCRHomePageAction.action\\nb,c https://www.scimagojr.com/journalrank.php\\nd https://www.scopus.com/sources\\ne https://www.journalindicators.com/indicators\\n‡\\n\\n4th out of 8\\n\\n\\x0cJournal of Optometry bibliometrics\\nas the Source Normalized Impact per Paper (SNIP) developed by Centre for Science and Technology Studies (CWTS)\\nof Leiden University weights citations based on the total\\nnumber of citations in a subject ﬁeld.12 As stated elsewhere\\n‘‘compares each journal’s citations per publication with the\\ncitation potential of its ﬁeld, deﬁned as the set of publications citing that journal’’.',\n"," 'A synthesis of this and other\\ncitation metrics can be found elsewhere.13,14\\nIt has to be highlighted that all metrics have about 1 to 2\\nyears of delay as the metrics usually available have been calculated considering the citations in papers published 2 years\\nbefore the yearly metric release.',\n"," 'This is the only way to capture virtually all the citations obtained by a given article,\\nauthor, journal or institution.',\n"," 'As authors, reviewers, professionals and students recognize the value of Journal of Optometry in dissemination of\\nthe knowledge this has been followed by prestige databases\\nas recognition of Pubmed, Scopus, SCIMago, SNIP, CiteScore,\\njust to mention some of the most widely adopted.',\n"," 'Noteworthy, the metrics achieved by J Optom are even more\\nremarkable considering that its level of autocitation is\\namong the lowest, under 10% of all the cites collected\\nbetween 2015 and 2019.',\n"," 'Journal of Optometry is certainly a\\nfully consolidated and respected journal in the ﬁeld and it\\nis our responsibility to keep this track record to strength the\\npublication capability of the optometry and vision science\\nﬁeld to contribute to the advance of scientiﬁc knowledge\\nand provide wider and better eyecare to populations Worldwide.',\n"," 'References\\n1.',\n"," 'Grzybowski A.',\n"," 'The journal impact factor: how to interpret its\\ntrue value and importance.',\n"," 'Med Sci Monit.',\n"," '2009;15.',\n"," 'SR1-4.',\n"," '2.',\n"," 'Grzybowski A.',\n"," 'Impact factor–strengths and weaknesses.',\n"," 'Clin\\nDermatol.',\n"," '2010;28:455---457,\\nhttp://dx.doi.org/\\n10.1016/j.clindermatol.2010.01.002.',\n"," '73\\n3.',\n"," 'Cardona G, Sanz JP.',\n"," 'Publication analysis of the\\ncontact lens ﬁeld: what are the current topics of\\ninterest?',\n"," 'J Optom.',\n"," '2015;8:33---39, http://dx.doi.org/\\n10.1016/j.optom.2014.02.003.',\n"," '4.',\n"," 'Ruiz-Pomeda A, et al.',\n"," 'Bibliometric study of scientiﬁc research\\non optometric visual therapy.',\n"," 'J Optom.',\n"," '2020 (in press).',\n"," '5.',\n"," 'Efron N, Brennan NA, Nichols JJ.',\n"," 'Citation analysis of\\nthe contact lens ﬁeld.',\n"," 'Optom Vis Sci.',\n"," '2012;89:70---79,\\nhttp://dx.doi.org/10.1097/OPX.0b013e318236dcca.',\n"," '6.',\n"," 'Efron N, Brennan NA.',\n"," 'Citation analysis of Australiatrained optometrists.',\n"," 'Clin Exp Optom.',\n"," '2011;94:600---605,\\nhttp://dx.doi.org/10.1111/j.1444-0938.2011.00652.x.',\n"," '7.',\n"," 'Villa-Collar C, Álvarez-Peregrina C, Hidalgo Santa Cruz\\nF, Povedano-Montero FJ.',\n"," 'Bibliometric Study of Scientiﬁc Research on Overnight Orthokeratology.',\n"," 'Eye\\nContact\\nLens.',\n"," '2018;44:344---349,\\nhttp://dx.doi.org/\\n10.1097/ICL.',\n"," '0000000000000545.',\n"," '8.',\n"," 'Journal Citation Reports.',\n"," 'Available at: https://jcr.clarivate.',\n"," 'com/JCRHomePageAction.action.',\n"," 'Accessed on March 22nd,\\n2020.',\n"," '9.',\n"," 'Scimago Journal Rankings.',\n"," 'Available at: https://www.',\n"," 'scimagojr.com/journalrank.php?category=3610.',\n"," 'Accessed on\\nMarch 22nd, 2020.',\n"," '10.',\n"," 'Hirsch JE.',\n"," 'An index to quantify an individual’s scientiﬁc research output.',\n"," 'PNAS.',\n"," '2005;102:16569---16572,\\nhttp://dx.doi.org/10.1073/pnas.0507655102.',\n"," '11.',\n"," 'CiteScore\\n2018\\nmetrics.',\n"," 'Available\\nat:\\nhttps://www.scopus.com/sources.',\n"," 'Accessed on March\\n22nd, 2020.',\n"," '12.',\n"," 'CWTS.',\n"," 'Available at: https://www.journalindicators.com/\\nproducts.',\n"," 'Accessed on March 22nd, 2020.',\n"," '13.',\n"," 'Measuring a journal’s impact.',\n"," 'Available at: https://www.',\n"," 'elsevier.com/authors/journal-authors/measuring-a-journalsimpact.',\n"," 'Accessed on March 2nd, 2020.',\n"," '14.',\n"," 'University of Maryland Libraries.',\n"," 'Available at: https://lib.',\n"," 'guides.umd.edu/c.php?g=327388&p=2196059.',\n"," 'Accessed on\\nMarch 22nd, 2020.',\n"," 'META-ANALYSIS\\n\\nVisual Deficits and Dysfunctions Associated with Traumatic Brain\\nInjury: A Systematic Review and Meta-analysis\\nNatalya Merezhinskaya, PhD,1,2 Rita K. Mallia, OD, MPA,3 DoHwan Park, PhD,4 Daniel W. Bryden, PhD,3 Karan Mathur, BS,3\\nand Felix M. Barker, II, OD, MS, FAAO1,2*\\n\\nDownloaded from https://journals.lww.com/optvissci by BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AWnYQp/IlQrHD3i3D0OdRyi7TvSFl4Cf3VC1y0abggQZXdgGj2MwlZLeI= on 10/31/2020\\n\\nSIGNIFICANCE: This study reports prevalence data combined independently for accommodative dysfunction, convergence insufficiency, visual field loss, and visual acuity loss in patients with traumatic brain injury in the absence\\nof eye injury.',\n"," 'OBJECTIVE: The objective of this study was to conduct a systematic review and meta-analysis to determine the\\nprevalence rates of accommodative dysfunction, convergence insufficiency, visual field loss, and visual acuity loss\\nin TBI patients without concomitant eye injury.',\n"," 'DATA SOURCES: The data sources used in this study were PubMed, EMBASE, EBSCO, and Cochrane Library.',\n"," 'STUDY APPRAISAL AND SYNTHESIS METHODS: Publications reporting the prevalence of diagnosed accommodative dysfunction, convergence insufficiency, visual field loss, or visual acuity loss to the level of legal blindness in\\nTBI patients of any age were included.',\n"," 'Univariate metaregression analyses and subgroup analyses were performed\\nto account for statistical heterogeneity.',\n"," 'RESULTS: Twenty-two eligible publications were identified across the four visual conditions.',\n"," 'Random-effects\\nmodels yielded combined prevalence estimates: accommodative dysfunction (42.8; 95% confidence interval\\n[CI], 31.3 to 54.7), convergence insufficiency (36.3%; 95% CI, 28.2 to 44.9%), visual field loss (18.2%; 95%\\nCI, 10.6 to 27.1%), and visual acuity loss (0.0%; 95% CI, 0.0 to 1.1%).',\n"," 'Metaregression and subgroup analyses\\nrevealed that visual field loss was significantly more prevalent in moderate to severe (39.8%; 95% CI, 29.8 to\\n50.3%) compared with mild TBI (6.6%; 95% CI, 0 to 19.5%).',\n"," 'CONCLUSIONS AND IMPLICATIONS OF KEY FINDINGS: This study demonstrates that accommodative dysfunction, convergence insufficiency, and visual field loss are common sequelae of TBI.',\n"," 'Prospective longitudinal research with rigorous and uniform methodology is needed to better understand short- and long-term effects of\\nTBI on the vision system.',\n"," 'Optom Vis Sci 2019;96:542–555.',\n"," 'doi:10.1097/OPX.0000000000001407\\nWritten work prepared by employees of the Federal Government as part of their official duties is, under the U.S.',\n"," 'Copyright Act, a\\n“work of the United States Government” for which copyright protection under Title 17 of the United States Code is not\\navailable.',\n"," 'As such, copyright does not extend to the contributions of employees of the Federal Government.',\n"," 'Supplemental Digital Content: Direct URL links are provided within the text.',\n"," 'Traumatic brain injury is defined as an alteration in brain function or other evidence of brain pathology caused by an external\\nforce.1 In 2013 alone, an estimated 2.8 million people in the\\nUnited States sustained a traumatic brain injury, most commonly\\nfrom falls, being struck by or against an object, and motor vehicle\\naccidents.2 In the military, more than 375,000 cases of traumatic\\nbrain injury were reported in service members since 2000,3 many\\nof them as a result of powerful explosive blast events.',\n"," 'Retrospective\\nstudies show that 65 to 79% of traumatic brain injury patients report subjective visual complaints4–9; however, prevalence of the\\nunderlying visual dysfunctions attributed to self-reported symptoms varies substantially between these studies for reasons including inconsistent diagnostic and reporting methods, varying sample\\npopulation demographics, and the many possible mechanisms of\\ninjury.',\n"," 'Given the limitations of available retrospective data and\\nthe dearth of studies that prospectively recruit unbiased patient\\nsamples, this study was undertaken to obtain more accurate prevalence estimates.',\n"," 'Thus, the purpose of this study is to use available\\npublished scientific data to estimate the prevalence of four visual\\noutcomes often considered to be associated with traumatic brain\\ninjury: accommodative dysfunction, convergence insufficiency, visual field loss, and visual acuity loss.10–16 Furthermore, univariate\\nwww.optvissci.com\\n\\nAuthor Afﬁliations:\\n1\\nVision Center of Excellence, Defense\\nHealth Agency, Department of Defense,\\nBethesda, Maryland\\n2\\nDepartment of Veterans Affairs,\\nWashington, District of Columbia\\n3\\nContractor in support of Vision Center of\\nExcellence, Bethesda, Maryland\\n4\\nDepartment of Mathematics and\\nStatistics, University of Maryland,\\nBaltimore County, Baltimore, Maryland\\n*felix.barker@va.gov\\n\\nmetaregression and subgroup analyses were performed to better\\naccount for the observed heterogeneity.',\n"," 'METHODS\\nSystematic Literature Search\\nFour databases (PubMed, EMBASE, EBSCO, and Cochrane Library) were queried for relevant literature published before August\\n2, 2017.',\n"," 'Although settings and interfaces varied between these\\ndatabases, an identical search strategy was adapted for each database.',\n"," 'The complete search strategy can be found in the Appendix\\n(available at http://links.lww.com/OPX/A408).',\n"," 'Briefly, search\\nterms were organized into four concepts: (1) prevalence, (2) head\\ninjury, (3) vision, and (4) deficit/dysfunction.',\n"," 'Terms within each\\ncategory were separated by the Boolean operator “OR,” and each\\ncategory was parenthesized and separated by the operator\\n“AND.” When possible, Medical Subject Heading terms or the “explode” qualifier was used to expand the search language.',\n"," 'All citations were imported and managed using EndNote X7.7.1 (Clarivate\\nAnalytics, Philadelphia, PA).',\n"," 'Two authors of the current study (DWB,\\nKM) worked independently to screen title and abstracts for relevant\\n\\nOptom Vis Sci 2019; Vol 96(8)\\n\\n542\\n\\n\\x0cVisual Dysfunctions in TBI — Merezhinskaya et al.',\n"," 'articles; arbitration of disagreements was performed by an independent\\nthird author (RKM).',\n"," 'Two authors (DWB, RKM) then worked independently to review full-text articles of all articles marked relevant to confirm\\neligibility; arbitration of disagreements was performed by two authors of\\nthe current study (FMB, NM).',\n"," 'Recent systematic reviews on the topic\\nwere scanned for appropriate literature10,14,17; bibliographies of all included articles were scanned for relevant references.',\n"," 'To the extent possible, an individual patient was represented\\nonly once for each visual outcome calculation.',\n"," 'When necessary,\\nstudy authors were contacted to determine the existence or degree\\nof patient overlap between their publications.',\n"," 'In instances of cohort overlap between two or more studies, the larger or more recent\\npublication was chosen for inclusion14; some notable studies were\\nexcluded as a result of this process.5,6,19–21\\n\\nInclusion and Exclusion Criteria\\n\\nData Extraction\\n\\nThe criteria for literature inclusion were as follows: (1) traumatic\\nbrain injury or comparable head injury was diagnosed by a trained\\nmedical professional; (2) screening and/or diagnostic testing for\\naccommodative dysfunction (insufficiency or infacility), convergence insufficiency, visual field loss, or visual acuity loss (visual\\nacuity equal to 20/200 or worse) was performed by an eye care provider; and (3) the article was published in English in a peer-reviewed\\njournal, and full text was available.',\n"," 'There were no restrictions for\\nperiod or patient age, with the exception that accommodation\\nwas only measured in nonpresbyopic traumatic brain injury populations 40 years or younger.',\n"," 'Studies were excluded based on the following criteria: (1)\\nsingle-case report design was used; (2) the sample population\\nwas artificially selected for one of the visual outcomes (i.e., patients were recruited because of visual symptoms likely secondary\\nto the visual outcome); (3) the sample population was previously diagnosed as having a chronic (or other) eye condition (e.g., glaucoma\\nand diabetic retinopathy); (4) brain injury was acquired in a manner\\nunrelated to trauma (e.g., stroke and infection); and (5) either traumatic brain injury or visual outcomes were self-reported or otherwise\\nnot clinically diagnosed.',\n"," 'Efforts were made to remove the impact of\\nocular/orbital injury on visual diagnoses: patients/publications were\\nexcluded if there was evidence of eye injury (e.g., intraocular hemorrhage and open globe injury) that could explain visual symptoms.',\n"," 'Applicable data were restricted to traumatic brain injury patients\\ndiagnosed as having one or more of these four visual outcomes.',\n"," 'These data did not include baseline prevalence comparisons, calculation of risk statistics, or assessment of the effectiveness of interventions for these outcomes.',\n"," 'Review articles rarely reported\\noriginal data and were therefore excluded from statistical analysis;\\nhowever, reviews were used as resources to find relevant literature.',\n"," 'Prevalence statistics of the four visual outcomes were extracted\\ndirectly from tables or the reported text.',\n"," 'Initial data extraction was\\nperformed by two authors who worked together (DWB, RKM); arbitration of disagreements was performed through discussion with\\ntwo additional authors (FMB, NM).',\n"," 'A second review of data extraction was performed by one author (RKM) with any issues resolved\\nthrough discussion with two additional authors (FMB, NM).',\n"," 'Confidence intervals were estimated according to the Clopper-Pearson\\nmethod22 at the 95% level.',\n"," 'When available, additional contextual\\ndata extracted from each study included the following: geographic\\nlocation (by country), age of participants, participant sex ratio, target population (i.e., defining characteristics of the recruited population), causes of traumatic brain injury (i.e., mechanism of injury),\\ntime elapsed from the traumatic brain injury until the eye\\nexamination/screening, severity of traumatic brain injury, study design, and visual deficit/dysfunction testing criteria.',\n"," 'Study Selection\\nReported data regarding the prevalence of accommodative dysfunction, convergence insufficiency, visual field loss, and visual acuity loss were gathered by conducting the systematic literature search\\ndescribed previously.',\n"," 'All reported accommodative dysfunction data\\nreflect accommodative measures relative to age-related thresholds.',\n"," 'Visual field loss was defined as any type of diagnosed visual field defect consistent with post-chiasmal injury such as hemianopia,\\nquadrantanopia, or scotoma; visual field defects attributed to prechiasmal optic nerve or retinal damage were excluded.',\n"," 'Visual acuity\\nloss was defined as a Snellen visual acuity estimate or comparable\\nmeasure at the level of “legal blindness” (20/200 or worse).18\\nDuplicate articles were removed, and the remaining publications were screened by title and abstract for possible inclusion.',\n"," 'A\\nthorough full-text review of all remaining articles was subsequently\\ncompleted.',\n"," 'Additional articles were added to the initial list after review of bibliographies contained in the included articles.',\n"," 'All steps\\nwere performed independently by two reviewers (DWB, KM); arbitration of disagreements was performed by an independent third\\nreviewer (RKM).',\n"," 'www.optvissci.com\\n\\nStatistical Analysis\\nAll statistical analyses were conducted using R statistical software (3.4.2)23 and its “meta” and “metafor” package.24 Prevalence rates were calculated by dividing the number of individuals\\nwith traumatic brain injury diagnosed with the visual outcome by\\nthe total number of individuals diagnosed as having traumatic\\nbrain injury.',\n"," \"These rates were transformed via Freeman-Tukey's25\\ndouble-arcsine method, as it best accounts for extreme values\\n(near 0 or 1) and is appropriate for meta-analyses of prevalence.26\\nStudies were weighted per their effect size using the reciprocal of\\nvariance (i.e., inverse variance) of the transformed proportions.\",\n"," 'A\\ncontinuity correction of 0.5 was applied to all prevalence estimates\\nof zero.27 Forest plots of each visual outcome were presented as\\nback-transformed data (i.e., raw prevalence) using the “metaprop”\\nand “forest” commands.',\n"," 'Variances were combined using the\\nDerSimonian-Laird28 random-effects model.',\n"," 'Between-study variance (τ2) was estimated using the restricted maximal likelihood\\nmethod,29 as it best accommodates metaregression analyses, and\\nheterogeneity was assessed using Cochran Q test and Higgins I2 (I2\\nvalues <40, 30 to 60, 50 to 90, and ≥75% were deemed low, moderate, substantial, and considerable heterogeneity, respectively).30\\nCochran Q has demonstrated low power under certain circumstances\\nand was therefore deemed statistically significant at P values less\\nthan .10.31 An iterative influence analysis using the leave-one-out\\nmethod was performed for each outcome to determine whether any\\nsingle study was disproportionately influential in any of the respective combined prevalence estimates.32,33 Subgroup analysis was\\nperformed for four moderators: (1) study design (prospective vs. retrospective), (2) traumatic brain injury severity, (3) diagnostic\\ncriteria, and (4) risk of bias to compare the prevalence rates among\\ndifferent levels of moderators by considering the meta-analysis result\\nfrom each group separately.',\n"," 'Methodological risk of bias of each\\nstudy was appraised via criteria validated by Hoy et al.34 Upon assessment of methodological risk of bias,34 studies ranged from 0\\nto 6 (Table 1).',\n"," 'The overall risk-of-bias score for each study was\\n\\nOptom Vis Sci 2019; Vol 96(8)\\n\\n543\\n\\n\\x0cVisual Dysfunctions in TBI — Merezhinskaya et al.',\n"," 'TABLE 1.',\n"," \"Risk-of-bias tool matrix\\n\\nStudy\\n\\nWas the study's\\npopulation\\na close\\nWas some\\nrepresentation\\nWas the\\nform of\\nof the national sampling frame random\\nWas the\\npopulation in a true or close selection\\nrelation to\\nrepresentation used to likelihood of\\nyour relevant\\nof the target select the nonresponse\\nvariable?\",\n"," 'population?',\n"," 'sample?',\n"," 'bias minimal?',\n"," 'Was the study\\ninstrument\\nthat measured\\nWas an the parameter\\nWere data acceptable of interest\\nshown to have\\ncollected\\ncase\\nreliability\\ndirectly definition\\nand validity\\nfrom the\\nused in\\nsubjects?',\n"," 'the study?',\n"," '(if necessary)?',\n"," 'Was the\\nsame mode\\nof data\\ncollection\\nused for all\\nsubjects?',\n"," 'Were the\\nWas the\\nlength of the numerator(s)\\nand\\nshortest\\nprevalence denominator(s)\\nfor the\\nperiod for the\\nparameter\\nparameter of\\nof interest\\ninterest\\nappropriate?',\n"," 'appropriate?',\n"," 'Alvarez\\net al.35\\n\\nNo (1)\\n\\nNo (1)\\n\\nNo (1)\\n\\nYes (0)\\n\\nYes (0)\\n\\nYes (0)\\n\\nYes (0)\\n\\nYes (0)\\n\\nYes (0)\\n\\nYes (0)\\n\\nBrahm\\net al.4\\n\\nNo (1)\\n\\nYes (0)\\n\\nYes (0)\\n\\nYes (0)\\n\\nYes (0)\\n\\nYes (0)\\n\\nYes (0)\\n\\nNo (1)\\n\\nYes (0)\\n\\nYes (0)\\n\\nBulson\\net al.36\\n\\nNo (1)\\n\\nNo (1)\\n\\nNo (1)\\n\\nNo (1)\\n\\nYes (0)\\n\\nYes (0)\\n\\nYes (0)\\n\\nNo (1)\\n\\nYes (0)\\n\\nYes (0)\\n\\nCapóAponte\\net al.7\\n\\nNo (1)\\n\\nYes (0)\\n\\nNo (1)\\n\\nYes (0)\\n\\nYes (0)\\n\\nYes (0)\\n\\nYes (0)\\n\\nYes (0)\\n\\nYes (0)\\n\\nYes (0)\\n\\nCapóAponte\\net al.37\\n\\nNo (1)\\n\\nNo (1)\\n\\nNo (1)\\n\\nYes (0)\\n\\nYes (0)\\n\\nYes (0)\\n\\nYes (0)\\n\\nYes (0)\\n\\nYes (0)\\n\\nYes (0)\\n\\nCiuffreda\\net al.38\\n\\nNo (1)\\n\\nYes (0)\\n\\nYes (0)\\n\\nNo (1)\\n\\nYes (0)\\n\\nNo (1)\\n\\nYes (0)\\n\\nYes (0)\\n\\nYes (0)\\n\\nYes (0)\\n\\nCohen\\net al.39\\n\\nYes (0)\\n\\nNo (1)\\n\\nNo (1)\\n\\nNo (1)\\n\\nYes (0)\\n\\nNo (1)\\n\\nYes (0)\\n\\nYes (0)\\n\\nYes (0)\\n\\nYes (0)\\n\\nGoodrich\\net al.9\\n\\nNo (1)\\n\\nNo (1)\\n\\nNo (1)\\n\\nYes (0)\\n\\nYes (0)\\n\\nYes (0)\\n\\nYes (0)\\n\\nYes (0)\\n\\nYes (0)\\n\\nYes (0)\\n\\nHellerstein\\net al.40\\n\\nNo (1)\\n\\nNo (1)\\n\\nNo (1)\\n\\nYes (0)\\n\\nYes (0)\\n\\nYes (0)\\n\\nYes (0)\\n\\nYes (0)\\n\\nYes (0)\\n\\nYes (0)\\n\\nJackowski\\net al.41\\n\\nNo (1)\\n\\nNo (1)\\n\\nNo (1)\\n\\nYes (0)\\n\\nYes (0)\\n\\nYes (0)\\n\\nYes (0)\\n\\nYes (0)\\n\\nYes (0)\\n\\nYes (0)\\n\\nLemke\\net al.42\\n\\nNo (1)\\n\\nNo (1)\\n\\nYes (0)\\n\\nYes (0)\\n\\nYes (0)\\n\\nYes (0)\\n\\nYes (0)\\n\\nYes (0)\\n\\nYes (0)\\n\\nYes (0)\\n\\nMagone\\net al.43\\n\\nNo (1)\\n\\nNo (1)\\n\\nYes (0)\\n\\nYes (0)\\n\\nYes (0)\\n\\nYes (0)\\n\\nYes (0)\\n\\nYes (0)\\n\\nYes (0)\\n\\nYes (0)\\n\\nMaster\\net al.44\\n\\nNo (1)\\n\\nNo (1)\\n\\nYes (0)\\n\\nYes (0)\\n\\nYes (0)\\n\\nYes (0)\\n\\nYes (0)\\n\\nYes (0)\\n\\nYes (0)\\n\\nYes (0)\\n\\nPadula\\net al.45\\n\\nNo (1)\\n\\nNo (1)\\n\\nYes (0)\\n\\nYes (0)\\n\\nYes (0)\\n\\nYes (0)\\n\\nYes (0)\\n\\nYes (0)\\n\\nYes (0)\\n\\nYes (0)\\n\\nPoggi\\net al.46\\n\\nNo (1)\\n\\nNo (1)\\n\\nNo (1)\\n\\nYes (0)\\n\\nYes (0)\\n\\nYes (0)\\n\\nYes (0)\\n\\nYes (0)\\n\\nYes (0)\\n\\nYes (0)\\n\\nSabates\\net al.47\\n\\nNo (1)\\n\\nNo (1)\\n\\nYes (0)\\n\\nYes (0)\\n\\nYes (0)\\n\\nYes (0)\\n\\nYes (0)\\n\\nYes (0)\\n\\nYes (0)\\n\\nYes (0)\\n\\nSchrupp\\net al.48\\n\\nNo (1)\\n\\nNo (1)\\n\\nNo (1)\\n\\nYes (0)\\n\\nYes (0)\\n\\nNo (1)\\n\\nNo (1)\\n\\nNo (1)\\n\\nYes (0)\\n\\nYes (0)\\n\\nShokunbi\\nand\\nAgbeja49\\n\\nNo (1)\\n\\nNo (1)\\n\\nNo (1)\\n\\nYes (0)\\n\\nYes (0)\\n\\nNo (1)\\n\\nNo (1)\\n\\nNo (1)\\n\\nYes (0)\\n\\nYes (0)\\n\\nStelmack\\net al.8\\n\\nNo (1)\\n\\nNo (1)\\n\\nNo (1)\\n\\nYes (0)\\n\\nYes (0)\\n\\nYes (0) for Yes (0)\\nAD, CI\\nfor AD, CI\\n\\nYes (0) for AD,\\nCI, VAL\\n\\nYes (0)\\n\\nYes (0)\\n\\nNo (1)\\nfor VFL\\n\\nNo (1) for VFL\\n\\nNo (1)\\nfor VFL\\n\\nStorey\\net al.50\\n\\nNo (1)\\n\\nNo (1)\\n\\nNo (1)\\n\\nYes (0)\\n\\nYes (0)\\n\\nYes (0)\\n\\nYes (0)\\n\\nYes (0)\\n\\nYes (0)\\n\\nYes (0)\\n\\nSuchoff\\net al.51\\n\\nNo (1)\\n\\nNo (1)\\n\\nYes (0)\\n\\nYes (0)\\n\\nYes (0)\\n\\nYes (0)\\n\\nYes (0)\\n\\nYes (0)\\n\\nYes (0)\\n\\nYes (0)\\n\\nVan Stavern\\net al.52\\n\\nYes (0)\\n\\nYes (0)\\n\\nYes (0)\\n\\nYes (0)\\n\\nYes (0)\\n\\nNo (1) for CI\\n\\nYes (0)\\n\\nYes (0)\\n\\nNo (1) for CI No (1) for CI\\nYes (0)\\nfor VFL\\n\\nYes (0) for VFL Yes (0) for VFL\\n\\nYes (0) represents low risk of bias; No (1), high risk of bias.',\n"," 'Subcategories: low risk, 0 to 3 score for risk of bias; moderate risk, 4 to 6 score for risk of bias;\\nhigh risk, 7 to 9 score for risk of bias.',\n"," 'AD = accommodative dysfunction; CI = convergence insufficiency; VAL = visual acuity loss; VFL = visual field loss.',\n"," 'www.optvissci.com\\n\\nOptom Vis Sci 2019; Vol 96(8)\\n\\n544\\n\\n\\x0cVisual Dysfunctions in TBI — Merezhinskaya et al.',\n"," 'grouped into low risk of bias (score of 0 to 3), medium risk of bias\\n(score of 4 to 6), and high risk of bias (score 7 to 9); a higher score\\nindicates greater risk of bias.34 All of the studies in this article\\nranged from low to medium risk of bias.',\n"," 'Univariate metaregression analyses of prevalence by several\\nmoderators were conducted to investigate the sources of heterogeneity in each of the four visual outcomes.',\n"," 'The moderators\\nwere considered as categorical variables with mostly binary outcomes.',\n"," 'The risk-of-bias moderator was a binary outcome with\\nlow and moderate categories of risk of bias, and severity of traumatic brain injury was a binary outcome with mild (Glasgow\\nComa Scale score 13 to 15) and moderate-to-severe (Glasgow\\nComa Scale score 3 to 12) categories.',\n"," 'When Glasgow Coma Scale, or comparable metric, was not reported, explicit attribution of mild or moderate/severe traumatic\\nbrain injury in the publication text was considered; for this analysis,\\nsports concussions were not considered mild traumatic brain injury.',\n"," 'Study authors were contacted when traumatic brain injury severity distinctions were unclear.',\n"," 'Many individual publications\\nreported visual outcome prevalence statistics stratified by traumatic\\nbrain injury severity, which provided an opportunity to use subpopulations from a single article in more than one category.4,35,42 Statistics reported for metaregression analyses were the test statistic for\\n\\nthe omnibus test of coefficients (i.e., the test for the effect of a\\nmoderator; Cochran Q), percentage of heterogeneity accounted\\nfor R2, and Higgins I2 for individual subgroups.',\n"," 'Bonferroni correction for multiple comparisons was applied to\\nmetaregression analyses such that Cochran Q was deemed statistically significant at less than 0.025.',\n"," 'RESULTS\\nSearch Results\\nDatabase searches yielded 2104 unique publications.',\n"," 'Of these,\\n2082 publications were excluded primarily because of a sample\\npopulation comprising non–traumatic brain injury patients, lack\\nof measurements for pertinent visual outcomes or being preselected\\nfor visual symptoms consistent with the visual outcome, not examined by an eye care provider, missing data, or being a foreignlanguage article.',\n"," 'After title and abstract screening and full-text\\nreview, 22 publications met the criteria for inclusion.4,7–9,35–51\\nThe selection process summarized in Fig.',\n"," '1 is in accordance with\\nstandardized Preferred Reporting Items for Systematic Reviews\\nand Meta-analyses guidelines.54 On several occasions, data on\\nmore than one visual outcome were extracted from the same\\n\\nFIGURE 1.',\n"," 'Flow diagram of the systematic literature search process according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses.53\\n\\nwww.optvissci.com\\n\\nOptom Vis Sci 2019; Vol 96(8)\\n\\n545\\n\\n\\x0cVisual Dysfunctions in TBI — Merezhinskaya et al.',\n"," 'publication.',\n"," 'Taking these into account, 11 publications reported\\naccommodative dysfunction data,4,7–9,35–38,43–45 14 reported\\nconvergence insufficiency data,4,7–9,35,37–41,43,44,50,52 14 reported visual field loss data,4,7–9,35–37,42,46–49,51,52 and 6 reported visual acuity loss data.4,7,8,35,41,43\\n\\nStudy Characteristics\\nCharacteristics of the included studies can be found in Table 2.',\n"," 'The studies were predominantly conducted in the United States\\n(86.3%), but patients from Africa, Asia, and Europe were also represented.',\n"," 'Patients ranged in age from 7 months to 91 years and\\nwere generally recruited from one of three subpopulations: (1) military service members and/or veterans, (2) athletes, or (3) the\\ncatchment area surrounding local hospitals; female patients were\\nunderrepresented, particularly among military groups.',\n"," 'The most\\ncommonly reported mechanisms of traumatic brain injury were motor vehicle accidents, blast-related injuries, sports-related injuries,\\nand falls.',\n"," 'Accommodative Dysfunction\\nThe combined sample represents 1271 traumatic brain injury\\npatients who were screened for accommodative dysfunction.',\n"," 'The\\nmethods of assessing accommodation varied among the studies\\n(Table 2); tests for accommodative insufficiency, infacility, or both\\nwere most common.',\n"," 'Prevalence of accommodative dysfunction\\nranged from 13 to 80.0% across the included studies with a combined prevalence of 42.8% (95% confidence interval, 31.3 to\\n54.7%; Fig.',\n"," '2).',\n"," 'This estimate was considerably heterogeneous (Q\\n[10] = 115.64; P < .0001; I2 = 91.35%), although no single study\\nwas disproportionately influential.',\n"," 'None of the four metaregression\\nanalyses (study design, traumatic brain injury severity, diagnostic\\ncriteria, and risk of bias) accounted for a significant portion of heterogeneity.',\n"," 'The combined prevalence estimate of studies explicitly\\nreporting on mild traumatic brain injury patients, the most common\\nform of traumatic brain injury, was 43.2% (95% confidence interval, 29.2 to 57.7%).',\n"," 'Convergence Insufficiency\\nAcross all studies, 2140 traumatic brain injury patients were\\nscreened for convergence insufficiency.',\n"," 'Other convergence dysfunctions were sought, but only one study evaluated for convergence excess,7 and none evaluated for convergence infacility.',\n"," 'Testing methods for convergence involved the current state of the\\ncommonly used clinical criteria accepted by the field; hence, either\\nthe singular use of near point of convergence or any combination of\\nnear point of convergence, fusional vergence, and eye alignment\\ntesting was used (Table 2); diagnostic cutoffs for the near point\\nof convergence test varied from 6 to 12.7 cm (5 inches).',\n"," 'The estimated prevalence in each study ranged from 14.7 to 71.4%.',\n"," 'The\\ncombined prevalence was 36.3% (95% confidence interval,\\n28.2 to 44.9%; Fig.',\n"," '3); these data were considerably heterogeneous (Q[13] = 129.20; P < .0001; I2 = 89.94%), but influence\\nanalysis did not specify any single study as disproportionately influential.',\n"," 'None of the four metaregression analyses (study design,\\ntraumatic brain injury severity, diagnostic criteria, and risk of bias)\\naccounted for a statistically significant portion of the reported heterogeneity (R2 < 0.21; P > .03).',\n"," 'The combined prevalence estimate of the studies explicitly reporting on mild traumatic brain\\ninjury patients, the most common form, was 37.2% (95% confidence interval, 24.3 to 51.1%).',\n"," 'www.optvissci.com\\n\\nVisual Field Loss\\nIn the combined sample, 2106 patients underwent visual field\\ntesting.',\n"," 'The specific types of visual field loss experienced by these\\npatients, when reported, included homonymous or nonhomonymous\\nhemianop(s)ia,4,35,42,47,49,51 quadrantanop(s)ia,4,35,42,47 visual\\nfield constriction/tunnel vision,4,47,51 and central or paracentral scotoma.4,47,51 Two publications in the included literature presented\\ndiagnoses of cortical blindness resulting from damage to the occipital region of the brain causing visual acuity and visual field loss.47,49\\nThe authors did not comment on the extent of visual impairment\\n(i.e., partial or complete) or the visual acuity estimate associated\\nwith cortical blindness; therefore, cortical blindness was treated as\\na post-chiasmal visual field defect rather than a loss of visual acuity.',\n"," 'Visual fields were most often assessed via confrontation and/or a\\nhandheld perimeter; however, Goldmann and automated perimetry\\nwere also used.',\n"," 'Individual publications presented prevalence estimates between 0.0 and 50.5%.',\n"," 'The combined prevalence estimate\\nwas 18.2% (95% confidence interval, 10.6 to 27.1%; Fig.',\n"," '4);\\nstatistical heterogeneity was considerable (Q[13] = 177.22;\\nP < .0001; I2 = 92.67%), but influence analysis did not reveal\\nany single study as disproportionately driving the combined estimate.',\n"," 'Metaregression analyses revealed that traumatic brain injury severity accounted for a significant portion of the observed\\nheterogeneity.',\n"," 'Patients with mild traumatic brain injury demonstrated visual field loss at a rate of 6.6% (95% confidence interval, 0 to 19.5%), whereas patients with moderate to severe\\ntraumatic brain injury had visual field loss at 39.8% (95% confidence interval, 29.8 to 50.3%; R2 = 64.80; P = .0006).',\n"," 'Risk of\\nbias, study design, and diagnostic criteria were not statistically\\nsignificant moderators (R2 = 0.22; P > .06).',\n"," 'Visual Acuity Loss\\nVisual acuity was measured in 1333 traumatic brain injury patients.',\n"," 'All studies used a Snellen chart/card or comparable metric\\nto assess visual acuity (Table 2); therefore, an analysis comparing\\ndiagnostic testing criteria was not performed.',\n"," 'Prevalence of visual\\nacuity loss at increasingly worse levels was reported, but inconsistent reporting methods across the studies made combined\\nprevalence estimates untenable.',\n"," 'However, data regarding the\\nprevalence of visual acuity worse than or equal to 20/200 (i.e., legal blindness)18 were available and ranged from 0.0 to 3.4%.',\n"," 'This\\ndegree of visual acuity loss is rare; the combined prevalence estimate was 0.0% (95% confidence interval, 0.0 to 1.1%; Fig.',\n"," '5);\\nthis estimate exhibited lower heterogeneity (Q[5] = 13.21;\\nP < .02; I2 = 62.2%) compared with previous cases, and no single\\nstudy was disproportionately influential.',\n"," 'The current study was unable to confirm a single case of visual acuity loss in mild traumatic\\nbrain injury patients (0.0%; 95% confidence interval, 0.0 to\\n0.0%), whereas moderate-to-severe traumatic brain injury patients\\nexperienced this deficit at a rate of 3.2% (95% confidence interval, 0.3 to 9.3%).',\n"," 'The result needs to be interpreted with caution\\nbecause only one study with moderate-to-severe data was available\\nfor the analysis.',\n"," 'DISCUSSION\\nAccommodative dysfunction and convergence insufficiency\\nare the most prevalent of the four visual outcomes examined in\\nthis study, occurring in 42.8 and 36.3% of traumatic brain injury patients, respectively.',\n"," 'The accommodation and convergence\\n\\nOptom Vis Sci 2019; Vol 96(8)\\n\\n546\\n\\n\\x0cVisual Dysfunctions in TBI — Merezhinskaya et al.',\n"," 'TABLE 2.',\n"," 'Characteristics of included studies\\n\\nStudy\\n\\nGeographic\\nlocation\\n\\nAge (y), mean\\nage ± SD\\nProportion,\\n(range)\\nfemale (%)\\n\\nTarget\\npopulation\\n\\nCauses of TBI\\n\\nRisk of bias\\nStudy design\\n(0–10)\\n\\nVisual deficit/\\ndysfunction\\ntesting criteria\\n\\nTime since TBI\\n\\nSeverity\\n\\nAlvarez\\net al.35\\n\\nUSA\\n\\n40.3 ± 17.4\\n(5–89)\\n\\n39\\n\\nGeneral\\nMVA, fall,\\npopulation\\nstrike or blow\\nto the head\\nfrom or\\nagainst an\\nobject, sport\\n\\nN/R\\n\\nN/R\\n\\nBrahm\\net al.4\\n\\nUSA\\n\\nInpatient:\\n28.6\\nOutpatient:\\n30.5\\n\\n4\\n\\nMilitary\\n\\nBlast, MVA,\\ngunshot, or\\nfall\\n\\nN/R\\n\\nBulson\\net al.36\\n\\nUSA\\n\\n29.9\\n(21–55)\\n\\n1\\n\\nMilitary\\n\\nBlast, MVA,\\nfall\\n\\nN/R\\n\\nN/R\\n\\nRetrospective Moderate\\n\\nAD: visual acuity, cover\\ntest, further binocular\\ntesting performed at\\ndiscretion of provider\\n(including PRA/NRA,\\nFCC, accommodative\\nfacility/amplitude,\\nphorias, and ranges);\\nVFL: confrontation\\n\\nCapóAponte\\net al.7\\n\\nUSA*\\n\\n29.33 ± 8.14\\n\\n9\\n\\nMilitary\\n\\nBlast, fall,\\nMVA rollover,\\nblunt force\\n\\n42 ± 343 d\\n\\nMild\\n\\nRetrospective\\n\\nLow\\n\\nAD: PRA, NRA;\\nCI: NPC (no amount\\nspecified), fusional\\nvergence, cover test,\\nworth-4-dot, fixation\\ndisparity;\\nVFL: confrontation;\\nVAL: Snellen chart,\\nSnellen card,\\nrefractive error\\n\\nCapóAponte\\net al.37\\n\\nUSA\\n\\n31.2 ± 7.36\\n\\n10\\n\\nMilitary\\n\\nBlast\\n\\n15–45 d\\n\\nMild\\n\\nProspective\\n\\nLow\\n\\nAD: AC/A ratio, minus\\nlens, facility tests with\\nlens flippers;\\nCI: NPC (no amount\\nspecified), fusional\\nvergence, cover test,\\nworth-4-dot,\\nfixation disparity;\\nVFL: confrontation;\\nVAL: Snellen chart,\\nrefraction\\n\\nCiuffreda\\net al.38\\n\\nUSA\\n\\n44.9 ± 15.8\\n(8–91)\\n\\nN/R\\n\\nGeneral\\npopulation\\n\\nN/R\\n\\nN/R\\n\\nRetrospective\\n\\nLow\\n\\nAD: refraction, visual\\nacuity, “binocular and\\noculomotor evaluation,”\\naccommodation,\\nversion, vergence,\\nfacility testing;\\nCI: accommodation,\\nversion, vergence,\\nbinocular and\\noculomotor evaluation\\n\\nCohen\\net al.39\\n\\nIsrael\\n\\nInpatient:\\n30 ± 18.1\\nOutpatient:\\n29 ± 9.9\\n\\nN/R\\n\\nGeneral\\npopulation\\n\\nN/R\\n\\n4.5 y\\n(0.1–43)\\n\\nInpatient: 3 y\\nOutpatient:\\n3 mo\\n\\nModerate\\nto severe;\\nmild\\n\\nSevere\\n\\nRetrospective\\n\\nLow\\n\\nAD: NPA, NRA, PRA,\\nAC/A ratio, cover test,\\nMaddox rod test;\\nCI: NPC (no amount\\nspecified), fusional\\nvergence, cover test;\\nVFL: confrontation,\\nHumphrey visual field,\\nOKN nystagmus drum;\\nVAL: Snellen chart,\\nretinoscopy\\n\\nRetrospective\\n\\nLow\\n\\nAD: pull-away method,\\ncover test;\\nCI: NPC (7 cm),\\ncover test;\\nVFL: confrontation,\\nGoldmann;\\nVAL: Feinbloom chart,\\nTeller Acuity Cards,\\nOKN drum, retinoscopy/\\nrefraction\\n\\nProspective\\n\\nModerate\\n\\nCI: NPC (RAF near-point\\nrule; no amount\\nspecified)\\n\\nContinued\\n\\nwww.optvissci.com\\n\\nOptom Vis Sci 2019; Vol 96(8)\\n\\n547\\n\\n\\x0cVisual Dysfunctions in TBI — Merezhinskaya et al.',\n"," 'TABLE 2.',\n"," 'Continued\\n\\nStudy\\n\\nGeographic\\nlocation\\n\\nAge (y), mean\\nage ± SD\\nProportion,\\n(range)\\nfemale (%)\\n5\\n\\nTarget\\npopulation\\nMilitary\\n\\nCauses of TBI\\nBlast, MVA,\\nfall, assault\\n\\nTime since TBI\\n\\nSeverity\\n\\nModerate\\nNonblast:\\nto severe;\\n0.32 ± 0.52 y\\nmild\\n(0.02–3.13)\\nBlast:\\n1.01 ± 1.18 y\\n(0.03–4.79)\\n\\nLow\\n\\nAD: pull-away method,\\nmonocular\\naccommodative\\namplitude;\\nCI: NPC (8 cm), cover\\ntest, Hirschberg test;\\nVFL: confrontation,\\ntangent screen, arc,\\nGoldmann\\n\\nMild\\n\\nProspective\\n\\nLow\\n\\nCI: fusional vergence,\\nrefraction, cover, test,\\nstereopsis, NPC, relative\\naccommodation, PRA,\\nNRA (if able to be\\nperformed)\\n\\nN/R\\n\\nProspective\\n\\nLow\\n\\nCI: NPC (12.7 cm);\\nVAL: refraction\\n\\nProspective\\nMild;\\nmoderate;\\nsevere;\\npenetrating\\n\\nLow\\n\\nVFL: automated perimetry\\n\\nRetrospective\\n\\nLow\\n\\nAD: amplitude of\\naccommodation;\\nCI: NPC (8 cm), fusional\\nvergence, cover test;\\nVAL: Snellen chart\\n\\nN/R\\n\\nProspective\\ncrosssectional\\nstudy\\n\\nLow\\n\\nAD: visual acuity,\\namplitude (push-up),\\naccommodative facility;\\nCI: NPC (6 cm),\\nfusional vergence, eye\\nalignment testing\\n(modified Thorington\\ntest), vergence facility\\n\\nN/R\\n\\nProspective\\n\\nLow\\n\\nAD: bell and book\\nretinoscopy, visual\\nacuity (with Feinbloom\\nand Lighthouse), NPC,\\ncover test, refraction\\n\\nProspective\\n\\nLow\\n\\nVFL: Goldmann, ring\\nperimeter, Crothers test\\n\\nN/R\\n\\nRetrospective\\n\\nLow\\n\\nVFL: Goldmann, tangent\\nscreen\\n\\n6.2 y\\n(11 mo–22 y)\\n\\nMild\\n\\nProspective\\n\\nModerate\\n\\nVFL: N/R\\n\\nN/R\\n\\nN/R\\n\\nRetrospective Moderate\\n\\nVFL: N/R\\n\\nUSA\\n\\nNonblast: 24\\n(19–63)\\nBlast: 26\\n(19–55)\\n\\nHellerstein\\net al.40\\n\\nUSA\\n\\n38.88\\n\\nN/R\\n\\nGeneral\\npopulation\\n\\nN/R\\n\\nJackowski\\net al.41\\n\\nUSA\\n\\n37.29 ± 4.3\\n(29–42)\\n\\n57\\n\\nGeneral\\npopulation\\n\\nN/R\\n\\n0.4–10.5 y\\n\\nLemke\\net al.42\\n\\nUSA\\n\\nMedian, 25\\n(19–45)\\n\\n5\\n\\nMilitary\\n\\nBlast\\n\\nMedian, 2 mo\\n(2 wk–6 y)\\n\\nMagone\\net al.43\\n\\nUSA\\n\\n30.5 ± 8.3\\n\\n6\\n\\nMilitary\\n\\nBlast\\n\\n50.5 ± 19.8 mo\\n(16–91)\\n\\nMild\\n\\nMaster\\net al.44\\n\\nUSA\\n\\n14.5\\n(13.5–14.8)\\n\\n58\\n\\nPediatric\\n\\n<1 mo; 1–3 mo;\\n>3 mo\\n\\nPadula\\net al.45\\n\\nUSA\\n\\n24\\n(22–46)\\n\\n30\\n\\nGeneral\\nMVA, fall\\npopulation\\n\\nN/R\\n\\nPoggi\\net al.46\\n\\nItaly\\n\\nMedian, 6.8\\n(0.5–12.1)\\n\\n34\\n\\nPediatric\\n\\nSabates\\net al.47\\n\\nUSA\\n\\n31\\n(5–74)\\n\\n30.9\\n\\n8.5 mo\\nGeneral\\nMVA, direct\\n(3 wk–3 y)\\npopulation\\ntrauma to the\\nskull, fall,\\nbicycle accident,\\nmountain\\nclimbing, blast\\n\\nSchrupp\\net al.48\\n\\nUSA\\n\\n42 ± 12\\n(18–59)\\n\\n71.4\\n\\nGeneral\\nMVA, fall, blow\\npopulation\\nto the head,\\nand unknown\\n\\nMVA, fall\\n\\nVisual deficit/\\ndysfunction\\ntesting criteria\\n\\nRetrospective\\n\\nGoodrich\\net al.9\\n\\nSports, fall\\n\\nRisk of bias\\nStudy design\\n(0–10)\\n\\nN/R\\n\\nMedian, 3.2 mo Moderate\\n(0.4–107.6)\\nto severe\\n\\nNigeria\\n\\n84.5 ±\\n57.3 mo\\n(7 mo–16 y)\\n\\n36\\n\\nPediatric\\n\\nMVA, fall,\\nmiscellaneous\\n\\nStelmack\\net al.8\\n\\nUSA\\n\\n31\\n\\n8\\n\\nMilitary\\n\\nMilitary\\n(OEF/OIF)\\n\\n<30 d\\n\\nN/R\\n\\nRetrospective Low (AD, CI, AD: accommodative\\nfacility, refraction;\\nand VAL),\\nmoderate CI: fusional vergence, eye\\nalignment test, vergence\\n(VFL)\\nfacility, refraction;\\nVFL: N/R;\\nVAL: refraction\\n\\nStorey\\net al.50\\n\\nUSA\\n\\n5–18 y\\n\\nN/R\\n\\nPediatric\\n\\nSport, fall,\\nrecreation\\n\\nN/R\\n\\nN/R\\n\\nRetrospective\\n\\nLow\\n\\nCI: NPC (6 cm)\\n\\nSuchoff\\net al.51\\n\\nUSA\\n\\nN/R\\n\\nGeneral\\npopulation\\n\\nN/R\\n\\nRetrospective\\n\\nLow\\n\\nVFL: confrontation, static\\nor kinetic perimetry\\n\\nShokunbi\\nand\\nAgbeja49\\n\\n44.9 ± 15.8\\n(8–91)\\n\\nN/R\\n\\n4.5 y\\n(0.1–42)\\n\\nContinued\\n\\nwww.optvissci.com\\n\\nOptom Vis Sci 2019; Vol 96(8)\\n\\n548\\n\\n\\x0cVisual Dysfunctions in TBI — Merezhinskaya et al.',\n"," 'TABLE 2.',\n"," 'Continued\\n\\nStudy\\nVan\\nStavern\\net al.52\\n\\nGeographic\\nlocation\\nUSA\\n\\nAge (y), mean\\nage ± SD\\nProportion,\\n(range)\\nfemale (%)\\n30\\n(2–86)\\n\\n37\\n\\nTarget\\npopulation\\n\\nCauses of TBI\\n\\nGeneral\\nMVA, fall,\\npopulation\\nbicycle\\naccidents,\\nprojectile,\\npedestrian\\naccident,\\nand others\\n\\nTime since TBI\\n\\nSeverity\\n\\n73.5 ± 291.8 d\\n(3 d–12 y)\\n\\nN/R\\n\\nRisk of bias\\nStudy design\\n(0–10)\\nRetrospective\\n\\nLow\\n\\nVisual deficit/\\ndysfunction\\ntesting criteria\\nCI: N/R;\\nVFL: Goldmann,\\nHumphrey\\nvisual field\\n\\nRisk of bias is based on 10 criteria formulated and validated by Hoy et al.,34 where a higher score indicates greater bias; two scores are presented in some\\ncases because of insufficient reporting of diagnostic criteria for some but not all visual outcomes.',\n"," 'Information presented in the “visual deficit/dysfunction\\ntesting criteria” column is discretized by the visual condition.',\n"," '*Evaluation was done by an American at Landstuhl Regional Medical Center, Germany.',\n"," 'AC/\\nA = accommodative convergence per unit of accommodation; AD = accommodative dysfunction; CI = convergence insufficiency; MVA = motor vehicle\\naccident; NPA = near point of accommodation; NPC = near point of convergence; N/R = not reported; NRA = negative relative accommodation; OEF = Operation Enduring Freedom; OIF = Operation Iraqi Freedom; PRA = positive relative accommodation; TBI = traumatic brain injury; UK = United Kingdom;\\nUSA = United States; VAL = visual acuity loss; VFL = visual field loss.',\n"," 'pathways rely on a decentralized and extensive neural architecture\\ninvolving mesencephalic brainstem nuclei, premotor and motor\\ncortex, cerebellum, and oculomotor, abducens, and trochlear\\nnerves.',\n"," 'Focal damage to a critical component of this system, diffuse or shearing forces along the visual pathway, or intracranial\\nedema, hematoma, or hemorrhage therefore can commonly lead\\nto deficient ability of the eyes to accommodate and/or converge,55\\nwhich is usually independent of any decrement in visual acuity.',\n"," 'The variety of damaging events that can lead to accommodative\\ndysfunction and/or convergence insufficiency provides plausible\\nreasoning for the high prevalence rates reported in this study.',\n"," 'Visual field loss occurs in approximately 18.2% of traumatic\\nbrain injury patients according to this study.',\n"," 'The assessment of visual field loss in a traumatic brain injury patient is complicated by\\nthe varied nature of head injuries and the probability of an associated ocular injury.',\n"," 'Individuals can demonstrate visual field loss\\nby sustaining a direct ocular injury and/or an injury to the intracranial visual pathways resulting in damage to segments of the visual\\npathway ranging from the retina to the occipital cortex.56,57 To ensure that the results of the current study were based solely on the\\nimpact of a brain injury and not ocular injury, only visual field loss\\nsecondary to post-chiasmal injury was considered.',\n"," 'Such defects\\nare often perceived bilaterally by the patient (e.g., hemianopia\\nand quadrantanopia)57 and are considered to occur secondary to\\nan injury to the intracranial portion of the visual pathway.',\n"," 'The current study indicates that visual acuity loss at the level of legal blindness is rarely associated with only traumatic brain injury.',\n"," 'A\\nprobable explanation is that visual sequelae resulting from ocular,\\nretinal, or optic nerve damage were excluded from this analysis.',\n"," 'In most cases, traumatic visual acuity loss is related to prechiasmal damage and occurs in the setting of severe head trauma\\nassociated with loss of consciousness.58 The relatively low prevalence of visual acuity loss due to neurologic consequences of traumatic brain injury suggests that the test for visual acuity, which is\\nthe most commonly performed measure of the visual system, is\\nan insufficient stand-alone surrogate for overall visual health.',\n"," 'In\\nfact, most traumatic brain injury patients in the current study had\\nlittle if any loss of acuity; three studies reported that all patients\\nwith mild forms of traumatic brain injury had better than or equal\\nto 20/25 vision.7,37,43 Therefore, patients with a history of head injury should be evaluated by an eye care provider (i.e., optometrist or\\nophthalmologist) who can render a comprehensive eye examination\\nwww.optvissci.com\\n\\nto look for these subtle changes in visual function, including direct\\ninjuries to the eye, which were not included in this study but are\\nknown to be commonly associated with head injuries and traumatic\\nbrain injury.59 Such a comprehensive examination would include\\nthe following: medical history, visual acuity, measurement of refractive error, external examination, pupillary testing, distance\\nand near cover testing, visual field testing, extraocular muscle\\nmovement assessment including version and vergence functions,\\naccommodative assessment, tonometry, slit-lamp biomicroscopy,\\nbinocular indirect ophthalmoscopy, and gonioscopy.',\n"," 'The current\\nstudy did not use comparative baseline rates of the studied visual\\noutcomes in otherwise healthy individuals that would allow for risk\\nmetrics to be calculated.',\n"," 'Although baseline rates or control groups\\nwere infrequently reported in the literature collected here, prevalence statistics for visual outcomes in populations with no history\\nof head injury have been reported previously.',\n"," 'Rates of accommodative dysfunction in otherwise healthy individuals were reported to\\nbe between 5.8 and 32.4%,37,60–64 which is lower than 42.8% reported in the current study.',\n"," 'Convergence insufficiency was previously reported in 4.2 to 31.4% of otherwise healthy\\npopulations11,37,61,63–67 compared with 36.3% reported in traumatic brain injury patients here.',\n"," 'Baseline visual field loss data\\nare rare and generally measured in older adults; however, CapóAponte et al.37 reported 0% visual field loss in otherwise healthy\\nmilitary personnel aged 20 to 43 years, and Ramrattan et al.68 reported a prevalence of 3% in civilians aged 55 to 64 years.',\n"," 'These\\nestimates are notably lower than 18.2% in the current study.',\n"," 'Lastly, baseline rates of visual acuity loss to the level of legal blindness were reported at less than 1%,60,69,70 which is comparable\\nwith the approximately 0% reported in traumatic brain injury\\npatients here.',\n"," 'Prevalence Stratified by Traumatic Brain\\nInjury Severity\\nThe prevalence estimates harvested from each study included\\nin the current analysis varied substantially.',\n"," 'It was hypothesized\\nthat this heterogeneity could be partially explained by the severity\\nof traumatic brain injury.',\n"," 'To address this question, the prevalence\\nof the four studied visual outcomes was stratified into either mild\\ntraumatic brain injury or moderate-to-severe traumatic brain injury\\ncategories, and metaregression analyses and subgroup analyses\\n\\nOptom Vis Sci 2019; Vol 96(8)\\n\\n549\\n\\n\\x0cVisual Dysfunctions in TBI — Merezhinskaya et al.',\n"," 'FIGURE 2.',\n"," 'Forest plot of accommodative dysfunction prevalence in traumatic brain injury patients.',\n"," 'Each data (square) and error band (horizontal line)\\nrepresent mean prevalence and 95% confidence interval (CI), respectively.',\n"," '“Events” refer to the number of patients with a positive diagnosis of accommodative dysfunction; “total” is the sample size of each study.',\n"," 'Weights and combined prevalence are calculated using the DerSimonian-Laird randomeffects model.',\n"," 'Sizes of the gray boxes are in proportion to the reported weights.',\n"," 'Mean prevalence is presented as a broken vertical line.',\n"," 'Asterisk indicates\\nstatistically significant heterogeneity (P < .10).',\n"," 'were performed (Fig.',\n"," '6).',\n"," 'The prevalence of accommodative dysfunction and convergence insufficiency did not differ in patients\\nwith mild versus moderate to severe traumatic brain injury according to the current analysis.',\n"," 'However, the data for accommodative\\ndysfunction need to be interpreted with caution because only one\\nstudy with moderate-to-severe traumatic brain injury data was\\n\\navailable for the analysis.',\n"," 'This study comparison combined data\\nacross studies frequently using different diagnostic approaches\\n(Table 2) and often did not stratify prevalence by the types of accommodative issues (e.g., accommodative insufficiency and\\ninfacility).',\n"," 'However, the study findings comport with Brahm et al.4\\nand Alvarez et al.,35 who did report these traumatic brain injury\\n\\nFIGURE 3.',\n"," 'Forest plot of convergence insufficiency prevalence in traumatic brain injury patients.',\n"," 'All conventions as in Fig.',\n"," '2.\\n\\nwww.optvissci.com\\n\\nOptom Vis Sci 2019; Vol 96(8)\\n\\n550\\n\\n\\x0cVisual Dysfunctions in TBI — Merezhinskaya et al.',\n"," 'FIGURE 4.',\n"," 'Forest plot of visual field loss prevalence in traumatic brain injury patients.',\n"," 'All conventions as in Fig.',\n"," '2.',\n"," 'The x axis is truncated for clarity.',\n"," 'severity comparisons using their respective, internally consistent,\\ndiagnostic methodologies and found no differences in visual dysfunctions between traumatic brain injury severity levels.',\n"," 'It should\\nalso be noted that the specific neurological abnormalities responsible for accommodative and convergence issues are rarely investigated in individual cases.',\n"," 'More detailed research is likely to shed\\ngreater light on this issue.',\n"," 'In contrast, post-chiasmal visual field loss demonstrated significance for higher prevalence associated with moderate to severe\\ntraumatic brain injury (39.8%) compared with mild traumatic brain\\ninjury (6.6).',\n"," 'This observation is consistent with previous research\\nshowing that more severe forms of traumatic brain injury, particularly with distributed cerebral pathology involving the occipital\\nlobe, optic radiations, or optic tract, lead to higher rates of postchiasmal visual field loss.57,71\\nWhen the prevalence of visual acuity loss (legal blindness equal\\nto or worse than 20/200) was stratified by the severity of traumatic\\nbrain injury, no cases were reported in mild traumatic brain injury\\n\\npatients compared with 3.2% in moderate to severe traumatic\\nbrain injury, but these data need to be interpreted with caution because only one reference with moderate to severe traumatic brain\\ninjury was found.',\n"," 'Although disparate visual acuity categorization\\npresented in the existing literature precluded a comparison of visual acuity at less severe levels in the current study, one study\\ndid report infrequent moderate visual acuity loss (worse than 20/\\n100) in Polytrauma Network Site outpatients (1.6%) compared\\nwith Polytrauma Rehabilitation Center inpatients (12.7%).4\\n\\nOther Moderating Variables and Their Relationship\\nwith Visual Outcome Prevalence\\nIn addition to traumatic brain injury severity, the studies were\\nevaluated on the association of the prevalence rates with risk of bias,\\ndiagnostic criteria, and study design (prospective vs. retrospective).',\n"," 'Methodological risk of bias was used not only to assess the literature\\nat large but also to determine if biased studies impacted reported\\n\\nFIGURE 5.',\n"," 'Forest plot of visual acuity loss (at the level of legal blindness) prevalence in traumatic brain injury patients.',\n"," 'The x axis is truncated for clarity.',\n"," 'All other conventions as in Fig.',\n"," '2.\\n\\nwww.optvissci.com\\n\\nOptom Vis Sci 2019; Vol 96(8)\\n\\n551\\n\\n\\x0cVisual Dysfunctions in TBI — Merezhinskaya et al.',\n"," 'FIGURE 6.',\n"," 'Forest plot of visual field loss prevalence in moderate-to-severe TBI compared with mild TBI.',\n"," 'All other conventions as in Fig.',\n"," '2.',\n"," 'TBI = traumatic brain injury.',\n"," 'prevalence rates in a meaningful way.',\n"," 'Criteria validated by Hoy\\net al.34 were used to appraise the studies on the recruited sample\\npopulation, the types of recruitment used, study instruments and\\nmeasurement validation, and statistical approach.',\n"," 'The general population was represented at higher rates (63%) than service members\\nand/or veterans (37%), which decreased the bias of recruited samples.',\n"," 'The studies used for the analysis had either low or medium risk\\nof bias, with overall risk of bias in the low category (mean, 3.18/10).',\n"," 'Most studies used validated screening/diagnostic criteria for\\nboth traumatic brain injury and visual outcome assessment (although some were not transparent about the tools used), and all\\nused appropriate statistical procedures.',\n"," 'The screening/diagnostic\\ncriteria for the visual dysfunctions varied significantly between different studies.',\n"," 'Despite this variability, we did not observe an association between the screening/diagnostic methodology and the\\nprevalence rates for all four visual outcomes.',\n"," 'No association was\\nobserved between the type of study (prospective vs. retrospective)\\nand the prevalence rates.',\n"," 'Traumatic Brain Injury Resulting from Blast versus\\nNonblast Events\\nPrevalence rates for the four studied visual outcomes may depend on the mechanism by which the brain injury was acquired.',\n"," 'Of particular interest is whether head injuries resulting from an explosive blast event (i.e., due to the blast overpressure wave and/or\\nhead injury secondary to events of the blast) were related to differential visual dysfunction rates when compared with head injuries\\nresulting from nonblast events (e.g., sports-related trauma, falls,\\nand motor vehicle accidents).',\n"," 'Several of the included publications\\nprovided descriptions of the type(s) of injuring event that resulted\\nin traumatic brain injury (Table 2).',\n"," 'Although the data for these parameters are very limited, our study did not show that the prevalence\\nwww.optvissci.com\\n\\nfor the four visual outcomes is different in blast versus nonblast traumatic brain injury events.',\n"," 'Trauma secondary to direct, blunt, or penetrating injury to the\\nbrain, as well as damage resulting from brain displacement (e.g.,\\ncoup-contrecoup injury), can occur both in explosive blast or\\nnonblast scenarios.',\n"," 'Animal studies, computational analyses, and human brain pathology research have been used to examine whether the physical impact\\nof the blast overpressure wave, the only component unique to blast,\\nproduces specific brain injuries separate from other traumatic brain\\ninjury mechanisms of injury.53,72–77 In recent work, Tagge et al.73\\ncompared the effects of the blast overpressure wave with direct head\\nimpacts using computational simulation.',\n"," 'This research showed that\\ndirect impact generated high-pressure force loading onto a focused\\ncontact area, whereas blast wave impact caused distributed, lowermagnitude force loading.',\n"," 'Direct impact produced sevenfold greater\\npeak shear stress to the brain as compared with the blast wave.',\n"," 'Therefore, any effects due purely to blast overpressure on the visual\\nsystem are likely to be subtle and may be obscured by the more powerful effects of direct impact during the same blast event.',\n"," 'Indeed, Capó-Aponte et al.78 studied the isolated effects of\\nblast overpressure in Marine Corps “breachers” who encounter repetitive subconcussive blast exposure as part of their training.',\n"," 'Although the results were suggestive of detrimental effects of the\\nlow-level repetitive blast on corneal endothelial cell count, near\\nvertical phoria, and visual field sensitivity, all test results in the experimental group were within or only slightly lower than normative\\nvalue ranges.',\n"," 'No differences were found in convergence, accommodation, or visual acuity measures.',\n"," 'Nevertheless, it should be acknowledged that, although the current study and others did not detect a difference between blast and\\nnonblast events in visual symptoms measures, recent publications\\nsuggest that blast events may evoke specific cellular and molecular\\n\\nOptom Vis Sci 2019; Vol 96(8)\\n\\n552\\n\\n\\x0cVisual Dysfunctions in TBI — Merezhinskaya et al.',\n"," 'effects in brain tissue.',\n"," 'Shively et al.72 described a distinct pattern\\nof interface astroglial scarring in tissues adjacent to cerebrospinal\\nfluid at junctions between gray and white matter and around blood\\nvessels in brain specimens from military service members who\\nexperienced blast exposure.',\n"," 'Comparable glial deposition patterns were not observed in brain specimens from individuals\\nwith a history of impact (i.e., nonblast) and traumatic brain injury or control cases with no history of traumatic brain injury.',\n"," 'Future\\nresearch is needed to establish whether these neuropathological\\nfindings are associated with specific short- and/or long-term\\nclinical manifestations.',\n"," 'It should also be noted that little is known about the visual complications that arise from the other possible mechanisms of traumatic brain injury (e.g., falls and assaults), as stratification by the\\nmechanism of injury in the literature is rare (however, see Alvarez\\net al.,35 who did stratify visual outcomes by specific etiology including motor vehicle accidents, falls, and sports injuries).',\n"," 'Persistence of Visual Dysfunctions Secondary to\\nTraumatic Brain Injury\\nThere is also conjecture in the field of vision science regarding\\nthe persistence of visual dysfunctions after an individual sustains\\na traumatic brain injury.',\n"," \"Studies assessing a traumatic brain injury\\npatient's visual status at numerous time points during recovery are\\ninfrequent and use subjective visual symptom data rather than administering comprehensive eye examinations.79,80 Despite the\\nlack of optimal evidence, a small number of publications, which\\nare included in the analyses previously, address the extent to which\\nvisual outcomes are diagnosed in the long-term (i.e., chronic)\\nphase.\",\n"," 'Capó-Aponte et al.7 compared three cohorts whose constituents received diagnostic eye examinations at different periods\\n(i.e., ≤45 days, between 46 and 365 days, or >365 days) after\\ntheir traumatic brain injury.',\n"," 'Although the small number of studies\\ndid not allow for the generalization of the conclusion, this study\\nfound no difference in the prevalence of accommodative dysfunction, convergence insufficiency, and visual field loss between the\\nthree groups.',\n"," 'In addition, Kowal81 documented the prevalence of\\naccommodative dysfunction (16%) and convergence insufficiency\\n(14%) in 161 patients shortly after head injury.',\n"," 'Most patients with\\naccommodation and convergence issues were followed up for more\\nthan 1 year, and at least 58 and 35% of these patients, respectively, experienced persisting symptoms.',\n"," 'Despite the paucity of evidence explicitly addressing the prevalence of visual outcomes in\\nthe chronic versus acute phase of traumatic brain injury recovery,\\nit is evident that traumatic visual dysfunctions can and do persist\\nin a substantial proportion of traumatic brain injury patients past\\n1 year after the injuring event.',\n"," 'Limitations\\nThe nature of meta-analyses requires the combination of data\\ncollected from various locations, sources, and authors.',\n"," 'There are,\\ntherefore, inherent limitations that should be acknowledged.',\n"," 'A\\nprimary limitation of the current study is the extent of statistical\\nheterogeneity in the data for accommodative dysfunction, convergence insufficiency, and visual field loss.',\n"," 'Each of these combined prevalence estimates (Figs.',\n"," '2 to 5) was associated with a\\nsignificantly high I2 statistic (each >90%).',\n"," 'To further account\\nfor some of the reported heterogeneity, univariate metaregression\\nanalyses were performed.',\n"," 'www.optvissci.com\\n\\nLimitations were apparent in the traumatic brain injury severity\\nanalysis; it was common that either publications did not report the\\nseverity of traumatic brain injury, or the patient sample was populated with individuals who sustained varying degrees of traumatic\\nbrain injury.',\n"," 'The traumatic brain injury severity analysis was further\\ncomplicated by the diagnosis of “concussion” in several publications,44,50 which lacks the same accepted severity distinctions\\nused in traumatic brain injury and is often but not always82,83\\ndeemed synonymous with mild traumatic brain injury.',\n"," 'For these\\nreasons, many publications were excluded from metaregression\\nanalyses, which reduced the power and generalizability of subsequent conclusions.',\n"," 'Similar challenges restricted the utility of the\\nscreening/diagnostic testing criteria moderator.',\n"," 'Categorization of disparate approaches into logical categories\\nwas exceedingly difficult; for example, testing criteria in a distinct\\ncategory necessarily overlapped with those of neighboring categories.',\n"," 'This problem is magnified by some studies not providing sufficient\\nmethodological detail for their testing criteria.',\n"," 'Additional attempts\\nwere made to account for differences between studies based on age\\nof participants, sex ratio, target population, geographic location, and\\nyear of study, but these factors largely failed to explain variability\\namong visual outcome prevalence estimates (data not shown).',\n"," 'The\\nmetaregression analyses suggest that no single factor was responsible\\nfor the observed statistical heterogeneity.',\n"," 'Recommendations\\nTraumatic brain injury is a time-related process involving injury,\\nshort-term change, and longer-term recovery, which can persist\\nchronically, all processes that are not well understood.',\n"," 'A carefully\\nconstructed prospective trial with a large sample and consistent\\nevaluation techniques would have a tremendous impact on the\\nfield and would address the various limitations outlined previously.',\n"," 'An ideal trial would recruit unbiased samples of consecutive patients from hospitals, emergency departments, military treatment facilities, and/or Veterans Affairs; record demographic\\ncharacteristics (e.g., age, sex, and occupation) and injury specifics (e.g., etiology, severity, comorbid conditions such as eye\\ninjuries, and imaging results); would require complete examinations from eye care providers within a restricted time after injury\\nand additional follow-up, regardless of overt visual symptoms;\\nwould mandate application of consistent diagnostic testing\\ncriteria for each visual outcome; and would maintain detailed records of dosage, use, and compliance information for prescribed\\ndrugs, devices, or interventions.',\n"," 'Furthermore, to better understand chronicity, recovery, and management outcomes, this\\nstudy should be extended to incorporate a natural history design\\nover a longitudinal timeline.',\n"," 'The current study clearly shows that traumatic brain injury\\ndamages the visual system in many ways and that, because visual\\nacuity is often unaffected, these visual outcomes are frequently\\nundetected.',\n"," 'Therefore, all service members, veterans, and/or civilians who have experienced a traumatic brain injury should seek\\n(or be referred to) an eye care provider for a comprehensive eye examination as specified by the Veterans Health Administration Notice 2017-3584 and the Vision Center of Excellence Clinical\\nRecommendations for the Eye Care Provider.',\n"," 'Further detail regarding the detection and management of traumatic brain injury–\\nassociated visual dysfunctions is available in the Department of\\nDefense– and Veterans Affairs–approved Vision Center of Excellence clinical recommendations.85–87\\n\\nOptom Vis Sci 2019; Vol 96(8)\\n\\n553\\n\\n\\x0cVisual Dysfunctions in TBI — Merezhinskaya et al.',\n"," 'ARTICLE INFORMATION\\nSupplemental Digital Content: The Appendix, available at\\nhttp://links.lww.com/OPX/A408, demonstrates the search\\nstrategy used for searching the databases PubMed,\\nEMBASE, EBSCO, and Cochrane Library to identify candidate literature articles for this meta-analysis.',\n"," 'Submitted: May 1, 2018\\nAccepted: May 4, 2019\\nFunding/Support: The Vision Center of Excellence.',\n"," 'Conflict of Interest Disclosure: None of the authors have\\nreported a financial conflict of interest.',\n"," 'Author Contributions and Acknowledgments: Conceptualization:\\nFMB; Data Curation: RKM, DWB, KM; Formal Analysis:\\nRKM, DP; Funding Acquisition: FMB; Investigation: NM,\\nRKM, DWB, KM, FMB; Methodology: NM, RKM, DWB,\\nKM, FMB; Project Administration: FMB; Resources: NM,\\nRKM, DWB, KM; Software: DP; Supervision: NM, RKM,\\nFMB; Validation: NM, RKM, DP, DWB, KM, FMB;\\nVisualization: RKM, DWB; Writing – Original Draft: DWB;\\nWriting – Review & Editing: NM, RKM, DP, FMB.',\n"," 'The views expressed in this article reflect the results of\\nresearch conducted by the authors and do not\\nnecessarily reflect the official policy or position of the\\nDefense Health Agency, Department of Defense,\\nDepartment of Veterans Affairs, or the U.S. government.',\n"," 'REFERENCES\\n1.',\n"," 'Menon DK, Schwab K, Wright DW, et al.',\n"," 'Position\\nStatement: Definition of Traumatic Brain Injury.',\n"," 'Arch\\nPhys Med Rehabil 2010;91:1637–40.',\n"," '2.',\n"," 'Taylor CA, Bell JM, Breiding MJ, et al.',\n"," 'Traumatic\\nBrain Injury–related Emergency Department Visits, Hospitalizations, and Deaths—United States, 2007 and\\n2013.',\n"," 'MMWR Surveill Summ 2017;66:1–16.',\n"," '3.',\n"," 'Department of Defense (DoD).',\n"," 'Worldwide Numbers\\nfor TBI.',\n"," 'Defense and Veterans Brain Injury Center;\\n2017.',\n"," 'Available at: http://dvbic.dcoe.mil/files/tbinumbers/worldwide-totals-2000-2017_feb-14-2018_\\nv1.0_2018-03-08.pdf.',\n"," 'Accessed April 20, 2018.\\n\\nthe Veteran Population.',\n"," 'Department of Veterans Affairs,\\nVHA Office of Patient Care Services, Technology Assessment Program 2009.',\n"," 'Available at: https://www.va.gov/\\nOPTOMETRY/docs/VISTBI-Vision-tbi-final-report-9-09.pdf.',\n"," 'Accessed April 2018.',\n"," '11. Cooper J, Jamal N. Convergence Insufficiency—A\\nMajor Review.',\n"," 'Optometry 2012;83:137–58.',\n"," '12.',\n"," 'Hunt AW, Mah K, Reed N, et al.',\n"," 'Oculomotor-based\\nVision Assessment in Mild Traumatic Brain Injury: A Systematic Review.',\n"," 'J Head Trauma Rehabil 2016;31:252–61.',\n"," '13.',\n"," 'Kapoor N, Ciuffreda KJ.',\n"," 'Vision Disturbances Following Traumatic Brain Injury.',\n"," 'Curr Treat Options Neurol\\n2002;4:271–80.',\n"," '14.',\n"," \"O'Neil M, Gleitsmann K, Motu'apuaka M, et al.\",\n"," 'Visual\\nDysfunction in Patients with Traumatic Brain Injury: A Systematic Review.',\n"," 'VA Evidence-based Synthesis Program\\nReports.',\n"," 'Washington, DC: U.S. Department of Veterans\\nAffairs; 2014.',\n"," '15.',\n"," 'Schlageter K, Gray B, Hall K, et al.',\n"," 'Incidence and\\nTreatment of Visual Dysfunction in Traumatic Brain Injury.',\n"," 'Brain Inj 1993;7:439–48.',\n"," '16.',\n"," 'Thiagarajan P, Ciuffreda KJ, Ludlam DP.',\n"," 'Vergence\\nDysfunction in Mild Traumatic Brain Injury (MTBI): A\\nReview.',\n"," 'Ophthalmic Physiol Opt 2011;31:456–68.',\n"," '17.',\n"," 'Barker F, Ciuffreda K, Jacobs R, et al.',\n"," 'Development of Traumatic Brain Injury Detection Using Oculomotor and Eye Movement Tracking.',\n"," 'Ft. Detrick, MD:\\nNon-Invasive Neurologic Device Integrated Product\\nTeam, U.S. Army Medical Research and Materiel\\nCommand; 2013.',\n"," '18.',\n"," 'Social Security Administration.',\n"," \"If You're Blind or\\nHave Low Vision—How We Can Help.\",\n"," 'Social Security\\nAdministration; 2018.',\n"," 'Available at: https://www.ssa.',\n"," 'gov/pubs/EN-05-10052.pdf.',\n"," 'Accessed April 20, 2018.',\n"," '19.',\n"," 'Ciuffreda KJ, Rutner D, Kapoor N, et al.',\n"," 'Vision\\nTherapy for Oculomotor Dysfunctions in Acquired\\nBrain Injury: A Retrospective Analysis.',\n"," 'Optometry 2008;\\n79:18–22.',\n"," '20.',\n"," 'Lemke S, Cockerham GC, Glynn-Milley C, et al.',\n"," 'Visual Quality of Life in Veterans with Blast-induced\\nTraumatic Brain Injury.',\n"," 'JAMA Ophthalmol 2013;131:\\n1602–9.',\n"," '4.',\n"," 'Brahm KD, Wilgenburg HM, Kirby J, et al.',\n"," 'Visual Impairment and Dysfunction in Combat-injured Service\\nmembers with Traumatic Brain Injury.',\n"," 'Optom Vis Sci\\n2009;86:817–25.',\n"," '21.',\n"," 'Uzzell BP, Obrist WD, Dolinskas CA, et al.',\n"," 'Relation\\nof Visual Field Defects to Neuropsychological Outcome\\nafter Closed Head Injury.',\n"," 'Acta Neurochir 1987;86:\\n18–24.',\n"," '5.',\n"," 'Goodrich GL, Kirby J, Cockerham G, et al.',\n"," 'Visual\\nFunction in Patients of a Polytrauma Rehabilitation Center: A Descriptive Study.',\n"," 'J Rehabil Res Dev 2007;44:\\n929–36.',\n"," '22.',\n"," 'Clopper CJ, Pearson ES.',\n"," 'The Use of Confidence or\\nFiducial Limits Illustrated in the Case of the Binomial.',\n"," 'Biometrika 1934;26:404–13.',\n"," '6.',\n"," 'Lew HL, Poole JH, Vanderploeg RD, et al.',\n"," 'Program\\nDevelopment and Defining Characteristics of Returning\\nMilitary in a VA Polytrauma Network Site.',\n"," 'J Rehabil\\nRes Dev 2007;44:1027–34.',\n"," '7.',\n"," 'Capó-Aponte JE, Jorgensen-Wagers KL, Sosa JA,\\net al.',\n"," 'Visual Dysfunctions at Different Stages after Blast\\nand Non-blast Mild Traumatic Brain Injury.',\n"," 'Optom Vis\\nSci 2017;94:7–15.',\n"," '8.',\n"," 'Stelmack JA, Frith T, Van Koevering D, et al.',\n"," 'Visual\\nFunction in Patients Followed at a Veterans Affairs\\nPolytrauma Network Site: An Electronic Medical Record\\nReview.',\n"," 'Optometry 2009;80:419–24.',\n"," '9.',\n"," 'Goodrich GL, Flyg HM, Kirby JE, et al.',\n"," 'Mechanisms of\\nTBI and Visual Consequences in Military and Veteran\\nPopulations.',\n"," 'Optom Vis Sci 2013;90:105–12.',\n"," '10.',\n"," 'Adams E. Visual Problems in Traumatic Brain Injury:\\nA Systematic Review of Sequelae and Interventions for\\n\\nwww.optvissci.com\\n\\n23.',\n"," 'R: A Language and Environment for Statistical Computing: Release 2012 [Computer Program].',\n"," 'Vienna,\\nAustria: R Foundation for Statistical Computing; 2012.',\n"," 'Available at: http://www.R-project.org/.',\n"," 'Accessed April\\n20, 2018.',\n"," '28.',\n"," 'DerSimonian R, Laird N. Meta-analysis in Clinical\\nTrials.',\n"," 'Control Clin Trials 1986;7:177–88.',\n"," '29.',\n"," 'Thompson SG, Sharp SJ.',\n"," 'Explaining Heterogeneity\\nin Meta-analysis: A Comparison of Methods.',\n"," 'Stat Med\\n1999;18:2693–708.',\n"," '30.',\n"," 'Schünemann H, Brożek J, Guyatt G, et al.',\n"," 'The Grade\\nHandbook.',\n"," 'London, UK: Cochrane Collaboration; 2013.',\n"," 'Available at: http://gdt.guidelinedevelopment.org/app/\\nhandbook/handbook.html.',\n"," 'Accessed June 5, 2019.',\n"," '31.',\n"," 'Huedo-Medina TB, Sanchez-Meca J, MarinMartinez F, et al.',\n"," 'Assessing Heterogeneity in Metaanalysis: Q Statistic or I2 Index?',\n"," 'Psychol Methods\\n2006;11:193–206.',\n"," '32.',\n"," 'Lau J, Schmid CH, Chalmers TC.',\n"," 'Cumulative Metaanalysis of Clinical Trials Builds Evidence for Exemplary\\nMedical Care.',\n"," 'J Clin Epidemiol 1995;48:45–57.',\n"," '33.',\n"," 'Treadwell JR, Tregear SJ, Reston JT, et al.',\n"," 'A System\\nfor Rating the Stability and Strength of Medical Evidence.',\n"," 'BMC Med Res Methodol 2006;6:52.',\n"," '34.',\n"," 'Hoy D, Brooks P, Woolf A, et al.',\n"," 'Assessing Risk of\\nBias in Prevalence Studies: Modification of an Existing\\nTool and Evidence of Interrater Agreement.',\n"," 'J Clin\\nEpidemiol 2012;65:934–9.',\n"," '35.',\n"," 'Alvarez TL, Kim EH, Vicci VR, et al.',\n"," 'Concurrent\\nVision Dysfunctions in Convergence Insufficiency\\nwith Traumatic Brain Injury.',\n"," 'Optom Vis Sci 2012;89:\\n1740–51.',\n"," '36.',\n"," 'Bulson R, Jun W, Hayes J.',\n"," 'Visual Symptomatology\\nand Referral Patterns for Operation Iraqi Freedom and\\nOperation Enduring Freedom Veterans with Traumatic\\nBrain Injury.',\n"," 'J Rehabil Res Dev 2012;49:1075–82.',\n"," '37.',\n"," 'Capó-Aponte JE, Urosevich TG, Temme LA, et al.',\n"," 'Visual Dysfunctions and Symptoms During the Subacute\\nStage of Blast-induced Mild Traumatic Brain Injury.',\n"," 'Mil Med 2012;177:804–13.',\n"," '38.',\n"," 'Ciuffreda KJ, Kapoor N, Rutner D, et al.',\n"," 'Occurrence\\nof Oculomotor Dysfunctions in Acquired Brain Injury:\\nA Retrospective Analysis.',\n"," 'Optometry 2007;78:155–61.',\n"," '39.',\n"," 'Cohen M, Groswasser Z, Barchadski R, et al.',\n"," 'Convergence Insufficiency in Brain-injured Patients.',\n"," 'Brain Inj\\n1989;3:187–91.',\n"," '40.',\n"," 'Hellerstein LF, Freed S, Maples WC.',\n"," 'Vision Profile of\\nPatients with Mild Brain Injury.',\n"," 'J Am Optom Assoc\\n1995;66:634–9.',\n"," '41.',\n"," 'Jackowski MM, Sturr JF, Taub HA, et al.',\n"," 'Photophobia in Patients with Traumatic Brain Injury: Uses of\\nLight-filtering Lenses to Enhance Contrast Sensitivity\\nand Reading Rate.',\n"," 'NeuroRehabilitation 1996;6:\\n193–201.',\n"," '42.',\n"," 'Lemke S, Cockerham GC, Glynn-Milley C, et al.',\n"," 'Automated Perimetry and Visual Dysfunction in Blastrelated Traumatic Brain Injury.',\n"," 'Ophthalmology 2016;\\n123:415–24.',\n"," '24.',\n"," 'Schwarzer G, Carpenter JR, Rücker G. Metaanalysis with R. Switzerland: Springer International\\nPublishing; 2015.',\n"," '43.',\n"," 'Magone MT, Kwon E, Shin SY.',\n"," 'Chronic Visual Dysfunction after Blast-induced Mild Traumatic Brain Injury.',\n"," 'J Rehabil Res Dev 2014;51:71–80.',\n"," '25.',\n"," 'Freeman MF, Tukey JW.',\n"," 'Transformations Related to\\nthe Angular and the Square Root.',\n"," 'Ann Math Stat 1950;\\n21:607–11.',\n"," '44.',\n"," 'Master CL, Scheiman M, Gallaway M, et al.',\n"," 'Vision\\nDiagnoses Are Common after Concussion in Adolescents.',\n"," 'Clin Pediatr 2016;55:260–7.',\n"," '26.',\n"," 'Barendregt JJ, Doi SA, Lee YY, et al.',\n"," 'Meta-analysis\\nof Prevalence.',\n"," 'J Epidemiol Community Health 2013;\\n67:974–8.',\n"," '45.',\n"," 'Padula WV, Argyris S, Ray J.',\n"," 'Visual Evoked Potentials (VEP) Evaluating Treatment for Post-trauma Vision\\nSyndrome (PTVS) in Patients with Traumatic Brain Injuries (TBI).',\n"," 'Brain Inj 1994;8:125–33.',\n"," '27.',\n"," 'Sankey SS, Weissfeld LA, Fine MJ, et al.',\n"," 'An Assessment of the Use of the Continuity Correction for Sparse\\nData in Meta-analysis.',\n"," 'Commun Stat Simul Comput\\n1996;25:1031–56.',\n"," 'Optom Vis Sci 2019; Vol 96(8)\\n\\n46.',\n"," 'Poggi G, Calori G, Mancarella G, et al.',\n"," 'Visual Disorders after Traumatic Brain Injury in Developmental Age.',\n"," 'Brain Inj 2000;14:833–45.',\n"," '554\\n\\n\\x0cVisual Dysfunctions in TBI — Merezhinskaya et al.',\n"," '47.',\n"," 'Sabates NR, Gonce MA, Farris BK.',\n"," 'Neuroophthalmological Findings in Closed Head Trauma.',\n"," 'J Clin Neuroophthalmol 1991;11:273–7.',\n"," '48.',\n"," 'Schrupp LE, Ciuffreda KJ, Kapoor N. Foveal versus\\nEccentric Retinal Critical Flicker Frequency in Mild\\nTraumatic Brain Injury.',\n"," 'Optometry 2009;80:642–50.',\n"," '49.',\n"," 'Shokunbi T, Agbeja A. Ocular Complications of\\nHead Injury in Children.',\n"," 'Child Nerv Syst 1991;7:147–9.',\n"," '50.',\n"," 'Storey EP, Master SR, Lockyer JE, et al.',\n"," 'Near Point\\nof Convergence after Concussion in Children.',\n"," 'Optom Vis\\nSci 2017;94:96–100.',\n"," '51.',\n"," 'Suchoff IB, Kapoor N, Ciuffreda KJ, et al.',\n"," 'The Frequency of Occurrence, Types, and Characteristics of\\nVisual Field Defects in Acquired Brain Injury: A Retrospective Analysis.',\n"," 'Optometry 2008;79:259–65.',\n"," '52.',\n"," 'Van Stavern GP, Biousse V, Lynn MJ, et al.',\n"," 'Neuro-ophthalmic Manifestations of Head Trauma.',\n"," 'J Neuroophthalmol 2001;21:112–7.',\n"," '53.',\n"," 'McKee AC, Cairns NJ, Dickson DW, et al.',\n"," 'The First\\nNINDS/NIBIB Consensus Meeting to Define Neuropathological Criteria for the Diagnosis of Chronic Traumatic\\nEncephalopathy.',\n"," 'Acta Neuropathol 2016;131:75–86.',\n"," '54.',\n"," 'Moher D, Liberati A, Tetzlaff J, et al.',\n"," 'Preferred\\nReporting Items for Systematic Reviews and Metaanalyses: The PRISMA Statement.',\n"," 'PLoS Med 2009;\\n6:e1000097.',\n"," 'in Tamil Nadu: Report 2 of Band Study.',\n"," 'Clin Exp Optom\\n2017;100:642–8.',\n"," '64.',\n"," 'Davis AL, Harvey EM, Twelker JD, et al.',\n"," \"Convergence Insufficiency, Accommodative Insufficiency, Visual Symptoms, and Astigmatism in Tohono O'odham\\nStudents.\",\n"," 'J Ophthalmol 2016;2016:6963976.',\n"," '65.',\n"," 'Scheiman M, Gallaway M, Frantz KA, et al.',\n"," 'Nearpoint of Convergence: Test Procedure, Target Selection, and Normative Data.',\n"," 'Optom Vis Sci 2003;80:\\n214–25.',\n"," '66.',\n"," 'Rouse MW, Borsting E, Hyman L, et al.',\n"," 'Frequency of\\nConvergence Insufficiency among Fifth and Sixth\\nGraders.',\n"," 'The Convergence Insufficiency and Reading\\nStudy (CIRS) Group.',\n"," 'Optom Vis Sci 1999;76:643–9.',\n"," '67.',\n"," 'Wajuihian SO, Hansraj R. Vergence Anomalies in a\\nSample of High School Students in South Africa.',\n"," 'J Optom 2016;9:246–57.',\n"," '68.',\n"," 'Ramrattan RS, Wolfs RC, Panda-Jonas S, et al.',\n"," 'Prevalence and Causes of Visual Field Loss in the Elderly and\\nAssociations with Impairment in Daily Functioning:\\nThe Rotterdam Study.',\n"," 'Arch Ophthalmol 2001;119:\\n1788–94.',\n"," '69.',\n"," 'Bourne RR, Jonas JB, Flaxman SR, et al.',\n"," 'Prevalence\\nand Causes of Vision Loss in High-income Countries and\\nin Eastern and Central Europe: 1990–2010.',\n"," 'Br J\\nOphthalmol 2014;98:629–38.',\n"," '55.',\n"," 'Green W, Ciuffreda KJ, Thiagarajan P, et al.',\n"," 'Accommodation in Mild Traumatic Brain Injury.',\n"," 'J Rehabil Res\\nDev 2010;47:183–99.',\n"," '70.',\n"," 'Vijaya L, George R, Asokan R, et al.',\n"," 'Prevalence and\\nCauses of Low Vision and Blindness in an Urban Population: The Chennai Glaucoma Study.',\n"," 'Indian J Ophthalmol\\n2014;62:477–81.',\n"," '56.',\n"," 'Barnett BP, Singman EL.',\n"," 'Vision Concerns after Mild\\nTraumatic Brain Injury.',\n"," 'Curr Treat Options Neurol 2015;\\n17:329.',\n"," '71.',\n"," 'Zhang X, Kedar S, Lynn MJ, et al.',\n"," 'Homonymous\\nHemianopias: Clinical-anatomic Correlations in 904\\nCases.',\n"," 'Neurology 2006;66:906–10.',\n"," '57.',\n"," 'Bruce BB, Zhang X, Kedar S, et al.',\n"," 'Traumatic Homonymous Hemianopia.',\n"," 'J Neurol Neurosurg Psychiatry\\n2006;77:986–8.',\n"," '72.',\n"," 'Shively SB, Horkayne-Szakaly I, Jones RV, et al.',\n"," 'Characterisation of Interface Astroglial Scarring in the\\nHuman Brain after Blast Exposure: A Post-mortem Case\\nSeries.',\n"," 'Lancet Neurol 2016;15:944–53.',\n"," '58.',\n"," 'Atkins EJ, Newman NJ, Biousse V. Post-traumatic\\nVisual Loss.',\n"," 'Rev Neurol Dis 2008;5:73–81.',\n"," '59.',\n"," 'Cockerham GC, Lemke S, Rice TA, et al.',\n"," 'Closedglobe Injuries of the Ocular Surface Associated with\\nCombat Blast Exposure.',\n"," 'Ophthalmology 2014;121:\\n2165–72.',\n"," '60.',\n"," 'Dougherty AL, MacGregor AJ, Han PP, et al.',\n"," 'Visual\\nDysfunction Following Blast-related Traumatic Brain Injury from the Battlefield.',\n"," 'Brain Inj 2011;25:8–13.',\n"," '61.',\n"," 'Hokoda SC.',\n"," 'General Binocular Dysfunctions in an\\nUrban Optometry Clinic.',\n"," 'J Am Optom Assoc 1985;56:\\n560–2.',\n"," '62.',\n"," 'Porcar E, Martinez-Palomera A.',\n"," 'Prevalence of General Binocular Dysfunctions in a Population of University\\nStudents.',\n"," 'Optom Vis Sci 1997;74:111–3.',\n"," '63.',\n"," 'Hussaindeen JR, Rakshit A, Singh NK, et al.',\n"," 'Prevalence of Non-strabismic Anomalies of Binocular Vision\\n\\nwww.optvissci.com\\n\\n73.',\n"," 'Tagge CA, Fisher AM, Minaeva OV, et al.',\n"," 'Concussion, Microvascular Injury, and Early Tauopathy in\\nYoung Athletes after Impact Head Injury and an Impact\\nConcussion Mouse Model.',\n"," 'Brain 2018;141:422–58.',\n"," '74.',\n"," 'Goldstein LE, Fisher AM, Tagge CA, et al.',\n"," 'Chronic\\nTraumatic Encephalopathy in Blast-exposed Military\\nVeterans and a Blast Neurotrauma Mouse Model.',\n"," 'Sci Transl Med 2012;4:134ra60.',\n"," '75.',\n"," 'Bricker-Anthony C, Hines-Beard J, Rex TS.',\n"," 'Eyedirected Overpressure Airwave-induced Trauma Causes\\nLasting Damage to the Anterior and Posterior Globe:\\nA Model for Testing Cell-based Therapies.',\n"," 'J Ocul\\nPharmacol Ther 2016;32:286–95.',\n"," '76.',\n"," 'Guley NH, Rogers JT, Del Mar NA, et al.',\n"," 'A Novel\\nClosed-head Model of Mild Traumatic Brain Injury Using\\nFocal Primary Overpressure Blast to the Cranium in\\nMice.',\n"," 'J Neurotrauma 2016;33:403–22.',\n"," 'Optom Vis Sci 2019; Vol 96(8)\\n\\n77.',\n"," 'Rossi T, Boccassini B, Esposito L, et al.',\n"," 'Primary\\nBlast Injury to the Eye and Orbit: Finite Element Modeling.',\n"," 'Invest Ophthalmol Vis Sci 2012;53:8057–66.',\n"," '78.',\n"," 'Capó-Aponte JE, Jurek GM, Walsh DV, et al.',\n"," 'Effects\\nof Repetitive Low-level Blast Exposure on Visual System\\nand Ocular Structures.',\n"," 'J Rehabil Res Dev 2015;52:\\n273–90.',\n"," '79.',\n"," 'Yeates KO, Taylor HG, Rusin J, et al.',\n"," 'Longitudinal\\nTrajectories of Postconcussive Symptoms in Children\\nwith Mild Traumatic Brain Injuries and Their Relationship to Acute Clinical Status.',\n"," 'Pediatrics 2009;123:\\n735–43.',\n"," '80.',\n"," 'Andersson EE, Bedics BK, Falkmer T. Mild Traumatic Brain Injuries: A 10-year Follow-up.',\n"," 'J Rehabil\\nMed 2011;43:323–9.',\n"," '81.',\n"," 'Kowal L. Ophthalmic Manifestations of Head Injury.',\n"," 'Aust N Z J Ophthalmol 1992;20:35–40.',\n"," '82.',\n"," 'McCrory P, Meeuwisse WH, Aubry M, et al.',\n"," 'Consensus Statement on Concussion in Sport: The 4th International Conference on Concussion in Sport Held in\\nZurich, November 2012.',\n"," 'Br J Sports Med 2013;47:\\n250–8.',\n"," '83.',\n"," 'Sharp DJ, Jenkins PO.',\n"," 'Concussion Is Confusing Us\\nAll.',\n"," 'Pract Neurol 2015;15:172–86.',\n"," '84.',\n"," 'Department of Veterans Affairs.',\n"," 'VHA Notice 2017-35:\\nRescission of VHA Directive 2008-065, Performance of\\nTraumatic Brain Injury Specific Ocular Health and Visual\\nFunctioning Examinations for Polytrauma Rehabilitation\\nCenter Patients.',\n"," 'Department of Veterans Affairs; 2017.',\n"," 'Available at: https://www.va.gov/OPTOMETRY/docs/VHA_\\nNotice_2017-35_Recission_of_VHA_Directive_2008065.pdf.',\n"," 'Accessed April 20, 2018.',\n"," '85.',\n"," 'Vision Center of Excellence.',\n"," 'Clinical Recommendations for the Eye Care Provider: Eye and Vision Care Following Blast Exposure and/or Possible Traumatic Brain\\nInjury.',\n"," 'DoD/VA; 2015.',\n"," 'Available at: https://vce.health.',\n"," 'mil/Resources/Products/Additional-Resources/TBI-CRPhoto.',\n"," 'Accessed April 20, 2018.',\n"," '86.',\n"," 'Vision Center of Excellence.',\n"," 'Clinical Recommendation for the Eye Care Provider: Assessment and Management of Oculomotor Dysfunctions Associated with\\nTraumatic Brain Injury.',\n"," 'DoD/VA.',\n"," 'Available at: https://\\nvce.health.mil/~/media/Files/VCE/Products/Clinical%\\n20 Rec om menda ti ons/Oc ul om ot or /VCE _OM S_\\nOculomotorDysfunction-CR_13Dec2016_revert.ashx.',\n"," 'Accessed January 30, 2019.',\n"," '87.',\n"," 'Vision Center of Excellence.',\n"," 'Clinical Recommendation for the Eye Care Provider and Rehabilitation Specialists.',\n"," 'Rehabilitation of Patients with Visual Field\\nLoss Associated with Traumatic or Acquired Brain Injury.',\n"," 'DoD/VA; 2016.',\n"," 'Available at: https://vce.health.',\n"," 'mil/~/media/Files/VCE/Products/Clinical%\\n20Recommendations/VFL/VCE_OMS_VisualFieldLoss\\n%20CR.ashx.',\n"," 'Accessed April 20, 2018.',\n"," '555',\n"," '1040-5488/17/9406-0638/0 VOL.',\n"," '94, NO.',\n"," '6, PP.',\n"," '638Y646\\nOPTOMETRY AND VISION SCIENCE\\nCopyright * 2017 The Author(s).',\n"," 'Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Optometry.',\n"," 'REVIEW\\n\\nThe Safety of Soft Contact Lenses in Children\\nMark A. Bullimore*\\nDownloaded from https://journals.lww.com/optvissci by BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AWnYQp/IlQrHD3i3D0OdRyi7TvSFl4Cf3VC4/OAVpDDa8KKGKV0Ymy+78= on 10/31/2020\\n\\nABSTRACT\\nPurpose.',\n"," 'There is increasing interest in fitting children with soft contact lenses.',\n"," 'This review collates data from a range of\\nstudies to estimate the incidence of complications, specifically corneal infiltrative events and microbial keratitis, in patients\\nunder the age of 18 years.',\n"," 'Methods.',\n"," 'Peer-review papers were identified using PubMed and the Web of Science.',\n"," 'A broad range of studies are summarized\\nincluding large-scale epidemiological studies of contact lensYrelated complications, hospital-based case series, long- and\\nshort-term prospective studies, and multicenter retrospective studies.',\n"," 'Results.',\n"," 'Nine prospective studies representing 1800 patient years of wear in 7- to 19-year-olds include safety outcomes.',\n"," 'In\\nthree large prospective studies representing between 159 and 723 patient years of soft contact lens wear in patients 8 to 14\\nyears, the incidence of corneal infiltrative events is up to 136 per 10,000 years.',\n"," 'Data from a large retrospective study show\\nsimilar rates of corneal infiltrative events: 97 per 10,000 years in 8- to 12-year-olds (based on 411 patient years of wear) and\\n335 per 10,000 years in 13- to 17-year-olds (based on 1372 patient years of wear).',\n"," 'None of the prospective studies report\\nany cases of microbial keratitis.',\n"," 'Five clinical studies where safety data are not reported constitute a further 493 patient years.',\n"," 'One retrospective study found no cases of microbial keratitis occurred in 8- to 12-year-olds (411 patient years) and an\\nincidence of 15 per 10,000 patient years in 13- to 17-year-olds (1372 patient years)Vno higher than the incidence of\\nmicrobial keratitis in adults wearing soft contact lenses on an overnight basis.',\n"," 'Conclusions.',\n"," 'The overall picture is that the incidence of corneal infiltrative events in children is no higher than in adults,\\nand in the youngest age range of 8 to 11 years, it may be markedly lower.',\n"," '(Optom Vis Sci 2017;94:638Y646)\\nKey Words: cornea, soft contact lens, incidence, children, complications, infiltrate, microbial keratitis\\n\\nI\\n\\nn the past decade, there has been increasing interest in fitting\\nchildren with contact lenses.',\n"," 'This has been driven by patients,\\nparents, practitioners, and the contact lens research community and is caused by the increased interest in myopia control1Y6\\nand the improved self-esteem and quality of life enjoyed by\\nchildren wearing contact lenses.7Y9 Furthermore, the introduction\\nof daily disposable soft lenses obviates the need for cleaning and\\nstorage, making them an attractive option for children and\\nteenagers alike.10,11 Indeed, Chalmers et al.12 recently reported\\nthat, among patients of all ages in a prospective registry, only two\\ncorneal infiltrative events occurred in 960 patient years of daily\\ndisposable soft lens wear (489 years silicone hydrogel and 471\\nyears hydrogel)Van incidence of corneal infiltrative events of 21\\nper 10,000 years.',\n"," '*MCOptom, PhD, FAAO\\nUniversity of Houston College of Optometry (MAB), Houston, Texas.',\n"," 'This is an open-access article distributed under the terms of the Creative\\nCommons Attribution-Non Commercial-No Derivatives License 4.0 (CCBYNC-ND), where it is permissible to download and share the work provided it is\\nproperly cited.',\n"," 'The work cannot be changed in any way or used commercially\\nwithout permission from the journal.',\n"," 'Contact lensYrelated adverse events fall into two categories:\\nseriousVnotably microbial keratitisVand non-serious.',\n"," 'The latter\\ncategory typically includes episodes of a painful red eye such as\\ncontact lensYinduced acute red eye (CLARE) with and without\\ninfiltrates, contact lens peripheral ulcer (CLPU), and infiltrative\\nkeratitis.',\n"," 'Of course, some events may be allergic in origin and may\\nnot involve the cornea, so researchers often use the term corneal\\ninfiltrative events to indicate corneal involvement beyond mere\\nstaining or superficial punctate keratitis.',\n"," 'Corneal infiltrative\\nevents (CIEs) may be defined as a noninfectious infiltration of\\nwhite blood cells into the avascular corneal stroma, often with\\naccompanying hyperemia.12 Microbial keratitis is a subset of this\\ncategory, but usually accounts for around 5% of all corneal\\ninfiltrative events.13,14 Microbial keratitis may be defined as one\\nor more corneal stromal infiltrates greater than 1 mm in size with\\npain more than mild, and one or more of the following: anterior\\nchamber reaction more than minimal, mucopurulent discharge,\\nor positive corneal culture,15 although variations are common.',\n"," 'All soft contact lenses approved by the United States Food and\\nDrug Administration for daily and overnight wear carry no age\\nrestriction, implying that they are safe in both adults and children.',\n"," 'Optometry and Vision Science, Vol.',\n"," '94, No.',\n"," '6, June 2017\\n\\n\\x0cSoft Contact Lens Safety in ChildrenVBullimore\\n\\nBut what is the evidence for this assertion?',\n"," 'Are soft contact lenses\\nless safe, equally safe, or safer in children than in adults?',\n"," 'This review\\nof the peer-reviewed scientific literature presents data from a range of\\ndifferent types of clinical studies related to the usage and safety of\\ncontact lenses in children in an attempt to address this question.',\n"," 'Surveys of Practitioner Attitudes and Behavior\\nSindt and Riley reported results of a survey mailed to 4004\\nAmerican Optometric Association practicing member optometrists\\nin July 2010.16 A total of 576 surveys were returned for a response\\nrate of 14.4%Va rate that can clearly result in bias.',\n"," 'Nearly all\\nresponding optometrists (97%) reported fitting contact lens patients\\nunder the age of 18, and these patients represent 41% of the total\\ncontact lens patient population in the practices of respondents.',\n"," 'Fig.',\n"," '1\\nshows the age at which practitioners feel it appropriate to introduce a\\nchild to soft contact lenses.',\n"," 'Over 70% feel that children can be introduced to these lenses at 12 years of age or younger.',\n"," 'Responding\\noptometrists most often fit spectacles as the primary method of vision\\ncorrection in children ages 8 to 9 (51%) and 10 to 12 (71%).',\n"," 'A\\ngradual shift in optometrists’ approach to vision correction occurs as\\nchildren get older, with 21% noting that they were more likely to fit\\n10- to 12-year-olds in contact lenses than they were a year before.',\n"," 'Nearly half (49%) prescribe contact lenses first for 13- to 14-year-olds,\\nand 66% recommend contact lenses as the main form of vision\\ncorrection for 15- to 17-year-olds.',\n"," 'Reasons for doctors who are now\\nmore likely to fit children in contact lenses include availability of daily\\ndisposable lenses (30%), improved contact lens materials (23%),\\nrequests from the child or parent (19%), recent research or studies\\n(10%), and children’s participation in activities and sports.',\n"," 'Efron et al.',\n"," 'summarized 13 years of survey data from 1650\\nresponses from US practitioners representing 7702 contact lens\\nfits.17 Each year, 1000 US-based practitioners were asked about\\nthe first 10 contact lens fits performed after receipt of the questionnaire.',\n"," 'They report that patients 15 years and under account\\nfor 11% of lens fits, although no further data on children are\\nprovided.',\n"," 'With respect to the global community, Efron et al.',\n"," 'sent\\n\\nFIGURE 1.',\n"," 'The age at which practitioners (N = 576) feel it appropriate to introduce a child\\nto soft contact lenses.',\n"," 'Replotted from data reported by Sindt and Riley.16\\n\\n639\\n\\nup to 1000 survey forms to contact lens fitters in each of 38\\ncountries between January and March every year from 2005 to\\n2009.10 Practitioners were asked to record data relating to the first\\n10 contact lens fits or refits performed after receiving the survey\\nform.',\n"," 'Data were received relating to 105,734 fits: 137 infants (0.1%),\\n1,672 children (6Y12 years, 1.6%), 12,117 teenagers (13Y17 years,\\n11.5%), and 91,808 adults (86.8%).',\n"," 'The proportion of minors (G18\\nyears old) fitted varied considerably between nations, ranging from\\n25% in Iceland to 1% in China, with the US ranked fourth with 17%:\\n13% 13- to 17-year-olds and 4% 6- to 12-year-olds.',\n"," 'Children are\\nfitted with the highest proportion of daily disposable lenses and have\\nthe highest rate of fits for part-time wear.',\n"," 'Teenagers have a similar lens\\nfitting profile to adults, with the main distinguishing characteristic\\nbeing a higher proportion of new fits.',\n"," 'Orthokeratology fits represented 28% of all rigid contact lenses prescribed to minors, including\\n47% of 6- to 12-year-olds, and the authors attribute this to growing\\npopularity of myopia control.',\n"," 'Children have the highest proportion\\n(925%) of newly prescribed daily disposable lensesVfollowed by\\nteenagers and adultsVconsistent with the view of Walline et al.',\n"," 'that\\nthis replacement frequency is especially suited to children and teenagers.11 The authors assert that the simplicity of daily replacement,\\nwithout the need for lens cleaning and maintenance, is likely to enhance compliance.',\n"," 'It should be noted that the above data represent the\\nproportions of contact lens fitsVboth new and refits.',\n"," 'The proportion\\nof children fit may thus overstate the proportion of children in the\\ntotal population of wearers, although the mean age for new fits did\\nincrease from 27.6 years in 2002 to 31.8 years in 2014.',\n"," 'Finally, only\\n1650 forms were returned over 13 years representing a response rate of\\n12.7% and leaving the potential for respondent bias.',\n"," 'Major Epidemiological Studies\\nContact lensYrelated adverse events have been studied extensively\\nand comprehensively for some 30 years.',\n"," 'Researchers have quantified\\nthe incidence of serious events, notably microbial keratitis, associated with different modalities along with the patient-related factors\\nassociated with non-serious and serious events.18Y22 Microbial keratitis was defined in these studies as either a positive corneal culture or a\\ncorneal infiltrate and overlying epithelial defect with at least one of the\\nfollowing: any part of the lesion being within the central 4 mm of the\\ncornea, an anterior chamber response, or pain.',\n"," 'Cases were usually\\nclassified as mild, moderate, or severe with the latter including loss of\\ntwo or more lines of best-corrected visual acuity, surgical intervention,\\nor both.',\n"," 'Overnight wear is an unequivocal risk factor for microbial\\nkeratitis among soft contact lens wearers.',\n"," 'Risk factors for microbial\\nkeratitis with daily wear include poor storage case hygiene, infrequent\\nstorage case replacement, solution type, male gender, high socioeconomic status, smoking, and occasional overnight lens use.20,22\\nChildren are rarely represented in these studies.',\n"," 'Dart et al.,18 Stapleton et al.,21 and Keay et al.19 all only report\\ncases in patients 15 years and older, although it is unclear in some\\ncases whether this represents the absence of pediatric cases or a\\nstudy design decision.',\n"," 'Collectively, these papers represent some\\n900 cases of presumed or confirmed microbial keratitis, but we\\ncannot assume that cases of microbial keratitis did not occur in\\nyounger children.',\n"," 'Stapleton et al.',\n"," 'state that daily disposable\\ncontact lens wear ‘‘seems to be associated with the lowest risk of\\nsevere microbial keratitis.’’21\\n\\nOptometry and Vision Science, Vol.',\n"," '94, No.',\n"," '6, June 2017\\n\\n\\x0c640 Soft Contact Lens Safety in ChildrenVBullimore\\n\\nWhen age is considered as a potential risk factor for contact\\nlensYrelated microbial keratitis, data on young children are absent\\nand the results on the youngest age groupVusually 15 to 24\\nyearsVare equivocal.',\n"," 'In a prospective, 12-month, population-based,\\ncaseYcontrol study, Stapleton et al.',\n"," 'identified 90 moderate and severe\\ncases related to daily wear of contact lenses and recruited 1090\\ncommunity controls using daily wear contact lenses.20 Data on\\nfrequency of case replacement were collected, but not frequency of\\nlens replacement or material.',\n"," 'They found that wearer age (15Y24 vs.\\n25Y54 vs. 55Y64 years) was not associated with moderate and severe\\ndisease.',\n"," 'In a similar study, Lim et al.',\n"," 'report 58 cases of contact lens\\nwearers presenting with microbial keratitis between 2008 and 2010\\nand recruited 152 contemporaneous controls.23 Eligible contact lens\\nwearers were individuals aged 14 to 67 years who had worn their\\nlenses in the 4 weeks before the event.',\n"," 'They found that patients aged\\nbetween 25 and 44 years were at three times increased risk compared\\nwith younger wearers (14Y24 years; 95% CI: 1.1Y9.6, P = .04).',\n"," 'Occasional overnight contact lens wear (less often than one night per\\nweek) was associated with a four times higher risk (95% CI:\\n1.2Y15.4, P = .03) compared with daily use.',\n"," 'Lim et al.',\n"," 'emphasize\\nthat daily disposable lens wear was associated with a significantly\\nreduced risk of microbial keratitis, compared to weekly, fortnightly,\\nand monthly replacement (P G .001).',\n"," 'Daily disposable lenses\\naccounted for only 10% of the cases, but 28% of the controls.',\n"," 'In a 1-year prospective study of 6245 overnight silicone hydrogel\\n(lotrafilcon A) lens wearers,15 Chalmers et al.',\n"," 'found 159 symptomatic corneal infiltrative events that were judged to be lens related\\n(2.5%) of which 10 were classified as microbial keratitis.13 The age\\ndistribution is not described in detail but included subjects as young\\nas 5 years.',\n"," 'None of the 10 cases of presumed microbial keratitis\\noccurred in patients under 18 years.15 Wearers who were at the\\nyounger and older ends of the age distribution had a significantly\\nhigher risk of developing infiltrates.',\n"," 'Age G25 years and 950 years was\\nsignificantly associated with the development of corneal infiltrates\\n(G25 years OR = 1.75, 95% CI: 1.24Y2.48 and 950 years OR = 2.04,\\n95% CI: 1.40Y2.98).',\n"," 'Chalmers et al.',\n"," 'used similar methodology in a 1-year prospective study of daily disposable soft lenses.12 Of the 977 patients\\ncompleting the 12-month survey, 13% were 15 years or younger.',\n"," 'Increasing patient age was significantly related to development of a\\ncontact lensYrelated adverse event for the 11 cases with office visits\\n(odds ratio 1.05, 95% CI: 1.01Y1.10, P = .03).',\n"," 'In other words, for\\nevery year older, there was a 5% increase in the risk of a contact\\nlensYrelated adverse event requiring an office visit.',\n"," 'The only adverse\\nevent among the patients younger than 18 years was an allergic\\nconjunctivitis.',\n"," 'Note that only two corneal infiltrative events occurred\\nin 960 patient years of daily disposable soft lens wear (489 years\\nsilicone hydrogel and 471 years hydrogel)Van incidence of corneal\\ninfiltrative events of 21 per 10,000 years.',\n"," 'Although not stated in the\\npublished paper, 202 children between 8 and 17 years were enrolled,\\naccounting for 171 patient years of wear and no infiltrates (Robin\\nChalmers, personal communication).',\n"," 'These conflicting results may be attributable to variations in\\nevent severity, definitions, material, wearing schedule, and study\\nsetting, but there is no clear evidence of increased risk among 15- to\\n24-year-olds.',\n"," 'The dogma in the literature is that the risk is higher in\\nyounger patients,22 but the data from the above studies conducted in\\nthe past decade do not support this narrative.',\n"," 'Regardless, most\\n\\nstudies use a broad range encompassing teenagers and college\\nstudents while ignoring younger children.',\n"," 'Hospital-Based Case Series of Microbial Keratitis in\\nChildren\\nSerious corneal infections can occur in children wearing contact\\nlenses, even if not being particularly prominent in the above\\nwell-conducted, large-scale, prospective epidemiological studies.',\n"," 'Although reports for Europe and the US are scarce, there are a number\\nof hospital-based case series, all from Taiwan and Hong Kong, describing the characteristics of children presenting with microbial\\nkeratitis over a 4- to 10-year period.',\n"," 'Fong et al.',\n"," 'conducted a retrospective 10-year study of microbial keratitis at National Taiwan\\nUniversity Hospital, reporting 453 patients of whom only 22 were\\n15 years or younger (4.9%).24 Contact lens use accounted for 44%\\nof cases with pseudomonal keratitis, the most common pathogen.',\n"," 'The authors attribute this high proportion to the high prevalence of\\nmyopia and the popularity of contact lens wear in Taiwan.',\n"," 'No\\ndetails are provided regarding the ages of the pediatric cases, their\\nseverity, nor the types of lenses worn.',\n"," 'Hsiao et al.',\n"," 'reviewed the medical records of 78 children (e16\\nyears) with microbial keratitis over a 4.5-year period at Chang Gung\\nMemorial Hospital, Taiwan.25 Contact lens wear was a factor in 33\\nof cases (41%), of which 8 (10%) were rigid gas permeable lenses\\nthat were worn overnight for orthokeratology and 25 (31%) were\\nsoft lenses.',\n"," 'No data are provided on soft lens replacement schedule.',\n"," 'The mean visual acuity at resolution in the 25 soft lens wearers was\\n0.24 logMAR (20/35), but the proportion undergoing surgical\\nintervention is not given (15% of all 81 eyes) nor the number with\\npoorer than 20/40 visual acuity.',\n"," 'Most of the 33 contact lens wearers\\nclaimed they did not use correct disinfectant with their lenses or\\nwore the lenses overnight.',\n"," 'Only one soft contact lensYrelated case of\\nmicrobial keratitis was under 12 years old, and the authors remark\\nthat most Taiwanese children who start to wear soft contact lenses\\nare aged approximately 13 years.',\n"," 'In a follow-up study at the same hospital, Lee et al.',\n"," 'reviewed the\\nmedical records of 67 children aged 16 years or younger who were\\ndiagnosed with and treated for microbial keratitis.26 Around half\\nthe cases occurred in patients 11 years and under.',\n"," 'The leading risk\\nfactor was again contact lens use, accounting for a significantly\\nhigher proportion of cases (53%) compared to the previous study.',\n"," 'This was entirely because of an increase in the number of cases\\nattributed to orthokeratology, which increased from 10 to 19% (P =\\n.011) likely reflecting higher numbers of orthokeratology wearers\\nrather any increase in the underlying risk.',\n"," 'Soft contact lens wear still\\naccounted for a little over 30% of cases of microbial keratitis (34%),\\nbut no data are given on soft lens replacement or wear schedule.',\n"," 'The\\npatients with orthokeratology were significantly younger than those\\nwith soft contact lens (11.9 years vs. 14.8 years, P G .001), but visual\\nacuity outcomes are not provided for either group.',\n"," 'Pseudomonas\\naeruginosa remained the most commonly isolated organism (31%).',\n"," 'Finally, Young et al.',\n"," 'reported 18 patients G18 years of age with\\nmicrobial keratitis who presented over a 10-year period in Hong\\nKong (mean age 12.4 years, range 3Y17 years).27 Contact lens\\nwear was the associated risk factor in 15 cases (83%), with 7 (39%)\\nassociated with orthokeratology lenses and 8 (44%) associated with\\nsoft lens wear including 1 user of colored contact lenses.',\n"," 'Pseudomonas\\n\\nOptometry and Vision Science, Vol.',\n"," '94, No.',\n"," '6, June 2017\\n\\n\\x0cSoft Contact Lens Safety in ChildrenVBullimore\\n\\nwas the most commonly isolated organism (10 cases, 63%).',\n"," 'The\\nauthors provide details of all cases in a comprehensive table demonstrating that among the eight cases in soft contact lens wearers, five\\nwere biweekly or monthly replacement, and one each were extended\\nwear, daily wear, and cosmetic.',\n"," 'Two soft lens wearers had final bestcorrected visual acuity worse than 20/40.',\n"," 'Although the above studies document that microbial keratitis\\ncan occur in children wearing contact lenses in Asia, it is not possible\\nto estimate the frequency or incidence of these serious events.',\n"," 'Likewise, few data are given on age distribution lens material or replacement schedule in these studies.',\n"," 'Only Young et al.27 make any\\nreference to replacement schedule and none of their cases were in daily\\ndisposable lenses.',\n"," 'Long-Term Prospective Studies of Contact Lenses in\\nChildren\\nA number of prospective, large-scale clinical trials have followed\\nchildren wearing contact lenses over a study period of 2 to 3 years.',\n"," 'A pair of studies was conducted 20 years ago at Indiana University.',\n"," 'Terry et al.',\n"," 'reported a 3-year study of changes in 10- to 13-year-old\\nchildren’s self-concepts after the replacement of their spectacles with\\ncontact lenses.28 From a sample of 125 children who wore spectacles, 69 children were randomly designated to receive reusable\\n(CIBASoft; CIBA Vision, now Alcon, Fort Worth, TX) soft contact\\nlenses.',\n"," 'Horner et al.',\n"," 'reported a 3-year, randomized clinical trial of\\nmyopia progression in 175 11- to 14-year-olds wearing reusable\\n(CIBASoft) soft contact lenses versus spectacles.29 Of those randomized to contact lenses, 68 completed the 3-year trial.',\n"," 'Unfortunately, no data on safety or adverse events are reported in either of\\nthe above publications.',\n"," 'Walline et al.',\n"," 'randomly assigned 116 subjects aged 8 to 11 years\\nto wear rigid gas permeable or 2-week replacement soft contact\\nlenses (CIBA Focus 2; CIBA Vision, now Alcon, Fort Worth, TX)\\nin a 3-year clinical trial.30 Of the 57 randomized to soft lenses, 53\\ncompleted the trial wearing soft lenses.',\n"," 'No subjects in either treatment\\ngroup experienced a sight-threatening adverse event.',\n"," 'No infections\\nwere reported, but four soft lens wearers experienced an adverse\\neventVthree caused by ‘‘tight-fitting soft lenses’’ that resolved\\ncompletely after refitting with other brands.',\n"," 'The other adverse event\\nwas a result of a ‘‘contact lens solution allergy, which resolved after\\nchanging the brand of solution.’’ Assuming these not to be corneal\\ninfiltrative events, the 95% CI are 0 to 233 per 10,000 patient years.',\n"," 'No adverse events were reported among the rigid gas permeable lens\\nwearers.',\n"," 'Sankaridurg et al.',\n"," 'reported comprehensive data on 240 children\\naged 7 to 14 years enrolled in a prospective randomized clinical\\ntrial of daily wear of monthly replacement, silicone hydrogel\\nlenses.31 Children were randomized to one commercial singlevision design and three experimental lens designs aimed at reducing\\nmyopia progressionVa central zone to correct for the distance refractive\\nerror and a peripheral optical zone that was relatively positive in power.',\n"," 'All were manufactured in lotrafilcon B silicone hydrogel (CIBA Vision,\\nnow Alcon, Fort Worth, TX) and worn bilaterally on a daily wear,\\nmonthly replacement schedule.',\n"," 'A total of 189 children completed 1\\nyear of contact lens wear, and 170 children completed 2 years.',\n"," 'There\\nwere no events of microbial keratitis, although 55 non-serious adverse\\nevents (annual incidence, 14.2%) were seen: contact lens papillary\\n\\n641\\n\\nconjunctivitis (16 events, 4.1%), superior epithelial arcuate lesions\\n(6 events, 1.5%), corneal erosions (8 events, 2.1%), infiltrative keratitis (5 events, 1.3%), asymptomatic infiltrative keratitis (7 events,\\n1.8%), and asymptomatic infiltrates (13 events, 3.4%).',\n"," 'The authors\\nconclude that adverse events with daily wear of silicone hydrogels in\\nchildren were mainly mechanical in nature, and significant infiltrative\\nevents were few.',\n"," 'Only the five cases of symptomatic infiltrative\\nkeratitis would meet the definition of symptomatic corneal infiltrative events used in other studies,13,14,22 representing an incidence\\nof corneal infiltrative events of 136 per 10,000 patient years (95%\\nCI = 50Y300).',\n"," 'In the largest clinical trial to date of contact lenses in children,\\nWalline et al.',\n"," 'randomized 8- to 11-year-old myopic children at\\nfive clinical centers in the United States.9,32 Of the 584 subjects,\\n237 were randomly assigned to wear spectacles and 247 to wear\\ndaily disposable (1-Day Acuvue; Johnson & Johnson Vision Care,\\nJacksonville, FL) or biweekly replacement (Acuvue 2; Johnson &\\nJohnson Vision Care) soft contact lenses.',\n"," 'Daily disposable lenses\\nwere fitted in 93% of children.',\n"," 'At the end of the 3-year trial, 241\\nsubjects were examined wearing contact lensesV224 originally\\nassigned to contact lenses and 17 assigned to spectacles.',\n"," 'Nine\\ncontact lens wearers (3.7%) experienced 13 adverse events, including\\ntwo cases of conjunctivitis (one bacterial and one viral), recurrent\\nphlyctenulosis, corneal dystrophy not noted at baseline, recurrent\\nanterior uveitis, six cases of keratitisVfour attributed by the authors to\\n‘‘poor compliance,’’ one to a ‘‘tight-fitting contact lens,’’ and one of\\n‘‘unknown etiology.’’ All adverse events completely resolved without\\npermanent decrease in best-corrected visual acuity.',\n"," 'Although not\\nexplicit, the implication is that the reported keratitis was not microbial\\nor serious in nature and confirmed by personal communication from\\nthe lead author.',\n"," 'Regardless of the underlying assumptions and\\nassertions regarding ‘‘tight-fitting lenses’’ and ‘‘poor compliance,’’\\nthe six cases of keratitis are assumed to be corneal infiltrative events\\nand represent an incidence of corneal infiltrative events of 83 per\\n10,000 patient years (95% CI = 34Y173).',\n"," 'Clinical Trials Where One or More Groups Wear Soft\\nContact Lenses\\nIn addition to the above studies, there have been a number of\\nreports of smaller samples wearing soft contact lenses in clinical\\nstudies of myopia control.',\n"," 'Unfortunately, only one of the six\\nstudies reports safety data.',\n"," 'Anstice and Phillips fitted 40 children, 11 to 14 years old, with a\\nDual-Focus soft contact lens in one eye and a single vision soft\\ncontact lens in the other.2 The lenses were made of hioxifilcon A,\\nworn on a daily wear basis and replaced every 2 months.',\n"," 'Subjects\\nwere followed for 20 months.',\n"," 'Six children dropped out because of\\ndifficulties with handling contact lenses (n = 3), adverse publicity\\nregarding contact lens solutions (n = 1), dislike of cycloplegia (n = 1),\\nor contact lensYrelated discomfort (n = 1).',\n"," 'Adverse events were\\nnot reported.',\n"," 'Sankaridurg et al.',\n"," 'fitted 45 Chinese children, aged 7 to 14 years,\\nwith novel myopia-control, monthly replacement, silicone hydrogel\\ncontact lenses and followed them for 12 months.',\n"," 'They were compared with a matched group (n = 40) wearing spectacles.',\n"," 'No safety\\ndata were reported.4\\n\\nOptometry and Vision Science, Vol.',\n"," '94, No.',\n"," '6, June 2017\\n\\n\\x0c642 Soft Contact Lens Safety in ChildrenVBullimore\\n\\nWalline et al.',\n"," 'fitted soft multifocal (Proclear Multifocal;\\nCooperVision, Victor, NY) contact lenses to forty 8- to 11-year-old\\nchildren, of whom 32 were examined after 1 year and 27 after\\n2 years.',\n"," '5 Lenses were replaced on a monthly basis and safety data\\nwere not reported.',\n"," 'Lam et al.',\n"," 'performed a 2-year double-masked randomized\\nclinical trial of soft contact lenses 221 children aged 8 to 13 years.3\\nSubjects were randomly assigned to a Defocus Incorporated Soft\\nContact (DISC) lens (n = 111) or single-vision contact lenses (n = 110).',\n"," 'The DISC lenses incorporated concentric rings that provided +2.50D\\nof addition power, alternating with the normal distance correction.',\n"," 'The lenses were replaced every 6 months.',\n"," 'Only 128 children (58%)\\ncompleted the 2-year study (DISC, n = 65; single vision, n = 63).',\n"," 'No\\nsafety data were reported, although the authors state that ‘‘adverse\\nreactions were low’’ and that ‘‘17 excluded due to ocular health\\nproblems.’’\\nCheng et al.',\n"," 'randomized 127 subjects (8Y11 years) to either soft\\ncontact lenses with positive spherical aberration or a spherical\\ncontrol lens, both made of the same material (etafilcon A with\\nLacreon technology).33 During this treatment phase, subjects were\\nfollowed for up to 2 years, with 109 completing at least 1 year of\\nfollow-up.',\n"," 'Thereafter, 82 subjects participated in a withdrawal\\nphase wherein all wore 1-Day Acuvue Moist soft contact lenses\\nwith 77 completing 18 months of follow-up.',\n"," 'No cases of microbial\\nkeratitis or corneal infiltrative events were reported, although\\nthere were two instances of contact dermatitis and four of allergic\\nconjunctivitis.',\n"," 'Aller et al.',\n"," 'randomized 79 myopic subjects (8Y18 years) to either\\nsingle-vision (Vistakon Acuvue 2) soft contact lenses or bifocal\\n(Acuvue Bifocal; Johnson & Johnson Vision Care) soft contact\\nlenses worn on a daily wear basis for 12 months, with a 2-week\\nreplacement schedule.1 Of these, 78 completed the 1-year clinical\\ntrial.',\n"," 'No safety data were reported.',\n"," 'Prospective Studies of Fitting Children and Teenagers\\nThere have also been a handful of short-term studies published,\\ndemonstrating the feasibility of fitting children as young as 8 years\\nwith soft contact lenses.',\n"," 'Although limited in duration, they all report\\ndata on adverse events.',\n"," 'The Contact Lenses in Pediatrics (CLIP) Study compared\\ncontact lens fitting and follow-up between 8- to 12-year-old\\nchildren and 13- to 17-year-old teenagers.34 The study enrolled\\n84 children and 85 teens and fit them with soft contact lenses\\n(Acuvue Advance with Hydraclear or Acuvue Advance for Astigmatism; Johnson & Johnson Vision Care), presumably on a 2-week\\nreplacement schedule.',\n"," 'All but 12 completed the 3-month study\\n(86%) and no serious adverse events were observed, but ‘‘three cases\\nof viral keratitis and two cases of suspected contact lens overwear’’\\nwere reported.',\n"," 'The authors’ Table 4 indicates one episode of a corneal\\ninfiltrate, although the severity is unclear.',\n"," 'In a similar study in Singapore, Li et al.',\n"," 'recruited and fitted\\n59 children (8Y11 years) with spherical or toric daily disposable soft\\nlenses.35 Of the 59 subjects enrolled, 53 (90%) completed the study\\nsuccessfully.',\n"," 'Six subjects discontinued due to lens handling\\ndifficulties (n = 4), unacceptable lens fit (n = 1), and an adverse event\\n(n = 1).',\n"," 'Adverse events were reported in three subjects, including the\\ndiscontinuation, all because of a chalazion.',\n"," 'Plowright et al.',\n"," 'randomized subjects (aged 13Y19 years) with no\\nprevious contact lens wear experience to daily disposable soft contact\\nlenses or spectacles for 6 months.8 A total of 110 teenagers were\\nenrolled; 13 discontinued before study completion, 10 from the\\ncontact lens group and 3 from the spectacle group (P = .04).',\n"," 'No\\nserious adverse events occurred during the study, although a\\n19-year-old discontinued the study at month 3 because of a\\ncontact lensYinduced peripheral ulcer (CLPU) and subsequent\\ntopical medication (chloramphenicol).',\n"," 'The CLPU was resolved at a\\nfollow-up visit 21 days later leaving a small peripheral scar.',\n"," 'Paquette et al.',\n"," 'recruited 179 children aged 8 to 16 years without\\nprevious soft contact lens experience and fitted them with soft\\ncontact lenses.36 Of those recruited, 90.5% (162/179) were successfully fitted and completed the 3-month study.',\n"," 'No serious adverse\\nevents occurred, although five subjects presented with non-clinically\\nrelevant corneal staining, one participant presented with a corneal\\ninfiltrate, and one participant presented with a lens care reaction.',\n"," 'The\\ncorneal infiltrate self-resolved within 1 week with the participant later\\nresuming lens wear.',\n"," 'Although not a prospective study, Turnbull et al.',\n"," 'reported a case\\nseries of 110 patients of whom 32 were prescribed dual focus soft\\ncontact lenses for myopia control (mean age: 11.4 T 2.4 years).37\\nOver a mean follow-up of 1.33 T 0.80 years for these soft lens wearers,\\nno adverse events were observed.',\n"," 'Large-Scale Retrospective Studies of SafetyVThe\\nCLAY Study\\nThe Contact Lens Assessment in Youth (CLAY) Study was a\\nmulticenter, retrospective, observational study to evaluate the risk\\nfactors that interrupt soft contact lens wear among children,\\nteenagers, and young adults in North America.',\n"," 'The goal was to assess\\nthe safety profile of soft contact lens wear in a pediatric population\\noutside the confines of prospective clinical studies.',\n"," 'The cohort\\nrepresented patients presenting to academic eye care clinics for\\nroutine and problem-oriented eye care and included both habitual\\nand newly prescribed soft contact lens wearers.',\n"," 'Lam et al.',\n"," 'described the methodology, including the important\\nover-sampling of youngest age to make statistical comparisons, the\\ndemographics, and clinical characteristics of this cohort at the first\\nobserved visit.38 Charts from 3,549 patients (14,276 visits) were\\nreviewed; 79% were existing soft contact lens wearers and 21%\\nwere new fits.',\n"," 'The age distribution was 8 to e13 years (n = 260,\\n7%), 13 to e18 years (n = 879, 25%), 18 to e26 years (n = 1274,\\n36%), and 26 to e34 years (n = 1136, 32%).',\n"," 'Seventy-seven\\npercent of current soft contact lens wearers had a documented\\nreplacement schedule.',\n"," 'Based on patient-reported replacement\\nschedules, daily replacement composed the smallest percentage\\n(9.9%) across all age groups, although this mode was most common\\n(15.8%) among the youngest soft contact lens wearers (8Y12 years).',\n"," 'Monthly and 1- to 2-week replacement each accounted for 39% in\\nthe overall population.',\n"," 'Microbial keratitis and other adverse events\\nare not reported in this first publication.',\n"," 'In a subsequent report, Chalmers et al.',\n"," 'reported the frequency\\nof corneal infiltrative events (microbial keratitis, CLARE with and\\nwithout infiltrates, CLPU, and infiltrative keratitis) in the aforementioned sample from 14,305 visits observing 4,663 soft contact\\nlens years including an average of 20 months of soft contact lens wear\\n\\nOptometry and Vision Science, Vol.',\n"," '94, No.',\n"," '6, June 2017\\n\\n\\x0cSoft Contact Lens Safety in ChildrenVBullimore\\n\\nin 1,054 patients under the age of 18 years.14 Reviewers masked to\\nwearer identity, age, and soft contact lens parameters adjudicated\\nevent diagnoses.',\n"," 'The chart review yielded 187 corneal infiltrative\\nevents in 168 wearers: 8 instances of microbial keratitis, 110 of\\ninfiltrative keratitis, 41 CLPUs, 14 CLARE with infiltrates, 13\\nCLARE without infiltrates, and 1 iritis.',\n"," 'Age was a significant nonlinear\\nrisk factor, peaking between 15 and 25 years (P = .008).',\n"," 'The risk of a\\ncorneal infiltrative event increased in a nonlinear fashion up to\\nage 21 and then decreased similarly, with the peak years at risk\\nfrom age 15 to 25 years.',\n"," 'Fig.',\n"," '2 replots the published data in terms\\nof incidence (cases per 10,000 patient years of wear) based on the\\nnumber of cases and duration of follow-up reported by the authors.',\n"," 'Note that all incidence rates have confidence intervals and those for\\nall corneal infiltrative events are given below.',\n"," 'The figure demonstrates the marked lower rate of corneal infiltrative events in patients\\n8 to 12 years old (97 per 10,000 patient years, 95% CI = 31Y235)\\nthan in patients 13 to 17 years old (335 per 10,000 patient years,\\n95% CI = 248Y443).',\n"," 'No cases of microbial keratitis occurred in\\nthe 8- to 12-year-olds and two occurred in the 13- to 17-year-olds\\nrepresenting an incidence of microbial keratitis events of 15 per\\n10,000 patient years (95% CI = 2Y48) in the latter age group,\\nsubstantially lower than the incidence for all corneal infiltrative\\nevents.',\n"," 'In addition to patient age, years of contact lens wear, use of\\na multipurpose lens care system, overnight wear, and use of silicone\\nhydrogel lenses (in decreasing order) were all significant risk factors.',\n"," 'Wagner et al.',\n"," 'subsequently reported that the risk of interruption to soft contact lens wear followed the same pattern as corneal\\ninfiltrative events, increasing from ages 8 to 18 years, showing\\nmodest increases between ages 19 and 25 years, and then declining\\n\\n643\\n\\nafter age 25 years.39 New lens wearers (e1 year) were less likely to\\nexperience interrupting events (P G .001).',\n"," 'The CLAY Study Group has subsequently begun to investigate\\nthe underlying behavioral, biological, or environmental factors\\nthat may potentially drive the above age-related complications.',\n"," 'They developed a Contact Lens Risk Survey to assess known or\\npresumed risk factors for soft contact lens complications and\\nadministered the survey to a nonclinical population of 542 soft\\ncontact lens wearers aged 12 to 33 years.39 Wearers aged 18 to\\n21 years reported more recent nights with less than 6 hours of\\nsleep (P G .001), more colds/flu (P = .049), and higher stress\\nlevels (P G .001).',\n"," 'Wearers 18 to 21 and 22 to 25 years were\\nmore likely to wear soft contact lenses when showering (P G\\n.001) and also reported more frequent naps with soft contact\\nlenses (P G .001).',\n"," 'The 18- to 25-year age group were more likely to\\nreport sleeping in SCLs after alcohol use (P = .031), when traveling\\n(P = .001), and when away from home (P = .024).',\n"," 'Finally, the researchers investigated whether the surveyed risk\\nfactors were correlated with their previously established agerelated risk profile for corneal infiltrative events (Fig.',\n"," '2).40 To\\nmatch the known age-related risk profile, a distribution should show\\na rise in behaviors from 12- to 17-year-olds, peaking among 18- to\\n25-year-olds, and declining in 26- to 33-year-olds.',\n"," 'Visual inspection\\nshowed good agreement between the age-related risk curve\\n(Fig.',\n"," '2) and age-binned survey responses for various behaviors,\\ne.g., showering and napping in soft contact lenses.',\n"," 'The rate of\\nall-risky behaviors was around twice as high in 18- to 21-yearolds compared to the 12- to 14-year-olds.',\n"," 'Although the presence of\\nrisky soft contact lens wearing behaviors does not imply a causal\\n\\nFIGURE 2.',\n"," 'The incidence of various corneal inﬁltrative events as a function of patient age.',\n"," 'Incidence was calculated per 10,000 patient years.',\n"," 'Calculated from data\\nreported by Chalmers et al.14\\nOptometry and Vision Science, Vol.',\n"," '94, No.',\n"," '6, June 2017\\n\\n\\x0c644 Soft Contact Lens Safety in ChildrenVBullimore\\n\\nrelationship, the prevalence of specific behaviors by age mirrors the\\nage-related risk of having an inflammatory event from the authors’\\nprevious study.',\n"," 'This suggests that the age-related variation in adverse\\nevents is a result of patient behavior rather than biological factors.',\n"," 'SUMMARY\\nThe publications reviewed above encompass a wide range of\\nstudy goals.',\n"," 'Studies were designed to evaluate the influence of a\\nlens design on myopia progression, the effects of contact lenses on\\nself-esteem, the ease of fitting and adaptation to wear, the safety of\\ncontact lens wear, or some combination.',\n"," 'Table 1 summarizes most of the prospective studies cited above.',\n"," 'In those representing at least 100 patient years of lens wear, the\\nincidence of corneal infiltrative events and the 95% confidence\\nintervals can be estimated based on the number of events reported,\\nthe number of patients completing the study, and the duration of\\nfollow-up.',\n"," 'For the three large clinical trials, the incidence of\\ncorneal infiltrative events for children wearing contact lenses is up\\nto 136 per 10,000 years with upper 95% confidence intervals of\\nup to 300 per 10,000 years.30Y32 Where specified by the authors,31\\nonly symptomatic infiltrates are included in Table 1.',\n"," 'There are\\nadditional asymptomatic events and non-infiltrative presentations\\nobserved at the many scheduled visits in prospective studies.',\n"," 'The\\nclinical significance of these may be unclear, but they cannot be\\ncaptured easily with retrospective study designs.41\\nThe largest of these numbers reflects the wearing of reusable\\nsilicone hydrogel lenses and includes subjects as old as 14 years.31\\n\\nThe estimate of corneal infiltrative events of 83 per 10,000 years\\nfor Walline et al.32 is probably high because it assumes their six\\ncases of lens-related keratitis to be corneal infiltrative events, although the authors make no mention of the presence or absence\\nof corneal infiltrates.',\n"," 'Thus, the incidence may be much lower.',\n"," 'The\\nincidence for the CLAY study is also calculated for two age groups\\nbased on their published data.14 The incidence of corneal infiltrative events for the three studies enrolling 8- to 11-year-olds30,32\\nor 7- to 14-year-olds31 agree well with the estimate for 8- to 12year-olds from the CLAY study (0, 83, and 136 per 10,000 years\\nvs. 97 per 10,000 years).14 Their incidence of corneal infiltrative\\nevents falls within the range for the three prospective studies and\\nthe upper 95% confidence intervals all fall between 173 and 300\\nper 10,000 years.',\n"," 'The summary of the incidence of corneal infiltrative events in\\nTable 1 can be placed in the context of epidemiological studies of\\nadult contact lens wearers (some described above, some not because they did not include patients under 18 years of age).',\n"," 'In the\\nlast decade, the annualized incidence of symptomatic corneal\\ninfiltrative events in adults has been reported as follows:\\n& 318 per 10,000 patient years in patients attempting 30-night\\ncontinuous wear of silicone hydrogel lenses13;\\n& 340 per 10,000 patient years for extended wear low Dk hydrogel\\nlenses and 720 per 10,000 patient years for extended wear\\nsilicone hydrogel lenses based on a meta-analysis42;\\n& 432 per 10,000 patient years in a retrospective chart review of\\nmostly daily wear14; and\\n\\nTABLE 1.',\n"," 'Summary of studies of contact lenses in children\\nAuthors\\nProspective studies\\nTerry et al.',\n"," '(1997)28\\nHorner et al.',\n"," '(1999)29\\nWalline et al.',\n"," '(2004)30\\nSankaridurg et al.',\n"," '(2013)31\\nWalline et al.',\n"," '(2008)32\\nChalmers et al.',\n"," '(2015)12\\nAnstice and Phillips (2011)2\\nSankaridurg et al.',\n"," '(2011)4\\nWalline et al.',\n"," '(2013)5\\nLam et al.',\n"," '(2014)3\\nCheng et al.',\n"," '(2016)33\\nAller et al.',\n"," '(2016)1\\nWalline et al.',\n"," '(2007)34\\nLi et al.',\n"," '(2009)35\\nPlowright et al.',\n"," '(2015)8\\nPaquette et al.',\n"," '(2015)36\\nRetrospective studies\\nTurnbull et al.',\n"," '(2016)37\\nChalmers et al.',\n"," '(2011)14\\nChalmers et al.',\n"," '(2011)14\\n\\nCountry Age Range (yr) Duration (yr)\\nUS\\nUS\\nUS\\nPRC\\nUS\\nUS\\nNZ\\nPRC\\nUS\\nHK\\nUS\\nUS\\nUS\\nSG\\nUK\\nCND\\n\\n10Y13\\n11Y14\\n8Y11\\n7Y14\\n8Y11\\n8Y17\\n11Y14\\n7Y14\\n8Y11\\n8Y13\\n8Y11\\n8Y18\\n8Y17\\n8Y11\\n13Y19\\n8Y16\\n\\nNZ\\nUS\\nUS\\n\\n6Y17\\n8Y12\\n13Y17\\n\\n3\\n3\\n3\\n2\\n3\\n1\\n1.7\\n1\\n2\\n2\\n1 + 1.5\\n1\\n0.25\\n0.25\\n0.5\\n0.25\\n\\nN\\n\\nIncidence of CIE\\nPatient years CIEs (per 10,000 patient years) 95% CI\\n\\n69\\n68\\n57\\n240\\n247\\n202\\n40\\n45\\n40\\n221\\n127\\n79\\n169\\n59\\n55\\n179\\n\\n159\\n369\\n723\\n171\\n57\\n43\\n59\\n256\\n262\\n78\\n39\\n13\\n23\\n41\\n\\n*\\n*\\n0\\n5\\n6\\n0\\n*\\n*\\n*\\n*\\n0\\n*\\n1\\n0\\n1\\n1\\n\\n32\\n243\\n811\\n\\n43\\n411\\n1,372\\n\\n0\\n4\\n46\\n\\n0\\n136\\n83\\n0\\n\\n0, 233\\n50, 300\\n34, 173\\n0, 216\\n\\n0\\n\\n0, 141\\n\\n97\\n335\\n\\n31, 235\\n248, 443\\n\\nWhere possible, the incidence of symptomatic corneal infiltrative events (per 10,000 patient years) is estimated based on the number of\\nevents, the number of patients, and the study duration.',\n"," 'Patient years based on study follow-up at each time point, not enrollment.',\n"," '*Data not reported.',\n"," 'CIEs indicates corneal infiltrative events; CND, Canada; PRC, China; HK, Hong Kong; NZ, New Zealand; SG, Singapore; UK, United\\nKingdom; US, United States.',\n"," 'Optometry and Vision Science, Vol.',\n"," '94, No.',\n"," ...]"]},"metadata":{"tags":[]},"execution_count":22}]},{"cell_type":"code","metadata":{"id":"Yw9uzW9P6HkQ","executionInfo":{"status":"ok","timestamp":1604211735565,"user_tz":-480,"elapsed":830,"user":{"displayName":"Nicholas Neo","photoUrl":"","userId":"02359484661843204503"}}},"source":["def getSentenceDistribution(sentences):\n","  #Initialize counter\n","  counter = {}\n","  #Loop for each sentence\n","  for sentence in sentences:\n","    #Tokenize the sentence into words\n","    words = word_tokenize(sentence)\n","    #Save length of sentence\n","    if (len(words) not in counter):\n","      counter[len(words)] = 1\n","    else:\n","      counter[len(words)] +=1\n","  #Return counter as a dictionary\n","  sorted_dict = sorted(counter.items())\n","  #Set new dict\n","  new_dict = {}\n","  #Loop for each item in dict\n","  for i in sorted_dict:\n","    #Store in ascending order\n","    new_dict[i[0]] = i[1]\n","  #Return dictionary\n","  return new_dict"],"execution_count":23,"outputs":[]},{"cell_type":"code","metadata":{"id":"cOn_E-X37HFT","executionInfo":{"status":"ok","timestamp":1604211738980,"user_tz":-480,"elapsed":1966,"user":{"displayName":"Nicholas Neo","photoUrl":"","userId":"02359484661843204503"}},"outputId":"f50d5800-652b-4e23-d6b1-cef9b70e751d","colab":{"base_uri":"https://localhost:8080/"}},"source":["#Get sentence distribution\n","distributed = getSentenceDistribution(sentences)\n","distributed"],"execution_count":24,"outputs":[{"output_type":"execute_result","data":{"text/plain":["{1: 7,\n"," 2: 765,\n"," 3: 176,\n"," 4: 171,\n"," 5: 126,\n"," 6: 256,\n"," 7: 395,\n"," 8: 411,\n"," 9: 246,\n"," 10: 174,\n"," 11: 198,\n"," 12: 447,\n"," 13: 160,\n"," 14: 149,\n"," 15: 164,\n"," 16: 125,\n"," 17: 151,\n"," 18: 141,\n"," 19: 124,\n"," 20: 123,\n"," 21: 134,\n"," 22: 81,\n"," 23: 114,\n"," 24: 106,\n"," 25: 91,\n"," 26: 76,\n"," 27: 96,\n"," 28: 77,\n"," 29: 77,\n"," 30: 81,\n"," 31: 75,\n"," 32: 55,\n"," 33: 69,\n"," 34: 75,\n"," 35: 55,\n"," 36: 65,\n"," 37: 54,\n"," 38: 57,\n"," 39: 57,\n"," 40: 46,\n"," 41: 41,\n"," 42: 29,\n"," 43: 40,\n"," 44: 20,\n"," 45: 39,\n"," 46: 21,\n"," 47: 16,\n"," 48: 23,\n"," 49: 23,\n"," 50: 23,\n"," 51: 20,\n"," 52: 21,\n"," 53: 17,\n"," 54: 19,\n"," 55: 22,\n"," 56: 16,\n"," 57: 24,\n"," 58: 13,\n"," 59: 11,\n"," 60: 11,\n"," 61: 8,\n"," 62: 11,\n"," 63: 15,\n"," 64: 8,\n"," 65: 11,\n"," 66: 7,\n"," 67: 11,\n"," 68: 14,\n"," 69: 15,\n"," 70: 5,\n"," 71: 5,\n"," 72: 7,\n"," 73: 8,\n"," 74: 6,\n"," 75: 7,\n"," 76: 5,\n"," 77: 5,\n"," 78: 1,\n"," 79: 4,\n"," 80: 3,\n"," 81: 4,\n"," 82: 1,\n"," 83: 3,\n"," 84: 7,\n"," 85: 1,\n"," 86: 4,\n"," 87: 6,\n"," 88: 4,\n"," 89: 5,\n"," 90: 3,\n"," 91: 2,\n"," 92: 2,\n"," 93: 3,\n"," 94: 4,\n"," 95: 3,\n"," 96: 1,\n"," 97: 3,\n"," 98: 2,\n"," 99: 4,\n"," 100: 3,\n"," 101: 2,\n"," 102: 2,\n"," 104: 2,\n"," 105: 3,\n"," 106: 2,\n"," 107: 1,\n"," 109: 1,\n"," 113: 1,\n"," 114: 2,\n"," 115: 3,\n"," 116: 1,\n"," 117: 2,\n"," 118: 1,\n"," 119: 1,\n"," 121: 1,\n"," 122: 4,\n"," 123: 1,\n"," 125: 1,\n"," 128: 2,\n"," 129: 1,\n"," 130: 1,\n"," 131: 2,\n"," 132: 3,\n"," 136: 3,\n"," 138: 2,\n"," 139: 1,\n"," 140: 1,\n"," 144: 1,\n"," 149: 1,\n"," 150: 1,\n"," 152: 1,\n"," 157: 1,\n"," 158: 1,\n"," 159: 3,\n"," 160: 1,\n"," 162: 1,\n"," 165: 1,\n"," 166: 1,\n"," 172: 1,\n"," 174: 2,\n"," 176: 1,\n"," 184: 1,\n"," 188: 2,\n"," 189: 1,\n"," 194: 2,\n"," 195: 1,\n"," 197: 1,\n"," 198: 1,\n"," 201: 1,\n"," 204: 2,\n"," 215: 1,\n"," 227: 1,\n"," 229: 1,\n"," 241: 1,\n"," 248: 1,\n"," 253: 1,\n"," 273: 1,\n"," 284: 1,\n"," 296: 1,\n"," 297: 1,\n"," 317: 1,\n"," 333: 1,\n"," 352: 1,\n"," 408: 1,\n"," 456: 1,\n"," 496: 1,\n"," 568: 1,\n"," 658: 1,\n"," 1023: 1}"]},"metadata":{"tags":[]},"execution_count":24}]},{"cell_type":"code","metadata":{"id":"RxO14EpB7OHt","executionInfo":{"status":"ok","timestamp":1604211742378,"user_tz":-480,"elapsed":2758,"user":{"displayName":"Nicholas Neo","photoUrl":"","userId":"02359484661843204503"}},"outputId":"c3e49e02-820f-488d-fe58-5459b3b5f62b","colab":{"base_uri":"https://localhost:8080/","height":623}},"source":["plt.figure(figsize=(20,10))\n","D = distributed\n","\n","plt.bar(range(len(D)), list(D.values()), align='center', alpha=0.5,label=\"Before Stemming\")\n","plt.xticks(range(len(D)), list(D.keys()))\n","plt.xticks(rotation=90)\n","\n","plt.title('Sentence Distribution')\n","plt.legend()\n","\n","plt.show()"],"execution_count":25,"outputs":[{"output_type":"display_data","data":{"image/png":"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\n","text/plain":["<Figure size 1440x720 with 1 Axes>"]},"metadata":{"tags":[],"needs_background":"light"}}]},{"cell_type":"code","metadata":{"id":"OFvHSzdM7YJD","executionInfo":{"status":"ok","timestamp":1604211745828,"user_tz":-480,"elapsed":806,"user":{"displayName":"Nicholas Neo","photoUrl":"","userId":"02359484661843204503"}}},"source":["#Random select three sentences from dataset\n","def randomSelectAndTag(sentences):\n","  selectedSentences = []\n","  #Save sentence 1\n","  selectedSentences.append(sentenceTagging(random.choice(sentences)))\n","  #Save sentence 2\n","  selectedSentences.append(sentenceTagging(random.choice(sentences)))\n","  #Save sentence 3\n","  selectedSentences.append(sentenceTagging(random.choice(sentences)))\n","  \n","  return selectedSentences\n","\n","#Tag a sentence\n","def sentenceTagging(sentence):\n","    #Initialize tagged list\n","    tagged_list = list()\n","    #Tokenize words\n","    wordsList = word_tokenize(sentence)\n","    # removing stop words from wordList \n","    wordsList = [w for w in wordsList if not w in stop_words]  \n","  \n","    #  Using a Tagger. Which is part-of-speech  \n","    # tagger or POS-tagger.  \n","    tagged = nltk.pos_tag(wordsList)\n","    for item in tagged:\n","      tagged_list.append(item)\n","    return tagged_list"],"execution_count":26,"outputs":[]},{"cell_type":"code","metadata":{"id":"bSXAI8tD8Pzb","executionInfo":{"status":"ok","timestamp":1604211749269,"user_tz":-480,"elapsed":934,"user":{"displayName":"Nicholas Neo","photoUrl":"","userId":"02359484661843204503"}},"outputId":"fe8de9f0-a147-4b99-a4bc-2b0dde3ad8f3","colab":{"base_uri":"https://localhost:8080/"}},"source":["#Get Three random sentences\n","randomSelectAndTag(sentences)"],"execution_count":27,"outputs":[{"output_type":"execute_result","data":{"text/plain":["[[('Three', 'CD'),\n","  ('months', 'NNS'),\n","  ('later', 'RB'),\n","  (',', ','),\n","  ('end', 'VB'),\n","  ('study', 'NN'),\n","  ('period', 'NN'),\n","  ('(', '('),\n","  ('17', 'CD'),\n","  ('months', 'NNS'),\n","  ('surgery', 'NN'),\n","  (')', ')'),\n","  (',', ','),\n","  ('patient', 'JJ'),\n","  ('reported', 'VBD'),\n","  ('improved', 'JJ'),\n","  ('symptoms', 'NNS'),\n","  (',', ','),\n","  ('0', 'CD'),\n","  ('10', 'CD'),\n","  ('pain', 'NN'),\n","  (',', ','),\n","  ('mild', 'JJ'),\n","  ('grittiness', 'NN'),\n","  ('dryness', 'NN'),\n","  (',', ','),\n","  ('intermittent', 'JJ'),\n","  ('light', 'JJ'),\n","  ('sensitivity', 'NN'),\n","  ('.', '.')],\n"," [('When', 'WRB'),\n","  ('I', 'PRP'),\n","  ('say', 'VBP'),\n","  ('gold', 'NN'),\n","  (',', ','),\n","  ('look', 'VBP'),\n","  ('gold', 'JJ'),\n","  ('ball', 'NN'),\n","  ('.', '.')],\n"," [('Almost', 'RB'),\n","  ('half', 'NN'),\n","  ('Lighthouse', 'NNP'),\n","  ('group', 'NN'),\n","  ('impaired', 'VBD'),\n","  ('vision', 'NN'),\n","  ('since', 'IN'),\n","  ('childhood', 'NN'),\n","  ('.', '.')]]"]},"metadata":{"tags":[]},"execution_count":27}]},{"cell_type":"code","metadata":{"id":"zPhnHSN08RIh"},"source":[""],"execution_count":null,"outputs":[]}]}